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I n t r o d u c t i o n :  T h e  C O L 5 A 1  g e n e  e n c o d e s  f o r  t h e  α 1  c h a i n  o f  t y p e  V  c o l l a g e n ,  
a  m i n o r  f i b r i l l a r  c o l l a g e n  p r o t e i n  w h i c h  p l a y s  a  v i t a l  r o l e  i n  f i b r i l  a s s e m b l y  
i n  t e n d o n s ,  l i g a m e n t s  a n d  o t h e r  c o n n e c t i v e  t i s s u e .  D N A  s e q u e n c e  v a r i a n t s  
w i t h i n  t h e  3 ’ - u n t r a n l a t e d  r e g i o n  ( U T R )  o f  t h i s  g e n e  h a v e  p r e v i o u s l y  b e e n  
a s s o c i a t e d  w i t h  t h e  c h r o n i c  f o r m  o f  t h e  d e g e n e r a t i v e  t e n d o n  d i s o r d e r  
A c h i l l e s  t e n d i n o p a t h y .  I n  a d d i t i o n ,  t w o  m a j o r  f u n c t i o n a l  f o r m s  o f  t h e  3 ’ - U T R  
w e r e  p r e v i o u s l y  i d e n t i f i e d .  T h e s e  d i s t i n c t  f o r m s  a r e  d e t e r m i n e d  b y  s e v e n  
s e q u e n c e  v a r i a n t s ,  f o u r  o f  w h i c h  a r e  i n d e p e n d e n t l y  a s s o c i a t e d  w i t h  A c h i l l e s  
t e n d i n o p a t h y .  T h e  “ a t  r i s k ”  a l l e l i c  f o r m  o f  t h e  3 ’ - U T R  ( t h e  “ T - a l l e l i c ”  f o r m )  
i s  h y p o t h e s i s e d  t o  g i v e  r i s e  t o  a  m o r e  s t a b l e  m R N A  w h e n  c o m p a r e d  t o  t h e  
w i l d  t y p e  a l l e l i c  f o r m  ( t h e  “ C - a l l e l i c ”  f o r m ) .  S i n c e  t h e  C O L 5 A 1  3 ’ - U T R  
c o n t a i n s  s e v e r a l  p u t a t i v e  m i R N A  b i n d i n g  s i t e s ,  t w o  o f  w h i c h  a r e  p o l y m o r p h i c ,  
w e  h y p o t h e s i s  t h a t  d i f f e r e n t i a l  m i R N A  b i n d i n g  t o  t h e  C O L 5 A 1  3 ’ - U T R  i s  a t  
l e a s t  i n  p a r t  r e s p o n s i b l e  f o r  t h e  d i f f e r e n c e s  i n  m R N A  s t a b i l i t y  b e t w e e n  t h e  
T -  a n d  C - a l l e l i c  f o r m s .  T w o  f o r m s  o f  t h e  m a t u r e  H s a - m i R - 6 0 8 ,  w h i c h  a r e  
p r o d u c e d  f r o m  t h e  p o l y m o r p h i c  ( S N P  r s 4 9 1 9 5 1 0 ,  C / G )  M I R 6 0 8  g e n e ,  c a n  
p o t e n t i a l l y  b i n d  t o  o n e  o f  t h e s e  p u t a t i v e  p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e s .  
T h e  a i m s  o f  t h i s  d i s s e r t a t i o n  t h e r e f o r e  w e r e  ( i )  t o  d e t e r m i n e  w h e t h e r  t h e  
t w o  p o l y m o r p h i c  a n d  a  t h i r d  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w i t h i n  t h e  3 ’ - U T R  
o f  t h e  C O L 5 A 1  g e n e  w e r e  c a p a b l e  o f  r e p r e s s i n g  t h e  C O L 5 A 1  m R N A  s t a b i l i t y  
i n  v i t r o  a n d  t o  d e t e r m i n e  w h e t h e r  t h e  t w o  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  
s h o w e d  a  s i g n i f i c a n t  d i f f e r e n c e  i n  r e s p o n s e  t o  m i R N A  r e g u l a t i o n  a n d  ( i i )  t o  
d e t e r m i n e  w h e t h e r  t h e  M I R 6 0 8  s i n g l e  n u c l e o t i d e  p o l y m o r p h i s m  r s 4 9 1 9 5 1 0  i s  
a s s o c i a t e d  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y .  
M e t h o d s :  P l a s m i d  c o n s t r u c t s  c o n t a i n i n g  t h e  C -  o r  T - a l l e l i c  f o r m s  o f  t h e  
C O L 5 A 1  3 ’ - U T R  d o w n s t r e a m  o f  a  l u c i f e r a s e  r e p o r t e r  g e n e  w e r e  c o - t r a n s f e c t e d  
w i t h  H s a - m i R - 6 0 8  o r  H a s - m i R - 1 2 5 a - 5 p  m i R N A  m i m i c  o r  n e g a t i v e  s i R N A  c o n t r o l  
i n t o  H T 1 0 8 0  f i b r o s a r c o m a  o r  S V W I - 3 8  S V 4 0  t r a n s f o r m e d  f i b r o b l a s t  c e l l s .  I n  
t h e  c a s e  o f  t h e  s e c o n d  p u t a t i v e  p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e ,  t e r m e d  t h e  
M b o I I  o c t a m e r ,  w h e r e  c o m m e r c i a l  m i R N A  m i m i c  w a s  u n a v a i l a b l e ,  a  s i t e -
d i r e c t e d  m u t a g e n e s i s  a p p r o a c h  w a s  u n d e r t a k e n .  T h e  r s 4 9 1 9 5 1 0  
p o l y m o r p h i s m  i n  t h e  M I R 6 0 8  g e n e  w a s  g e n o t y p e d  u s i n g  g e n o m i c  D N A  f r o m  
1 6 6  C a u c a s i a n  c h r o n i c  A c h i l l e s  t e n d i n o p a t h i c  p a r t i c i p a n t s  ( T E N )  a n d  3 4 2  
a p p a r e n t l y  h e a l t h y  C a u c a s i a n  c o n t r o l  p a r t i c i p a n t s  ( C O N )  u s i n g  f l u o r e s c e n c e  
b a s e d  T a q m a n ®  P C R .  
R e s u l t s :  T h e  r s 4 9 1 9 5 1 0  v a r i a n t  w i t h i n  t h e  M I R 6 0 8  g e n e  i s  i n d e p e n d e n t l y  
a s s o c i a t e d  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  i n  a  c o m b i n e d  S o u t h  A f r i c a n  
a n d  A u s t r a l i a n  C a u c a s i a n  p o p u l a t i o n  ( p = 0 . 0 2 3 ) .  S p e c i f i c a l l y ,  t h e  C C  g e n o t y p e  
w a s  s i g n i f i c a n t l y  o v e r - r e p r e s e n t e d  i n  t h e  T E N  ( 6 8 . 5 % )  c o m p a r e d  t o  t h e  C O N  
( 5 7 . 1 % )  p a r t i c i p a n t s .  F u n c t i o n a l  a n a l y s i s  o f  l u c i f e r a s e  a c t i v i t y  o f  c o n s t r u c t s  












t r a n s f e c t e d  w i t h  H s a - m i R - 6 0 8  m i m i c ,  w i t h  t h e  p o l y m o r p h i c  b i n d i n g  s i t e  
w i t h i n  t h e  T - a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R  s h o w i n g  g r e a t e r  r e p r e s s i o n  i n  
t h e  H T 1 0 8 0  f i b r o s a r c o m a  c e l l  l i n e  ( p = 0 . 0 0 3 )  b u t  n o t  i n  t h e  S V 4 0  t r a n s f o r m e d  
S V W I - 3 8  f i b r o b l a s t  c e l l  l i n e .  C o - t r a n s f e c t i o n  w i t h  H s a - m i R - 1 2 5 a - 5 p  m i m i c  
s i g n i f i c a n t l y  r e d u c e d  t h e  l u c i f e r a s e  a c t i v i t y  o f  t h e  C O L 5 A 1  3 ’ - U T R  c o n s t r u c t s  
w i t h  t h e  T - a l l e l i c  f o r m  s h o w i n g  a  s i g n i f i c a n t l y  g r e a t e r  d e c r e a s e  i n  m R N A  
s t a b i l i t y  t h a n  t h e  C - a l l e l i c  f o r m  a t  1 0  p m o l  ( p = 0 . 0 1 1 )  a n d  2 0  p m o l  ( p = 0 . 0 2 1 )  
b u t  n o t  a t  t h e  1  p m o l  c o n c e n t r a t i o n  ( p = 0 . 9 9 9 )  i n  H T 1 0 8 0  f i b r o s a r c o m a  c e l l s .  
T h e  M b o I I  o c t a m e r  m u t a n t s  s h o w  i n c r e a s e d  m R N A  s t a b i l i t y  w h e n  c o m p a r e d  
t o  t h e  p a r e n t a l  c o n s t r u c t s  i n  b o t h  t h e  H T 1 0 8 0  ( C O N  M u t  2  ( 1 . 4 3  ± 0 . 0 6  f o l d ) ,  
M u t  3 ( 1 . 1 9  ± 0 . 0 5  f o l d )  T E N  M u t  1  ( 1 . 8 7  ± 0 . 0 6  f o l d )  M u t 2  ( 1 . 6 7  ± 0 . 0 6  f o l d )  
M u t  3  ( 1 . 7 7  ± 0 . 0 3  f o l d ) )  a n d  S V W I - 3 8  ( C O N  M u t  2  ( 1 . 6 5  ± 0 . 0 4  f o l d ) ,  M u t  
3 ( 1 . 1 7  ± 0 . 0 7  f o l d )  T E N  M u t  1  ( 1 . 6 6  ± 0 . 0 5  f o l d )  M u t 2  ( 1 . 2 5  ± 0 . 0 5  f o l d )  M u t  3  
( 1 . 1 9  ± 0 . 0 3  f o l d ) )  c e l l  l i n e s  ( p < 0 . 0 0 1 ) ,  i n d i c a t i n g  t h e  p r e s e n c e  o f  a  n e g a t i v e  
r e g u l a t o r  o f  t h e  C O L 5 A 1  g e n e .  F i n a l l y ,  t h e  t w o  m a j o r  f u n c t i o n a l  f o r m s  o f  t h e  
3 ’ - U T R  h a d  d i s t i n c t  s e c o n d a r y  s t r u c t u r e s  w h e n  f o l d e d  i n  s i l i c o  u s i n g  t h e  S f o l d  
a l g o r i t h m .  W e  h y p o t h e s i s e  t h a t  t h i s  d i f f e r e n c e  m a y  h a v e  i m p l i c a t i o n s  i n  t h e  
r e g u l a t i o n  o f  t h e  C O L 5 A 1  3 ’ - U T R  b y  c i s - e l e m e n t s .  
C o n c l u s i o n :  T h i s  d i s s e r t a t i o n  s h o w s  f o r  t h e  f i r s t  t i m e  t h a t  t h e r e  i s  a n  
a s s o c i a t i o n  o f  t h e  C C  g e n o t y p e  o f  t h e  r s 4 9 1 9 5 1 0  v a r i a n t  i n  t h e  M I R 6 0 8  g e n e  
w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y .  A d d i t i o n a l l y ,  t h i s  s t u d y  s h o w s  t h a t  a l l  
t h r e e  i n v e s t i g a t e d  p u t a t i v e  m i R N A  b i n d i n g  w e r e  p o t e n t i a l l y  f u n c t i o n a l .  I t  i s  
h o w e v e r ,  u n l i k e l y  t h a t  t h e s e  t h r e e  r e g u l a t o r y  e l e m e n t s  w i t h i n  t h e  C O L 5 A 1  
3 ’ - U T R  a r e  r e s p o n s i b l e  f o r  t h e  o b s e r v e d  i n c r e a s e d  m R N A  s t a b i l i t y  o f  t h e  T -
a l l e l i c  f o r m  i n  t h e  H T 1 0 8 0  f i b r o s a r c o m a  c e l l  l i n e .  T h e s e  r e s u l t s  h a v e  
i m p o r t a n t  i m p l i c a t i o n s  f o r  o u r  u n d e r s t a n d i n g  o f  t h e  m o l e c u l a r  b a s i s  o f  
m u s c u l o s k e l e t a l  s o f t  t i s s u e  i n j u r i e s  a n d  o t h e r  e x e r c i s e - r e l a t e d  p h e n o t y p e s .  
A d d i t i o n a l  r e s e a r c h  i s  h o w e v e r ,  r e q u i r e d  t o  i d e n t i f y  a n d  e l u c i d a t e  t h e  
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A  n u m b e r  o f  i n j u r i e s  a f f e c t  t h e  A c h i l l e s  t e n d o n  a n d  t h e  s u r r o u n d i n g  t i s s u e s  
s u c h  a s  c h r o n i c  t e n d i n o p a t h y ,  c o m p l e t e  o r  p a r t i a l  r u p t u r e ,  b u r s i t i s  a n d  
p e r i t e n d i n i t i s  [ 1 ] .  A l t h o u g h  i n j u r i e s  t o  t h e  A c h i l l e s  t e n d o n  a r e  c o m m o n  a s  a  
r e s u l t  o f  p a r t i c i p a t i o n  i n  p h y s i c a l  a c t i v i t y  a n d  c e r t a i n  o c c u p a t i o n a l  a c t i v i t i e s  
[ 2 ] ,  t h e y  a l s o  o c c u r  i n  s e d e n t a r y  i n d i v i d u a l s  [ 3 ] .   
 
A c h i l l e s  t e n d o n  i n j u r i e s  h a v e  b e e n  r e p o r t e d  t o  a c c o u n t  f o r  b e t w e e n  6  a n d  
1 8 %  o f  a l l  t e n d o n  i n j u r i e s  [ 4 ] ,  [ 5 ] .  F o r t y - o n e  p e r c e n t  o f  p a t i e n t s  w i t h  c h r o n i c  
t e n d i n o p a t h y  e v e n t u a l l y  p r e s e n t  w i t h  p a t h o l o g y  i n  t h e  c o n t r a l a t e r a l  t e n d o n  
[ 6 ] .  I t  h a s  b e e n  e s t i m a t e d  t h a t  i n  t h e  U n i t e d  S t a t e s  a l o n e ,  8 2 5  0 0 0  r u n n e r s  
w o u l d  p r e s e n t  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  p e r  y e a r  [ 7 ] .  I n  a d d i t i o n ,  
t h e  p r e v a l e n c e  o f  A c h i l l e s  t e n d o n  i n j u r i e s  a p p e a r s  t o  b e  i n c r e a s i n g  w i t h  t h e  
a n n u a l  i n c i d e n c e  i n c r e a s i n g  f r o m  1 8 . 2  p e r  1 0 0  0 0 0  i n d i v i d u a l s  i n  1 9 8 4  t o  3 7 . 3  
i n  1 9 9 6  i n  t h e  D a n i s h  p o p u l a t i o n  [ 8 ] .  
 
A c h i l l e s  t e n d o n  i n j u r i e s  h a v e  b e e n  w e l l  c h a r a c t e r i z e d  a t  t h e  c l i n i c a l  l e v e l  
w i t h  b o t h  i n t r i n s i c  a n d  e x t r i n s i c  r i s k  f a c t o r s  h a v i n g  b e e n  d e s c r i b e d  ( T a b l e  
1 . 1 )  [ 9 ] ,  [ 1 0 ] ,  [ 1 1 ] ,  [ 1 2 ] .  Th e  m o l e c u l a r  m e c h a n i s m s  r e s p o n s i b l e  f o r  A c h i l l e s  
t e n d o n  i n j u r i e s  a r e  h o w e v e r  l a r g e l y  u n k n o w n  a n d  t h e  k n o w n  m e c h a n i s m s  w i l l  
b e  b r i e f l y  r e v i e w e d  i n  s e c t i o n  1 . 4  o f  t h i s  i n t r o d u c t o r y  c h a p t e r .  A s  
s u m m a r i z e d  i n  T a b l e  1 . 2 ,  D N A  s e q u e n c e  p o l y m o r p h i s m s  a r e  e m e r g i n g  a s  
i m p o r t a n t  i n t r i n s i c  r i s k  f a c t o r s  f o r  A c h i l l e s  t e n d i n o p a t h y .  O f  p a r t i c u l a r  
i n t e r e s t  t o  t h e  c u r r e n t  s t u d y  i s  a  c o m m o n  C / T  s i n g l e  n u c l e o t i d e  
p o l y m o r p h i s m  ( S N P  r s 1 2 7 2 2 ;  a l s o  k n o w n  a s  t h e  B s t U I  R F L P )  i n  t h e  3 ′ -
u n t r a n s l a t e d  r e g i o n  ( 3 ′ - U T R )  o f  C O L 5 A 1 ,  w h i c h  w a s  s h o w n  t o  b e  a s s o c i a t e d  
w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  [ 1 3 ] ,  [ 1 4 ]  a n d  a n t e r i o r  c r u c i a t e  l i g a m e n t  
( A C L )  i n j u r i e s  i n  f e m a l e s  [ 1 5 ] .  I n  a l l  o f  t h e s e  s t u d i e s  t h e  C C  g e n o t y p e  a t  
r s 1 2 7 2 2  w a s  s h o w n  t o  b e  o v e r - r e p r e s e n t e d  i n  t h e  r e s p e c t i v e  a s y m p t o m a t i c  
c o n t r o l s .  A n  a g e - r e l a t e d  i n c r e a s e  i n  r a n g e  o f  m o t i o n  m e a s u r e m e n t s  h a s  a l s o  
















Table 1.1 Intrinsic and extrinsic risk factor for Achilles tendinopathy 
E x t r i n s i c  f a c t o r s  R e f e r e n c e  I n t r i n s i c  f a c t o r s  R e f e r e n c e  
O c c u p a t i o n  
[ 9 ]  
A g e  
[ 9 ]  
F o o t w e a r  G e n d e r  
T r a i n i n g  e r r o r s  P o o r  n u t r i t i o n  
R u n n i n g  s u r f a c e  S ys t e m i c  d i s e a s e  
L e v e l  o f  p h ys i c a l  
a c t i v i t y  
[ 1 8 ]  G e n e t i c s  [ 1 3 ] ,  [ 1 4 ]  
P l a n t a r  f l e x o r  
s t r e n g t h  
[ 1 9 ]  
F l u o r o q u i n o l o n e  
a n t i b i o t i c  t r e a t m e n t  
[ 2 0 ]  
 
 
T h e  C O L 5 A 1  g e n e  e n c o d e s  f o r  t h e  α 1 ( V )  c h a i n  o f  t y p e  V  c o l l a g e n  [ 2 1 ]  a n d  
g e n e t i c  a s s o c i a t i o n  s t u d i e s  h a v e  f o u n d  f o u r  v a r i a n t s  w i t h i n  a n d  a r o u n d  
p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w i t h i n  t h e  3 ’ - U T R  o f  C O L 5 A 1  w h i c h  a r e  
i n d e p e n d e n t l y  a s s o c i a t e d  w i t h  A c h i l l e s  t e n d i n o p a t h y  [ 1 4 ] ,  [ 2 2 ] .  A s  t h e  3 ′ -
U T R  o f  e u k a r y o t i c  g e n e s  h a s  b e e n  s h o w n  t o  c o n t a i n  e l e m e n t s  w h i c h  a r e  
e m e r g i n g  a s  i m p o r t a n t  p o s t - t r a n s c r i p t i o n a l  r e g u l a t o r s  [ 2 3 ] ,  [ 2 4 ] ,  t h e  f o c u s  
o f  t h i s  d i s s e r t a t i o n  i s  t o  i n v e s t i g a t e  t h e  r o l e  t h e  C O L 5 A 1  3 ’ - U T R  h a s  i n  t h e  
r e g u l a t i o n  o f  t h e  C O L 5 A 1  g e n e .  T h e s e  e l e m e n t s ,  i n  p a r t i c u l a r  m i c r o R N A  
b i n d i n g  s i t e s ,  w i l l  b e  r e v i e w e d  i n  s e c t i o n  1 . 6 .  A  b r i e f  s u m m a r y  o f  t h e  
s t r u c t u r e  a n d  f u n c t i o n  o f  t e n d o n s  ( s e c t i o n s  1 . 1  a n d  1 . 2 ) ,  t y p e  V  c o l l a g e n  a n d  













Table 1.2 Genetic polymorphisms associated with Achilles tendinopathy 
Gene Description Polymorphism 
Association (increased  
{ ↓ } or decreased { ↑ } 
risk of AT) 
Reference 
TNC Tenascin C : ECM glycoprotein GT repeat, intron 17 
13 and 17 repeats ↓ risk 
[25] 
12 and 14 repeats ↑ risk 
COL5A1 
Fibrillar type V collagen pro-
α1 subunit 
rs12722 (T/C) CC genotype ↓ risk [13], [14] 
MMP-3 
Matrix Metalloproteinase 3 : 
zinc-dependent endopeptidase 
rs591058 (T/C) CC genotype ↑ risk 
[ 2 6 ]   rs679620 (A/G) 
GG genotype and G allele 
↑ risk 
rs650108 (G/A) AA genotype ↑ risk 
TIMP-2 
Tissue inhibitor of 
Metalloproteinase -2 
rs4789932 (C/T) 
CC genotype ↓ risk 
[27] 
CT genotype ↑ risk 
GDF5 
Growth and Differentiation 
factor 5 :cytokine signalling 
molecule 
rs143383 (T/C) TT genotype ↑ risk [ 2 8 ]   
IL-1β 
Interleukin 1 β: pro-
inflammatory cytokine 
rs16944 (T/C) 
TT genotype modulates 
risk (↓) 
[ 2 9 ]   
rs1143627 (T/C) C allele modulates risk (↓) 
IL-1RN 
Interleukin 1 receptor 
antagonist, competes for 
binding to the Interleukin 1 




genotypes not containing 
A2 allele modulates risk (↓) 
[29] 
IL-6 
Interleukin 6: cytokine with 
both pro- and anti-
inflammatory capabilities 
rs1800795 (G/C) 





















1.1 Anatomy of the Achilles tendon 
 
H e a l t h y  t e n d o n s  a r e  d e n s e  c o l l a g e n - c o n t a i n i n g  f i b r o u s  s t r u c t u r e s  c o n n e c t i n g  
m u s c l e s  t o  b o n e  w h i c h  a c t  t o  t r a n s m i t  e n e r g y  f r o m  m u s c u l a r  c o n t r a c t i o n .  
T e n d o n  m o r p h o l o g y  v a r i e s  d e p e n d i n g  o n  t h e  m e c h a n i c a l  e n v i r o n m e n t ,  w i t h  
t e n d o n s  e x p o s e d  t o  c o m p l e x  l o a d i n g  s u c h  a s  t h e  r o t a t o r  c u f f  h a v i n g  d i v e r s e  
o r i e n t a t i o n s  o f  c o l l a g e n  f i b r e s .  I n  c o n t r a s t ,  t e n d o n s  e x p e r i e n c i n g  m a i n l y  
u n i a x i a l  t e n s i l e  l o a d i n g ,  s u c h  a s  f l e x o r  t e n d o n s  a n d  t h e  A c h i l l e s  t e n d o n  h a v e  
c l o s e ,  p a r a l l e l  c o l l a g e n  f i b r e  o r i e n t a t i o n s  [ 3 0 ] ,  [ 3 1 ] ,  [ 3 2 ] .   
 
T h e  d r y  w e i g h t  o f  a  h e a l t h y  t e n d o n  i s  c o m p o s e d  o f  a p p r o x i m a t e l y  7 0  –  8 0 %  
t y p e  I  c o l l a g e n  w i t h  t h e  r e m a i n i n g  p e r c e n t a g e  c o m p o s e d  o f  m i n o r  c o l l a g e n s  
( s u c h  a s  t y p e s  I I I ,  V ,  X I I  a n d  X I V ) ,  e l a s t i n ,  g l y c o p r o t e i n s  ( s u c h  a s  f i b r i l l i n ,  
t e n a s c i n  C ,  f i b r o n e c t i n ,  l a m i n i n  a n d  t h r o m b o s p o n d i n s )  a n d  p r o t e o g l y c a n s  
( s u c h  a s  d e c o r i n ,  h y u l a r a n ,  b i g l y c a n  a n d  f i b r o m o d u l i n )  a n d  c e l l s  [ 3 3 ] ,  [ 3 4 ] .  
T e n d o n s  c o n t a i n  r e l a t i v e l y  f e w  c e l l s  w i t h  t h e  r e s i d e n t  f i b r o b l a s t s ,  c a l l e d  
t e n o c y t e s ,  r e g u l a t i n g  e x t r a c e l l u l a r  m a t r i x  ( E C M )  t u r n o v e r  [ 3 5 ] .  T h e  A c h i l l e s  
t e n d o n  i s  t h e  l a r g e s t  a n d  s t r o n g e s t  t e n d o n  i n  t h e  h u m a n  b o d y ,  c a p a b l e  o f  
w i t h s t a n d i n g  s t r e s s  l o a d s  o f  u p  t o  1 2 . 5  t i m e s  t h e  b o d y  w e i g h t  w h i l e  r u n n i n g .  
T h e  A c h i l l e s  t e n d o n  o r i g i n a t e s  a t  b o t h  t h e  s o l e u s  a n d  g a s t r o c n e m i u s  m u s c l e s  
a n d  i n s e r t s  a t  t h e  c a l c a n e u s  ( F i g u r e  1 . 1 ) .  I t  l a c k s  a  s y n o v i a l  m e m b r a n e  a n d  
i s  i n s t e a d  c o v e r e d  b y  t h e  p a r a t e n o n  [ 5 ] .  T h e  A c h i l l e s  t e n d o n  i s  c o m p o s e d  
l a r g e l y  o f  c o l l a g e n  f i b r i l s ,  a r r a n g e d  i n  p a r a l l e l  f i b r e s  [ 1 2 ] ,  [ 3 5 ] ,  [ 3 6 ] .  T h i s  
p a r a l l e l  o r g a n i s a t i o n  o f  c o l l a g e n  f i b r i l s ,  f a c i l i t a t e d  b y  p r o t e o g l y c a n s  a n d  
g l y c o p r o t e i n s ,  a l l o w  t h e  t e n d o n  t o  r e s i s t  a n d  t r a n s m i t  t h e  t e n s i l e  f o r c e s  














F i g u r e  1 . 1  D i a g r a m  s h o w i n g  Ac h i l l e s  t e n d o n  a n a t o m y  ( l e f t )  a n d  c o l l a g e n  
f i b r e  h i e r a r c h y  f r o m  c o l l a g e n  t o  t e n d o n  u n i t  ( r i g h t ) .  
T h e  A c h i l l e s  t e n d o n  i s  c o n n e c t e d  t o  t h e  g a s t r o c n e m i u s  a n d  s o l e u s  m u s c l e s  
a n d  i n s e r t s  a t  t h e  c a l c a n e u s  ( l e f t ) .  T h e  c o l l a g e n  f i b r i l s  a r e  p a c k a g e d  i n t o  
p a r a l l e l  b u n d l e s  c a l l e d  c o l l a g e n  f i b r e s .  T h e s e  f i b r e s  a r e  g r o u p e d  t o g e t h e r  a n d  
c o v e r e d  b y  t h e  e n d o t e n o n  i n t o  f a s c i c l e s .  T h e s e  g r o u p s  o f  f a s c i c l e s  a r e  b o u n d  
b y  t h e  e p i t e n o n  i n t o  t h e  f u n c t i o n a l  t e n d o n  u n i t  ( I m a g e  a d a p t e d  f r o m  L i u  e t  a l  
2 0 0 8 ) [ 3 7 ] .  
 
1.2 Collagens and the Collagen fibril 
 
The term “collagen”  col lectively represents a  group of  29 dist inct structural  
macromolecules,  al l  of  which are formed as either hetero-  or homotrimers 
consist ing of three polypept ides known as α-chains.  Al l  col lagen molecules have at  
least one triple  hel ica l  protein domain which is  stabi l ized by a  repeating Gly-X-Y 
motif  where approximately 30% of the X and Y posit ions are occupied by prol ine 
and hydroxyproline amino acid res idues [38],  [39] .  These prol ine and 
hydroxyproline res idues have their hydrophobic side chains fac ing outward of the 
helix  whi le the glycine proton side chains face inwards to reduce steric  pressure,  
thereby stabi l iz ing the helix.  The f ibri l lar col lagens (such as types I ;  I I  and I I I)  are  
transcribed as procol lagens,  with a m i n o -  a n d  c a r b o x y - t e r m i n a l  p r o p e p t i d e s  
w h i c h  f l a n k  a n  u n i n t e r r u p t e d  t r i p l e  h e l i c a l  r e g i o n  ( F i g u r e  1 . 2 ) .  After 
processing within the endoplasmic reticulum and Golgi  apparatus and secretion into 
the ECM, these terminal g lobular domains  are cleaved by N- and C-procollagen 
proteinases,  leaving short non-hel ical  regions cal led telopeptides  which f lank the 
helix .  Pr ior to secretion, th e  p r o c o l l a g e n  p r o t e i n s  u n d e r g o  p o s t - t r a n s l a t i o n a l  
m o d i f i c a t i o n  b y  l y s y l  o x i d a s e s  t o  c r e a t e  a l d e h y d e  r e s i d u e s  w i t h i n  t h e  t r i p l e  












[ 3 9 ] .  T h e s e  m o d i f i e d  r e s i d u e s  t h e n  s p o n t a n e o u s l y  f o r m  i n t e r -  a n d  
i n t r a m o l e c u l a r  c r o s s - l i n k s  w i t h  o t h e r  l y s i n e ,  h y d r o x y l y s i n e  o r  a l d e h y d e  
r e s i d u e s  c a u s i n g  p o l y m e r i s a t i o n  o f  t h e  i n d i v i d u a l  c o l l a g e n  m o l e c u l e s  w h i c h  




F i g u r e  1 . 2  S c h e m a t i c  d i a g r a m  s h o w i n g  c o l l a g e n  f i b r i l  s y n t h e s i s  b y  
f i b r o b l a s t  c e l l .  
C o l l a g e n  p e p t i d e  c h a i n s  w i t h  t h e  G l y - X - Y  m o t i f  a s s e m b l e  t o  f o r m  s o l u b l e  
p r o c o l l a g e n  r i g h t - h a n d e d  t r i p l e  h e l i c e s  w i t h  N  a n d  C - t e r m i n a l  p r o p e p t i d e s .  N -  
a n d  C - t e r m i n a l  p r o p e p t i d e s  a r e  c l e a v e d  b y  N -  a n d  C - p r o c o l l a g e n  p r o t e i n a s e s  
r e s p e c t i v e l y  a n d  t h e  c o l l a g e n  m o l e c u l e  i s  t h e n  m o d i f i e d  b y  l ys y l  o x i d a s e  t o  
p r o d u c e  a l d e h yd e  r e s i d u e s  w h i c h  s p o n t a n e o u s l y  f r o m  d i v a l e n t  i n t e r -  a n d  
i n t r a m o l e c u l a r  c r o s s l i n k s ,  f o r m i n g  t h e  c o l l a g e n  f i b r i l .  I m a g e  a d a p t e d  f r o m  
K a d l e r  e t  a l .  ( 1 9 9 6 )  [ 4 0 ]  a n d  V a n  d e r  R e s t  a n d  G a r r o n e  ( 1 9 9 1 )  [ 3 9 ] .  
 
T h e  c o l l a g e n  f i b r i l  i s  t h e  s m a l l e s t  f u n c t i o n a l  u n i t  o f  t e n d o n s  a n d  l i g a m e n t s  
a n d  i s  c o m p o s e d  o f  t h e  f i b r i l l a r  c o l l a g e n s  t y p e s  I ,  I I I  a n d  V  a s  w e l l  a s  f i b r i l  













F A C I T s ,  s u c h  a s  c o l l a g e n  t y p e s  X I I  a n d  X I V ,  a s s o c i a t e  w i t h  t h e  e x t e r n a l  
s u r f a c e  o f  t h e  f i b r i l  a n d  r e g u l a t e  i t s  d i a m e t e r ,  i n t e r a c t  w i t h  t h e  s u r r o u n d i n g  
m a t r i x  a n d  a r r a n g e  f i b r i l s  i n t o  p a r a l l e l  c o n f o r m a t i o n s  [ 3 8 ] ,  [ 4 0 ] ,  [ 4 1 ] .  T h e  
F A C I T  c o l l a g e n s  h a v e  n u m e r o u s  f u n c t i o n s  w h i c h  i s  b e y o n d  t h e  s c o p e  o f  t h i s  
d i s s e r t a t i o n  a n d  h a s  b e e n  e x t e n s i v e l y  r e v i e w e d  b y  S h a w  a n d  O l s e n  ( 1 9 9 1 )  




F i g u r e  1 . 3  S c h e m a t i c  r e p r e e n t a t i o n  o f  c o l l a g e n  f i b r e  f r o m  t e n d o n  w i t h  
a s s o c i a t e d  c o l l a g e n  m o l e c u l e s  ( a d a p t e d  f r o m  C o l l i n s  a n d  R a l e i g h  ( 2 0 0 9 )  
[ 1 2 ] ) .   
T yp e  I  c o l l a g e n  ( h a t c h e d )  i s  c o m p o s e d  s o l e l y  o f  h e l i c a l  d o m a i n s  w h i l e  t yp e  V  
c o l l a g e n  h a s  2  h e l i c a l  d o m a i n s  w i t h i n  t h e  f i b r i l  a n d  1  g l o b u l a r  d o m a i n  w h i c h  
p r o t r u d e s  t o  t h e  e x t e r i o r .  F A C I T  c o l l a g e n s  h a v e  a  s h o r t  h e l i c a l  d o m a i n  a n d  
i n t e r a c t  w i t h  t h e  e x t e r i o r  s u r f a c e  o f  t h e  f i b r i l  
 
 
1.2.1 Type I collagen 
 
T y p e  I  c o l l a g e n ,  t h e  m a j o r  c o m p o n e n t  o f  t e n d o n s  i s  e n c o d e d  b y  t h e  C O L 1 A 1  
a n d  C O L 1 A 2  g e n e s  w h i c h  e n c o d e  t h e  α 1 ( I )  a n d  α 2 ( I )  c h a i n s  r e s p e c t i v e l y .  T h e  
p r e d o m i n a n t  f o r m  o f  t y p e  I  c o l l a g e n  i n  t e n d o n s  i s  a  h e t e r o t r i m e r  c o m p o s e d  
o f  t w o  α 1 ( I )  a n d  o n e  α 2 ( I )  c h a i n s .  T h e  o r i e n t a t i o n  o f  t h e s e  f i b r i l s  g i v e s  t h e  












n o t e d  f o r  t e n d o n s  e x p o s e d  m a i n l y  t o  t e n s i l e  a n d  c o m p r e s s i v e  f o r c e s  a n d  a  
m u l t i d i r e c t i o n a l  a r r a n g e m e n t  n o t e d  i n  t h e  s m a l l  i n t e s t i n e  [ 4 3 ] .  
 
1.2.2 Type III collagen 
 
T y p e  I I I  c o l l a g e n  i s  a  q u a n t i t a t i v e l y  m i n o r  c o l l a g e n  w h i c h  i s  e x p r e s s e d  a s  a  
h o m o t r i m e r  c o m p o s e d  o f  t h r e e  α 1 ( I I I )  c h a i n s  e n c o d e d  b y  t h e  C O L 3 A 1  g e n e .  
T y p e  I I I  c o l l a g e n  e x p r e s s i o n  i s  m a r k e d l y  i n c r e a s e d  a t  t h e  s i t e  o f  t e n d o n  
r u p t u r e  a n d  i n  h e a l i n g  t e n d o n s  [ 4 4 ] .  I n  v i t r o  w o u n d i n g  e x p e r i m e n t s  s h o w  
t h a t  w o u n d e d  t e n o c y t e s  e x p r e s s e d  i n c r e a s e d  a m o u n t s  o f  t y p e  I I I  c o l l a g e n  a s  
o p p o s e d  t o  t y p e  I  [ 4 5 ] .  I t  i s  b e l i e v e d  t h a t  i n c r e a s e d  e x p r e s s i o n  o f  t y p e  I I I  
c o l l a g e n  i n  t e n d o n s  d e c r e a s e s  c o l l a g e n  f i b r i l  s t r e n g t h  a n d ,  o v e r  t i m e ,  
i n c r e a s e s  s u s c e p t i b i l i t y  t o  t e n d o n  r u p t u r e  [ 9 ] ,  [ 4 4 ] . 
 
1.2.3 Type V collagen 
 
A s  t y p e  V  c o l l a g e n  i s  t h e  f o c u s  o f  t h i s  d i s s e r t a t i o n ,  i t  w i l l  t h e r e f o r e  b e  
d i s c u s s e d  i n  g r e a t e r  d e t a i l .  I t  i s  a  q u a n t i t a t i v e l y  m i n o r  f i b r i l l a r  c o l l a g e n  m o s t  
n o t a b l y  p r e s e n t  i n  t e n d o n s ,  l i g a m e n t s ,  s k i n  a n d  t h e  c o r n e a  w i t h  i t s  
c o m p o n e n t  c h a i n s  b e i n g  e n c o d e d  b y  t h e  C O L 5 A 1 ,  C O L 5 A 2  a n d  C O L 5 A 3  g e n e s .  
T h e  m a j o r  i s o f o r m  w h i c h  i s  p r e s e n t  i n  t e n d o n s  h o w e v e r ,  i s  c o m p o s e d  o f  t w o  
α 1 ( V )  c h a i n s  a n d  o n e  α 2 ( V )  c h a i n .  T y p e  V  c o l l a g e n  h a s  b e e n  s h o w n  t o  p l a y  a  
v i t a l  r o l e  i n  t h e  i n i t i a t i o n  o f  c o l l a g e n  f i b r i l l o g e n e s i s  ( f i b r i l  c r e a t i o n ) ,  f o r m i n g  
h e t e r o t y p i c  f i b r i l s  t o g e t h e r  w i t h  c o l l a g e n  t y p e s  I  a n d  I I I  [ 4 6 ] .  A l t h o u g h  t y p e  
V  c o l l a g e n  i s  p r e s e n t  i n  r e l a t i v e l y  l o w  q u a n t i t i e s  c o m p a r e d  t o  c o l l a g e n  t y p e  
I ,  t h e r e  i s  s i g n i f i c a n t  e v i d e n c e  t o  s u g g e s t  t h a t  i t  h a s  a n  i m p o r t a n t  f u n c t i o n  
i n  t h e  f o r m a t i o n  o f  c o n n e c t i v e  t i s s u e  [ 4 7 ] .  
 
T y p e  V  c o l l a g e n ,  u n l i k e  m o s t  f i b r i l l a r  c o l l a g e n s ,  m a i n t a i n s  i t s  N - t e r m i n a l  
g l o b u l a r  p e p t i d e  d o m a i n .  D u r i n g  f i b r i l l o g e n e s i s ,  t h e  t y p e  V  m o l e c u l e s  
a s s o c i a t e s  w i t h  t y p e  I  m o l e c u l e s  i n  s u c h  a  w a y  t h a t  t h e  g l o b u l a r  d o m a i n  o f  
t y p e  V  p r o t r u d e s  o u t w a r d s  o f  t h e  f i b r i l  l i m i t i n g  l a t e r a l  e x p a n s i o n  ( F i g u r e  1 . 3 )  
[ 4 0 ] .  I n  a n  e x p e r i m e n t  c o n d u c t e d  b y  B i r k  e t  a l .  ( 1 9 9 0 )  t y p e  I  a n d  V  c o l l a g e n  
m o l e c u l e s  w e r e  e x t r a c t e d  f r o m  c h i c k  e m b r y o s  a n d  p u r i f i e d  [ 4 6 ] .  T h e s e  












a n d  t h e  d i a m e t e r s  o f  t h e  r e s u l t i n g  f i b r i l s  w e r e  m e a s u r e d  u s i n g  t r a n s m i s s i o n  
e l e c t r o n  m i c r o s c o p y .  T h e  a u t h o r s  c o n c l u d e d  t h a t  t h a t  a n  i n c r e a s e d  r a t i o  o f  
t y p e  V  c o l l a g e n  t o  c o l l a g e n  t y p e  I  s i g n i f i c a n t l y  r e d u c e s  f i b r i l  d i a m e t e r .  I n  t h e  
c o r n e a  o f  t h e  e y e  w h e r e  v e r y  t h i n  f i b r i l s  a r e  r e q u i r e d  t o  a l l o w  f o r  t h e  
t r a n s p a r e n c y  o f  t h e  o r g a n ,  t h e  h e t e r o t y p i c  t y p e  I / V  b u n d l e s  h a v e  i n c r e a s e d  
t y p e  V  c o n t e n t  r e l a t i v e  t o  t e n d o n s  a n d  o t h e r  n o n - c a r t i l a g i n o u s  c o n n e c t i v e  
t i s s u e s  [ 4 8 ] .  
 
I t  h a s  p r e v i o u s l y  b e e n  s h o w n  t h a t  t e n d o n s  w i t h  f i b r i l s  w i t h  l a r g e  d i a m e t e r s  
a r e  m o r e  r e s i s t a n t  t o  m e c h a n i c a l  d a m a g e  a n d  L u  e t  a l .  ( 2 0 1 1 )  a t t e m p t e d  t o  
e n g i n e e r  C O L 5 A 1 -  a n d  C O L 5 A 2 -  s i R N A  p r o d u c i n g  t e n o c y t e s  i n  a  S p r a g u e -
D a w l e y  r a t  m o d e l  [ 4 9 ] ,  [ 5 0 ] .  T h e s e  e n g i n e e r e d  t e n o c y t e s  w e r e  h y p o t h e s i s e d  
t o  p r o d u c e  m o r e  r o b u s t  c o l l a g e n  f i b r i l s  a n d  i n j u r y  r e s i s t a n t  t e n d o n s .  T h e  
e n g i n e e r e d  t e n o c y t e s  d i d  i n d e e d  h a v e  s i g n i f i c a n t l y  r e d u c e d  C O L 5 A 1  a n d  
C O L 5 A 2  e x p r e s s i o n .  T h i s  r e d u c t i o n  h o w e v e r ,  h a d  d e l e t e r i o u s  e f f e c t s  o n  o t h e r  
m a t r i x  c o m p o n e n t s  s u c h  a s  C O L 3 A 1 ,  C O L 1 1 A 1 ,  a n d  t h e  p r o t e o g l y c a n  d e c o r i n  
w i t h  t h e  r e s u l t i n g  C O L 5 A 1 - s i R N A  p r o d u c i n g  t e n d o n s  w i t h  a b n o r m a l  f i b r i l  
m o r p h o l o g y .  
 
I t  a p p e a r s  t h a t  t h e r e  i s  l i m i t e d  b i o l o g i c a l  r e d u n d a n c y  i n  t h e  f o r m a t i o n  o f  t h e  
c o l l a g e n  f i b r i l .  M u t a t i o n s  w i t h i n  m a n y  o f  t h e  g e n e s  w h i c h  e n c o d e  f o r  
c o l l a g e n s  s u c h  a s  C O L 1 A 1 ,  C O L 1 A 2 ,  C O L 3 A 1 ,  C O L 5 A 1  a n d  C O L 5 A 2  c a u s e  s e v e r e  
c o n n e c t i v e  t i s s u e  d i s o r d e r s  s u c h  a s  o s t e o g e n e s i s  i m p e r f e c t a  a n d  E h l e r s -
D a n l o s  s y n d r o m e  ( E D S ) .  
 
1.3 Ehlers-Danlos syndrome 
 
E D S  i s  a  h e t e r o g e n e o u s  s o f t  t i s s u e  d i s o r d e r  i n  w h i c h  p a t i e n t s  e x h i b i t  j o i n t  
h y p e r m o b i l i t y ,  s k i n  h y p e r - e x t e n s i b i l i t y  a n d  u n u s u a l  s k i n  s c a r r i n g  [ 5 1 ] .  T h e  
c l a s s i c a l  f o r m  o f  E D S  a r i s e s  f r o m  d e l e t e r i o u s  m u t a t i o n s  i n  t h e  g e n e s  w h i c h  
e n c o d e  t h e  f i b r i l l a r  c o l l a g e n  w i t h  m o r e  t h a n  4 0 %  o f  c l a s s i c a l  E D S  a r i s i n g  f r o m  
h a p l o i n s u f f i c i e n c y  o f  t h e  C O L 5 A 1  g e n e  a l o n e  [ 5 2 ] .  W h i l e  C o l 5 a 1  m i c e  d i e  i n  
u t e r o  a t  e m b r y o n i c  d a y  1 0 . 5  d u e  t o  c a r d i a c  f a i l u r e  [ 4 7 ] ,  [ 5 3 ] ,  e x p e r i m e n t s  












m i c e  ( c o l 5 a 1 + / - )  s u r v i v e  i n f a n c y  b u t  s h o w  s y m p t o m s  c h a r a c t e r i s t i c  o f  E D S  
s u c h  a s  s k i n  h y p e r - e x t e n s i b i l i t y  [ 5 4 ] .  
 
T h e  f i b r i l  a r c h i t e c t u r e  o f  t h e  t e n d o n s  o f  c o l 5 a 1 + / -  m i c e  w a s  h o w e v e r  
c o m p a r a b l e  t o  t h e  w i l d  t y p e  f i b r i l  a r c h i t e c t u r e .  T o  i n v e s t i g a t e  t h i s  p r o t e c t i o n  
o f  t h e  t e n d o n  f i b r i l  m o r p h o l o g y ,  t h e  a u t h o r s  i n t r o d u c e d  a  m u t a t i o n  i n  t h e  
s t r u c t u r a l l y  s i m i l a r  t y p e  X I  c o l l a g e n  g e n e  i n  c o l 5 a 1 + / -  m i c e .  T h e  f i b r i l s  o f  t h e  
r e s u l t i n g  m i c e  s h o w e d  a  d i s r u p t e d  a r c h i t e c t u r e  i n  t e n d o n s .  T y p e  X I  c o l l a g e n  
p r e d o m i n a n t l y  f o r m s  h e t e r o t y p i c  f i b r i l s  w i t h  t y p e  I I  c o l l a g e n  i n  c a r t i l a g i n o u s  
t i s s u e s  [ 5 5 ] .  T o  i n v e s t i g a t e  w h e t h e r  t y p e  X I  c o l l a g e n  w a s  p r e s e n t  i n  t h e  a d u l t  
m o u s e  t e n d o n ,  W e n s t r u p  e t  a l .  ( 2 0 1 1 )  i n v e s t i g a t e d  t h e  e x p r e s s i o n  p a t t e r n s  
o f  c o l l a g e n  t y p e s  V  a n d  X I  i n  a  m u r i n e  m o d e l  [ 5 4 ] .  T h e  a u t h o r s  o b s e r v e d  t h a t  
r e l a t i v e l y  h i g h  l e v e l s  o f  c o l 1 1 a 1 ,  c o l 1 1 a 2  a n d  c o l 1 1 a 3  a r e  e x p r e s s e d  i n  t h e  
d e v e l o p i n g  t e n d o n  ( e m b r y o n i c  d a y  1 8 )  t o g e t h e r  w i t h  c o l 5 a 1  a n d  c o l 5 a 2 .  T h i s  
e x p r e s s i o n  h o w e v e r ,  d e c r e a s e s  a s  t h e  t e n d o n  m a t u r e s  w i t h  b a s a l  l e v e l s  
a t t a i n e d  a t  p o s t - n a t a l  d a y  3 0 .  T h i s  d a t a  i n d i c a t e s  a  c o - o p e r a t i v e  e f f e c t  o f  
c o l l a g e n  t y p e s  V  a n d  X I  d u r i n g  t e n d o n  d e v e l o p m e n t  b u t  t h i s  i n t e r a c t i o n  m a y  
b e  a b s e n t  d u r i n g  m a t u r e  t e n d o n  h e a l i n g .  T h e  a b s e n c e  o f  t y p e  X I  c o l l a g e n  
e x p r e s s i o n  w i t h  i n c r e a s e d  e x p r e s s i o n  o f  t h e  f i b r i l  w e a k e n i n g  t y p e  I I I  c o l l a g e n  
m a y  c a u s e  a  r e d u c t i o n  i n  t h e  s t r e n g t h  o f  t h e  r e c o v e r e d  t i s s u e ,  i n c r e a s i n g  t h e  
r i s k  o f  t e n d o n  p a t h o l o g y .  
 
1.4 Pathology of Achilles tendinopathy 
 
M e c h a n i c a l  l o a d i n g  i s  g e n e r a l l y  a g r e e d  t o  b e  t h e  p r i m a r y  s t i m u l u s  t h a t  
c a u s e s  A c h i l l e s  t e n d o n  i n j u r i e s  a n d  s e v e r a l  t h e o r i e s  h a v e  b e e n  p r o p o s e d  t o  
e x p l a i n  h o w  i t  c a u s e s  d e g e n e r a t i o n  o f  t h e  t e n d o n  [ 3 1 ] .  T h e s e  i n c l u d e  ( i )  t h e  
m e c h a n i c a l  t h e o r y  w h i c h  s t a t e s  t h a t  r e p e a t e d  l o a d i n g  o f  t h e  t e n d o n  w i t h i n  
t h e  p h y s i o l o g i c a l  r a n g e  e v e n t u a l l y  l e a d s  t o  m a t r i x  d e g e n e r a t i o n  ( r e v i e w e d  
b y  A r c h a m b a u l t  e t  a l  ( 1 9 9 5 )  [ 5 6 ] )  a n d  C o o k  a n d  P u r d a m  ( 2 0 1 2 )  [ 5 7 ] ) ,  ( i i )  t h e  
v a s c u l a r  t h e o r y  w h i c h  s t a t e s  t h a t  c e r t a i n  r e g i o n s  o f  t e n d o n s  a r e  s u s c e p t i b l e  
t o  v a s c u l a r  c o m p r o m i s e  a n d  n e o v a s c u l a r i s a t i o n  a n d  i n a p p r o p r i a t e  
v a s c u l a r i s a t i o n  o f  t h e  t e n d o n  m a y  c a u s e  t e n d i n o p a t h y  ( r e v i e w e d  b y  P u f e  e t  
a l .  ( 2 0 0 5 )  [ 5 8 ] )  a n d  ( i i i )  t h e  n e u r a l  t h e o r y  w h i c h  s t a t e s  t h a t  n e u r a l  c e l l s  












s u c h  a s  s u b s t a n c e  P  a n d  c a l c i t o n i n  g e n e  r e l a t e d  p e p t i d e  w h i c h  a f f e c t  m a s t  
c e l l s  w i t h i n  t h e  t e n d o n  a n d  c a u s e  d e g e n e r a t i o n  o f  t h e  f i b r i l s  ( r e v i e w e d  b y  
A b a t e  e t  a l .  ( 2 0 0 9 )  [ 5 9 ] ) .  A l l  t h r e e  t h e o r i e s  a r e  p r o p o s e d  t o  r e s u l t  i n  t h e  
d e g e n e r a t i o n  o f  t h e  t e n d o n  a n d  d i s r u p t i o n  o f  t h e  c o l l a g e n  f i b r i l s .   
 
U s i n g  b o t h  c l i n i c a l  a n d  b i o c h e m i c a l  d a t a ,  s e v e r a l  i n j u r y  m o d e l s  h a v e  b e e n  
p r o p o s e d ,  o f  w h i c h  t w o ,  t h e  “ i c e b e r g ”  a n d  “ c o n t i n u u m  o f  t e n d o n  p a t h o l o g y ”  
m o d e l s ,  w i l l  b e  r e v i e w e d  h e r e .  T h e  “ i c e b e r g  t h e o r y ”  i n j u r y  m o d e l  p r o p o s e d  
b y  F r e d b e r g  a n d  S t e n g a a r d - P e d e r s o n ,  s t a t e s  t h a t  r e p e a t e d  h e a v y  l o a d i n g  
p r o d u c e s  p a t h o l o g i c a l  c h a n g e s  t o  t h e  e x t r a c e l l u l a r  m a t r i x  o r  c e l l u l a r  
c o m p o n e n t  o f  t h e  t e n d o n  [ 6 0 ] .  T h i s  p r o g r e s s i v e  d a m a g e  l e a d s  t o  c h a n g e s  i n  
t h e  m i c r o -  a n d  m a c r o s t r u c t u r e s  o f  t h e  t e n d o n  a n d  c a u s e s  c o l l a g e n  f i b r e s  t o  
s l i d e  p a s t  o n e  a n o t h e r  c a u s i n g  d e n a t u r a t i o n  a n d  i n d u c i n g  i n f l a m m a t i o n ,  
o e d e m a  a n d  p a i n .  I n  a d d i t i o n ,  t h e  a u t h o r s  p r o p o s e d  t h a t  c y t o k i n e s  a n d  p r o -
i n f l a m m a t o r y  m o l e c u l e s  s u c h  a s  p r o s t a g l a n d i n  E 2  ( P G E 2 )  s e c r e t e d  f r o m  
i n f l a m m a t o r y  c e l l s  w i t h i n  t h e  t e n d o n  a n d  s u r r o u n d i n g  t i s s u e s  d u r i n g  l o a d i n g  
e x e r c i s e  c o n t r i b u t e  s i g n i f i c a n t l y  t o  t e n d o n  d e g e n e r a t i o n  [ 6 1 ] .   
 
A c c o r d i n g  t o  t h e  “ i c e b e r g  t h e o r y ”  i f  a n  i n d i v i d u a l  c o n t i n u e s  t o  o v e r l o a d  t h e  
t e n d o n  w i t h o u t  s u f f i c i e n t  p e r i o d s  o f  r e s t ,  t h e  m i c r o t r a u m a  a c c u m u l a t e s  a n d  
t h e  t e n d o n  d e v e l o p s  a s y m p t o m a t i c  t e n d o n  p a t h o l o g y .  I f  t h i s  i n d i v i d u a l  
c o n t i n u e s  t o  e x p o s e  t h e  t e n d o n  i n  q u e s t i o n  t o  e x c e s s i v e  l o a d i n g ,  t h e  t e n d o n  
a b n o r m a l i t i e s  a c c u m u l a t e  t o  t h e  p o i n t  w h e r e  s y m p t o m s  o c c u r  a n d  t h i s  i s  
k n o w n  a s  t h e  “ t i p  o f  t h e  i c e b e r g ”  ( F i g u r e  1 . 4 ) .  T h e  s t r e n g t h  o f  t h i s  m o d e l  i s  
t h a t  i t  e x p l a i n s  r e c u r r e n t  t e n d i n o p a t h y ,  a s  i n d i v i d u a l s  w h o  b e c o m e  
s y m p t o m a t i c  m a y  t e m p o r a r i l y  l o w e r  t h e  l o a d i n g  o f  t h e  t e n d o n  u n t i l  
s y m p t o m s  s u b s i d e  b u t  n o t  l o n g  e n o u g h  f o r  t h e  t e n d o n  t o  r e a c h  h o m e o s t a s i s  
a n d ,  a s  s u c h ,  w i l l  f l u c t u a t e  b e t w e e n  s y m p t o m a t i c  a n d  a s y m p t o m a t i c  s t a t e s .  
 
A c c o r d i n g  t o  t h e  m o d e l  o f  t e n d o n  p a t h o l o g y  p r o p o s e d  b y  C o o k  a n d  P u r d a m  
( 2 0 0 9 )  ( F i g u r e  1 . 5 ) ,  t e n d o n  p a t h o l o g y  o c c u r s  a s  a  c o n t i n u u m  w h i c h  m a y  b e  
d i v i d e d  i n t o  t h r e e  m a j o r  s t a g e s .  T h e  f i r s t  s t a g e  i s  r e a c t i v e  t e n d i n o p a t h y ,  i n  
w h i c h  t h e r e  i s  a  n o n - i n f l a m m a t o r y  p r o l i f e r a t i v e  r e s p o n s e  w i t h i n  t h e  c e l l s  o f  












o v e r l o a d  o f  t h e  t e n d o n  a n d  o f t e n  r e s u l t s  i n  t h i c k e n i n g  o f  t h e  o v e r l o a d e d  
p o r t i o n  o f  t h e  t e n d o n .  H i s t o l o g i c a l l y ,  t h e  m a j o r  f e a t u r e s  o f  t h i s  s t a g e  a r e  
t h e  r a p i d  i n c r e a s e  i n  l a r g e ,  w a t e r  s e q u e s t e r i n g  p r o t e o g l y c a n s  s u c h  a s  
a g g r e c a n .  T h i s  s e q u e s t r a t i o n  o f  w a t e r  i s  b e l i e v e d  t o  t h i c k e n  t h e  o v e r l o a d e d  
p o r t i o n  o f  t h e  t e n d o n  b y  i n c r e a s i n g  t h e  c r o s s - s e c t i o n a l  a r e a  a n d  d e c r e a s i n g  
t h e  f o r c e  p e r  u n i t  a r e a .  T h e  i n t e g r i t y  o f  t h e  c o l l a g e n  m o l e c u l e s  i s  m o s t l y  
m a i n t a i n e d  a t  t h i s  s t a g e  a n d  t h e  t e n d o n  h a s  t h e  p o t e n t i a l  t o  r e v e r t  t o  i t s  
n o r m a l  s t a t e  i f  t h e  l o a d  i s  r e d u c e d  o r  t h e r e  i s  s u f f i c i e n t  p e r i o d  b e t w e e n  




F i g u r e  1 . 4  S c h e m a t i c  d i a g r a m  o f  t h e  I c e b e r g  t h e o r y  s h o w i n g  
a s y m p t o m a t i c  t e n d o n  p a t h o l o g y  b e f o r e  t h e  o n s e t  o f  s y m p t o m a t i c  
t e n d i n o p a t h y .  Ad a p t e d  f r o m  F r e d b e r g  a n d  S t e n g a a r d - P e d e r s o n  ( 2 0 0 8 )  [ 6 0 ]  
 
 
T h e  s e c o n d  s t a g e  i s  t e n d o n  d i s r e p a i r  w h e r e  t h e r e  i s  a n  o v e r a l l  i n c r e a s e  i n  
t h e  t o t a l  n u m b e r  o f  c e l l s  w i t h i n  t h e  t e n d o n  i n c l u d i n g  c h o n d r o c y t e s  a n d  
m y o f i b r o b l a s t s ,  w h i c h  i n c r e a s e  t h e  p r o d u c t i o n  o f  c o l l a g e n  a n d  
p r o t e o g l y c a n s .  T h e  i n c r e a s e d  p r o t e o g l y c a n - r i c h  g r o u n d  s u b s t a n c e  c a u s e s  
s e p a r a t i o n  o f  t h e  c o l l a g e n  s t r a n d s  a n d  d i s r u p t i o n  o f  t h e  m a t r i x .  T h i s  s t a g e  i s  
h a r d  t o  c l i n i c a l l y  d i s t i n g u i s h  b u t  t h e  m a j o r  s y m p t o m s  a r e  t h i c k e n i n g  o f  t h e  
t e n d o n  a n d  f o c a l  s t r u c t u r a l  c h a n g e s ,  w h i c h  a r e  s o m e t i m e s  a c c o m p a n i e d  b y  
i n c r e a s e d  v a s c u l a r i t y .  P a r t i a l  r e v e r s a l  o f  s y m p t o m s  i s  p o s s i b l e  w i t h  p r o p e r  














F i g u r e  1 . 5  S c h e m a t i c  d i a g r a m  o f  t h e  p a t h o l o g i c a l  c o n t i n u u m  o f  
t e n d i n o p a t h y  s h o w i n g  t r a n s i t i o n  f r o m  h e a l t h y  t e n d o n  t o  d e g e n e r a t i v e  
t e n d i n o p a t h y  a l o n g  w i t h  t h e  t e n d o n ’ s  a d a p t i v e  r e s p o n s e  w h e n  e x c e s s i v e  




T h e  f i n a l  s t a g e  i s  d e g e n e r a t i v e  t e n d i n o p a t h y ,  w h e n  t h e  t e n d o n  c o n s i s t s  o f  
h e t e r o g e n e o u s  r e g i o n s  o f  d i s r u p t e d  m a t r i x  a n d  h e a l t h y  t e n d o n .  
H i s t o l o g i c a l l y ,  t h e r e  a r e  l a r g e  a r e a s  o f  a c e l l u l a r i t y  d u e  t o  a p o p t o s i s  a n d  l a r g e  
p o r t i o n s  o f  t h e  m a t r i x  a r e  d i s o r d e r e d .  T h e  m o s t  s t r i k i n g  f e a t u r e  h o w e v e r ,  i s  
t h e  d i s r u p t i o n  o f  t h e  c o l l a g e n  f i b r i l s .  I t  h a s  b e e n  p r o p o s e d  t h a t  t h e  n a t u r e  
o f  t h e  c o l l a g e n  f i b r i l s  d i r e c t l y  a f f e c t  t h e  m e c h a n i c a l  p r o p e r t i e s  o f  t h e  t e n d o n  
a n d  i t s  s u s c e p t i b i l i t y  t o  i n j u r y .  A l t h o u g h  s e v e r a l  m o l e c u l a r  p r o c e s s e s  a r e  












p r o p o s e d  t h a t  t h e  n a t u r e  o f  t h e  c o l l a g e n  f i b r i l s  m a y  d i r e c t l y  a f f e c t  t h e  
m e c h a n i c a l  p r o p e r t i e s  o f  t h e  t e n d o n  a n d  i t s  s u s c e p t i b i l i t y  t o  i n j u r y  [ 6 3 ] .  
R e c e n t  e v i d e n c e  h a s  s u g g e s t e d  t h a t  r e g u l a t i o n  o f  t h e  3 ’ - u n t r a n s l a t e d  r e g i o n  
( 3 ’ - U T R )  o f  t h e  C O L 5 A 1  g e n e  m a y  p l a y  a n  i m p o r t a n t  r o l e  i n  r e g u l a t i n g  t h e  
m e c h a n i c a l  p r o p e r t i e s  o f  t e n d o n s  [ 6 4 ] .  
 
1.5 3’-UTR regulatory elements 
 
S e v e r a l  d i f f e r e n t  r e g u l a t o r y  m e c h a n i s m s  m a y  b e  p r e s e n t  w i t h i n  t h e  3 ’ - U T R  
i n c l u d i n g  p o l y a d e n y l a t i o n  ( p o l y ( A ) )  s i g n a l s ,  R N A - b i n d i n g  p r o t e i n  a n d  m i R N A  
b i n d i n g  s i t e s .  T h e s e  m e c h a n i s m s  a f f e c t  p r o t e i n  l e v e l s  b y  i n f l u e n c i n g  t h e  
s p e e d  o f  t r a n s l a t i o n ,  t h e  r a t e  o f  m R N A  d e c a y  a n d / o r  a f f e c t i n g  t h e  a b i l i t y  o f  
t h e  r i b o s o m e  t r a n s l a t i o n  c o m p l e x  t o  t r a n s l a t e  t h e  g e n e  t r a n s c r i p t s  w i t h  h i g h  
f i d e l i t y  [ 6 5 ] ,  [ 6 6 ] ,  [ 6 7 ] ,  [ 6 8 ] .  
 
1.5.1 Poly(A) signals 
 
T h e  p o l y ( A )  s i g n a l  i s  a  h e x a n u c l e o t i d e  s e q u e n c e  A A U A A A ,  w h i c h  i s  f o l l o w e d  
b y  a  G U  r i c h  r e g i o n  2 0 - 4 0  b a s e s  d o w n s t r e a m  [ 6 9 ] .  T o g e t h e r ,  t h e s e  t w o  
r e g i o n s  d e t e r m i n e  t h e  s i t e  o f  p r e - m R N A  c l e a v a g e  a n d  t h e  p o s i t i o n  a t  w h i c h  
t h e  a d e n o s i n e  p o l y m e r  i s  i n i t i a t e d .  T h e  s p e e d  a t  w h i c h  t h e  p o l y a d e n o s i n e  
t a i l  d e g r a d e s  i n f l u e n c e s  t h e  h a l f - l i f e  o f  t h e  t r a n s c r i p t  b y  a  p r o c e s s  o f  
d e a d e n y l a t i o n - d e p e n d a n t  m R N A  d e c a y  [ 7 0 ] .  T h e  t r a n s c r i p t  i s  d e - a d e n y l a t e d  
a n d  d e c a p p e d  a t  t h e  5 ’  e n d  b e f o r e  d e g r a d a t i o n  b y  e n d o -  a n d  e x o n u c l e a s e s  
[ 6 6 ] .  T h e  C O L 5 A 1  g e n e  h a s  3  p u t a t i v e  p o l y ( A )  s i g n a l s  w i t h i n  i t s  3 ’ - U T R .  
L a g u e t t e  e t  a l .  ( 2 0 1 1 )  g e n e r a t e d  a  C O L 5 A 1  3 - U T R  l u c i f e r a s e  c o n s t r u c t  i n  
w h i c h  2  o f  t h e  p o l y ( A )  s i g n a l s  w e r e  r e m o v e d  b y  d e l e t i n g  t h e  f i n a l  4 7 7  b p  o f  
t h e  C O L 5 A 1  3 ’ - U T R  a n d  f o u n d  t h a t ,  a l t h o u g h  t h e r e  w a s  a n  o v e r a l l  i n c r e a s e  i n  
m R N A  s t a b i l i t y  i n  b o t h  t h e  C -  a n d  T - a l l e l i c  f o r m s ,  t h e  T - a l l e l e  s t i l l  s h o w e d  
i n c r e a s e d  m R N A  s t a b i l i t y  o v e r  i t  C - a l l e l e  c o u n t e r p a r t  [ 6 4 ] .  T h i s  i n d i c a t e s  t h a t  
t h e  w h i l e  t h e  p o l y ( A )  s i g n a l s  m a y  b e  i m p o r t a n t  i n  t h e  r e g u l a t i o n  o f  t h e  
C O L 5 A 1  3 ’ - U T R ,  t h e y  d o  n o t  p l a y  a  r o l e  i n  t h e  d i f f e r e n c e  i n  m R N A  s t a b i l i t y  
o b s e r v e d  b e t w e e n  t h e  C -  a n d  T - a l l e l i c  f o r m s .  
 













R N A - b i n d i n g  p r o t e i n s  ( R B P s )  a r e  p r o t e i n s  w h i c h  b i n d  t o  s i n g l e -  o r  d o u b l e -
s t r a n d e d  R N A  t h r o u g h  a  R N A  r e c o g n i t i o n  m o t i f  [ 7 1 ] .  T h i s  g r o u p  o f  p r o t e i n s  
h a v e  a  v a r i e t y  o f  f u n c t i o n s  i n c l u d i n g  p r o t e c t i o n  f r o m  d s R N A - v i r a l  i n f e c t i o n ,  
m R N A  t r a n s p o r t ,  R N A  s p l i c i n g  a n d  i n f l u e n c i n g  m R N A  t r a n s l a t i o n  [ 7 2 ] ,  [ 7 3 ] ,  
[ 7 4 ] ,  [ 7 5 ] ,  [ 7 6 ] ,  [ 7 7 ] ,  [ 7 8 ] .  T h e r e  i s ,  t o  d a t e ,  n o  l i t e r a t u r e  a v a i l a b l e  o n  t h e  




M i c r o - r i b o n u c l e i c  a c i d s  ( m i R N A s )  a r e  s h o r t  n o n - c o d i n g  R N A s  b e t w e e n  1 8  a n d  
2 4  n u c l e o t i d e s  ( n t )  l o n g  t h a t  a r e  c a p a b l e  o f  r e p r e s s i n g  p r o t e i n  s y n t h e s i s  a t  
t h e  m R N A  l e v e l  [ 7 9 ] .  T h i s  i s  a c h i e v e d  b y  m i R N A s  m o d u l a t i n g  t h e  s t a b i l i t y  
a n d / o r  t h e  t r a n s l a t i o n a l  e f f i c i e n c y  o f  t a r g e t  m R N A s  b y  b i n d i n g  t o  t h e i r  3 ’ -
U T R  [ 8 0 ] .  T h e  p r o d u c t  o f  a  s i n g l e  m i R N A  g e n e  i s  c a p a b l e  o f  r e g u l a t i n g  
h u n d r e d s  o f  d i f f e r e n t  m e s s e n g e r  R N A s  [ 8 1 ] .  F u r t h e r m o r e ,  t h e  m e s s e n g e r  
R N A s  m a y  h a v e  b i n d i n g  s i t e s  f o r  s e v e r a l  m i R N A s  i n  t h e i r  r e s p e c t i v e  3 ’ - U T R s .  
T h i s  l e a d s  t o  a  c o m p l e x  r e g u l a t o r y  s y s t e m  w i t h  b u i l t - i n  r e d u n d a n c y  a n d  f e e d -
f o r w a r d  m e c h a n i s m s  [ 8 2 ] .  
 
M i c r o R N A s  a c t  t o g e t h e r  w i t h  a  g r o u p  o f  p r o t e i n s  c a l l e d  t h e  R N A - i n d u c e d  
s i l e n c i n g  ( R I S )  c o m p l e x  t o  c a r r y  o u t  t h e i r  f u n c t i o n .  A r g o n a u t e  I I ,  t h e  
e n d o r i b o n u c l e a s e  p r e s e n t  i n  t h i s  c o m p l e x ,  i s  r e s p o n s i b l e  f o r  m R N A  c l e a v a g e  
[ 7 5 ] ,  [ 8 3 ] .  I t s  e n z y m a t i c  a c t i v i t y  i s  d e p e n d e n t  o n  t h e  m i R N A  h a v i n g  a  h i g h  
l e v e l  o f  c o m p l e m e n t a r i t y  t o  i t s  t a r g e t  s e q u e n c e .  m R N A  c l e a v a g e  b y  p e r f e c t  
b a s e  p a i r  c o m p l e m e n t a r i t y  i s  r a r e  i n  h u m a n s  b u t  i s  t h e  d o m i n a n t  f o r m  o f  
m R N A  r e g u l a t i o n  i n  p l a n t s  [ 8 4 ] .  I f  t h e  c o m p l e m e n t a r i t y  b e t w e e n  t h e  m i R N A  
a n d  i t s  m R N A  t a r g e t  i s  i n s u f f i c i e n t  t o  i n d u c e  m R N A  c l e a v a g e ,  s e c o n d a r y  
r e p r e s s i o n  m e c h a n i s m s  s u c h  a s  s i l e n c i n g  c o m p l e x - i n d u c e d  t r a n s l a t i o n  
i n t e r f e r e n c e  a n d  m i R N A - d i r e c t e d  d e - a d e n y l a t i o n  m a y  c o m e  i n t o  e f f e c t  [ 6 5 ] ,  
[ 8 5 ] .   
 
T h e  f i r s t  r e p r e s s i o n  m e c h a n i s m  r e l i e s  o n  t h e  s t e r i c  i n t e r f e r e n c e  b e t w e e n  t h e  
m u l t i p l e  s i l e n c i n g  c o m p l e x e s  b o u n d  t o  t h e  3 ’ - U T R  a n d  t h e  R N A  p o l y m e r a s e  I I  












i n c r e a s e d  t r u n c a t e d  n o n - f u n c t i o n a l  p r o d u c t  f o r m a t i o n .  T h e  s e c o n d  
r e p r e s s i o n  m e c h a n i s m ,  h y p o t h e s i z e d  t o  b e  t h e  d o m i n a n t  m e c h a n i s m  b y  w h i c h  
m i R N A  r e g u l a t e s  m R N A ,  c a u s e s  r a p i d  m i R N A - i n d u c e d  d e - a d e n y l a t i o n  o f  t h e  
t a r g e t  m R N A  [ 6 5 ] .  T h e  t a r g e t  m R N A  i s  t h e n  q u i c k l y  d e g r a d e d  b y  e n d o g e n o u s  
e x o n u c l e a s e s .  T o g e t h e r  t h e s e  p r o c e s s e s  e f f e c t i v e l y  l o w e r  t h e  t o t a l  t a r g e t  
p r o t e i n  c o n c e n t r a t i o n .   
 
B o t h  o f  t h e s e  m e c h a n i s m s  r e l y  o n  t h e  t a r g e t  m i R N A  r e c o g n i z i n g  i t s  b i n d i n g  
s i t e  w i t h i n  t h e  t a r g e t  m R N A .  T h e  c u r r e n t  t h e o r y  i s  t h a t  t h i s  b i n d i n g  o c c u r s  
t h r o u g h  a n  m R N A - m i R N A  “ p i v o t ”  m e c h a n i s m  [ 8 6 ] .  T h i s  t h e o r y  s t a t e s  t h a t  a  
t r a n s i t i o n  n u c l e a t i o n  b u l g e  o c c u r s  w h e n  5  c o n s e c u t i v e  b a s e s  ( n t  2 - 6 )  o f  t h e  
m i R N A  s e e d  r e g i o n  b i n d s  t o  t h e  t a r g e t  s e q u e n c e  i n  a  “ p i v o t - p a i r i n g ”  m a n n e r .  
T h i s  m e c h a n i s m  r a i s e s  t h e  i m p o r t a n t  p o s s i b i l i t y  t h a t  n o n - c a n o n i c a l  m R N A -
m i R N A  b i n d i n g  s i t e s ,  w h i c h  d o  n o t  r e q u i r e  c o m p l e t e  m i R N A  s e e d  
c o m p l e m e n t a r i t y  w o u l d  b e  a l l o w e d  a s  l o n g  a s  a  G - b u l g e  o c c u r s  a t  p o s i t i o n s  
5 - 6 .  T h i s  w o u l d  h a v e  i m p o r t a n t  i m p l i c a t i o n s  f o r  t h e  r o l e  o f  m R N A  s e c o n d a r y  
s t r u c t u r e  w i t h  r e g a r d  t o  m i R N A - m e d i a t e d  r e g u l a t i o n  a n d  t a r g e t  r e c o g n i t i o n .   
 
T o  d a t e ,  o n l y  m i R 6 0 8  h a s  b e e n  s h o w n  t o  r e g u l a t e  t h e  C O L 5 A 1  m R N A  [ 6 4 ] .  
 
1.6 RNA Secondary structure 
 
R N A  s e c o n d a r y  s t r u c t u r e  r e f e r s  t o  t h e  2 - d i m e n s i o n a l  c o n f o r m a t i o n  t h a t  t h e  
R N A  m o l e c u l e  f o r m s  s h o r t l y  a f t e r  t r a n s c r i p t i o n  b y  t h e  r i b o s o m e .  T h i s  f o l d i n g  
i s  d i r e c t l y  i n f l u e n c e d  b y  t h e  p r i m a r y  s e q u e n c e  o f  t h e  R N A  m o l e c u l e  w h i c h  
g o v e r n s  t h e  f r e e  e n e r g y  l a n d s c a p e  f o r  t h e  f o l d i n g  m e c h a n i c s  [ 8 7 ] ,  [ 8 8 ] .  T h i s  
f o l d i n g  i s  b e l i e v e d  t o  b e  m o r e  c o m p l e x  t h a n  t h a t  o f  D N A  d u e  t o  t w o  m a i n  
f a c t o r s .  F i r s t l y ,  R N A  b a s e  p a i r i n g  a l l o w s  g u a n i n e  t o  u r a c i l  p a i r i n g  ( G > U )  
i n c r e a s i n g  t h e  p o s s i b l e  R N A  c o n f o r m a t i o n s  a n d  s e c o n d l y ,  R N A  i s  p r o n e  t o  
s p o n t a n e o u s  f o r m a t i o n  o f  t e r t i a r y  s t r u c t u r e s  a n d  p s e u d o - k n o t s  [ 8 9 ] .  
 
R N A  s e c o n d a r y  s t r u c t u r e  i s  i m p o r t a n t  f o r  c o r r e c t  r e g u l a t i o n  o f  c e r t a i n  
p r o c e s s e s  a t  t h e  m R N A  l e v e l .  I n  o r d e r  t o  r e g u l a t e  m R N A ,  c i s - e l e m e n t s  s u c h  
a s  R N A - b i n d i n g  p r o t e i n s  a n d  m i R N A s  b i n d  t o  u n s t a b l e ,  s i n g l e - s t r a n d e d  












n o n - r e g u l a t o r y  “ s p a c e r ”  r e g i o n s  o f  3 - U T R  w e r e  d e l e t e d  a n d  t h e  e f f e c t  o n  
m i R N A  b i n d i n g  o b s e r v e d  [ 9 1 ] .  T h e s e  r e g i o n s  w e r e  f o u n d  t o  b e  v i t a l  f o r  
c o r r e c t  r e g u l a t i o n ,  a n d  i n  s o m e  i n s t a n c e s ,  w h e n  d e l e t e d  t h e  e f f e c t s  o f  
m i R N A - m e d i a t e d  m R N A  d e c a y  w a s  c o m p l e t e l y  a b o l i s h e d .  
 
O n e  o f  t h e  c u r r e n t  h y p o t h e s e s  e x p l a i n i n g  t h i s  o b s e r v e d  p h e n o m e n a ,  s t a t e s  
t h a t  c h a n g e s  i n  t h e  p r i m a r y  R N A  s e q u e n c e  c a u s e  a l t e r a t i o n s  i n  t h e  s e c o n d a r y  
s t r u c t u r e  o f  t h e  m R N A  w h i c h  r e n d e r  t h e  R I S  c o m p l e x  u n a b l e  t o  b i n d  t o  t h e  
r e l e v a n t  r e g i o n  w i t h i n  t h e  3 ’ - U T R  [ 9 0 ] .  T h e  g u i d e - s t r a n d  o f  t h e  m i R N A  
m o l e c u l e  w i t h i n  t h e  R I S  c o m p l e x  b i n d s  t o  u n s t a b l e  R N A  w h i c h  i s  f r e e  s i n g l e -
s t r a n d e d ,  w i t h i n  a  b u l g e  o r  a  h a i r p i n  l o o p  [ 9 1 ] .  S h o u l d  t h e  b i n d i n g  s i t e  
b e c o m e  s t a b i l i z e d  b y  b a s e - p a i r i n g ,  t h e  c i s - e l e m e n t  b e c o m e s  u n a b l e  t o  
r e c o g n i z e  a n d  b i n d  t o  t h e  r e s p e c t i v e  s i t e  [ 9 2 ] .  
 
T h e  p o s i t i o n s  o f  t h e s e  u n s t a b l e  r e g i o n s  a r e  c o n s t a n t l y  i n  f l u x  d u e  t o  s e v e r a l  
f a c t o r s  i n c l u d i n g  t h e  f l u i d  n a t u r e  o f  t h e  c y t o p l a s m ,  c h a n g e s  i n  t e m p e r a t u r e ,  
t h e  b i n d i n g  o f  R N A - b i n d i n g  p r o t e i n s ,  t h e  e f f e c t  o f  s m a l l  m o l e c u l e s  s u c h  a s  
A T P  a n d  M g 2 +  a n d  K +  i o n  c o n c e n t r a t i o n s  [ 7 8 ] ,  [ 8 9 ] ,  [ 9 3 ] .  T h e r e  a r e  h o w e v e r ,  
f a v o u r e d  c o n f o r m a t i o n s  o f  R N A  s e c o n d a r y  s t r u c t u r e  w h i c h  e x i s t  i n  v i v o .  
T h e s e  c o n f o r m a t i o n s  a r e  p r e s e n t  i n  “ c o n f o r m a t i o n  w e l l s ” ,  w h i c h  a r e  p o i n t s  
i n  t h e  f r e e  e n e r g y  l a n d s c a p e  i n  w h i c h  o n l y  a  f e w  c o n f o r m a t i o n s  o f  t h e  
s e c o n d a r y  s t r u c t u r e  a r e  f a v o u r a b l e .  A t  a  g i v e n  t e m p e r a t u r e  a n d  u n d e r  
h o m e o s t a t i c  c o n d i t i o n s ,  t h e  R N A  s e c o n d a r y  s t r u c t u r e  m a y  c y c l e  t h r o u g h  o n l y  
a  s u b s e t  o f  a l l  t h e  p o s s i b l e  p e r m u t a t i o n s  [ 9 3 ] .  T h e  p r e s e n c e  o f  t h e s e  
c o n f o r m a t i o n  w e l l s  a l l o w s  t h e  R N A  t o  s p e n d  s i g n i f i c a n t  a m o u n t s  o f  t i m e  i n  
c o n f o r m a t i o n s  t h a t  a r e  s u i t a b l e  f o r  r e g u l a t i o n  b y  t r a n s - e l e m e n t s  r a t h e r  t h a n  
c o n s t a n t l y  s h i f t i n g  t h r o u g h  a l l  p o s s i b l e  c o n f o r m a t i o n s .  S i g n i f i c a n t  
a l t e r a t i o n s  t o  t h e  p r i m a r y  s e q u e n c e ,  e s p e c i a l l y  s e q u e n c e  d u p l i c a t i o n s ,  
i n s e r t i o n s  a n d  d e l e t i o n s ,  m a y  a l t e r  t h e  s e c o n d a r y  s t r u c t u r e  o f  m R N A  t h e r e b y  
s h i f t i n g  t h e  l o c a t i o n  o f  l o c a l  m i n i m a  w i t h i n  t h e  f r e e  e n e r g y  l a n d s c a p e .  T h e s e  
a l t e r e d  l a n d s c a p e s  c o u l d  a f f e c t  R N A  r e g u l a t i o n  b y  t r a n s - a c t i n g  m e c h a n i s m s  
s u c h  a s  R N A - b i n d i n g  p r o t e i n s  a n d  m i R N A s  a n d  m a y  l e a d  t o  m R N A  













1.7 Characterizing the structure and function of the COL5A1 3’-UTR 
 
A s  p r e v i o u s l y  s t a t e d ,  A c h i l l e s  t e n d i n o p a t h y  i s  a  m u l t i f a c t o r i a l  d i s o r d e r  a n d  
a s  s u c h ,  t h e  r i s k  p r o f i l e  w i l l  d i f f e r  s i g n i f i c a n t l y  b e t w e e n  i n d i v i d u a l s  
d e p e n d i n g  o n  t h e i r  e x p o s u r e  t o  t h e  e x t r i n s i c  a n d  i n t r i n s i c  f a c t o r s  d e s c r i b e d  
i n  T a b l e  1 . 1 .  W i t h  r e s p e c t  t o  t h e  i d e n t i f i e d  i n t r i n s i c  g e n e t i c  c o m p o n e n t ,  
i n d e p e n d e n t  g e n e t i c  a s s o c i a t i o n s  w i t h  v a r i a n t s  i n  s e v e r a l  g e n e s  s u c h  a s  t h e  
E C M  g l y c o p r o t e i n  t e n a s c i n  C  ( T N C )  [ 2 5 ] ,  m a t r i x  m e t a l l o p r o t e a s e  3  ( M M P - 3 )  
[ 2 6 ] a n d  C O L 5 A 1  [ 1 3 ] ,  [ 1 4 ] ,  t i s s u e  i n h i b i t o r  o f  m e t a l l o p r o t e i n a s e - 2  ( T I M P - 2 )  
[ 2 7 ]  a n d  c a s p a s e  8  ( C A S P 8 )  [ 9 4 ]  a n d  v a r i a t i o n  i n  t h e  e x p r e s s i o n  o f  t h e s e  
g e n e s  o r  f u n c t i o n a l i t y  o f  t h e i r  p r o d u c t s  m a y  c o n t r i b u t e  s i g n i f i c a n t l y  t o  t h e  
d e v e l o p m e n t  o f  t e n d i n o p a t h y .  
  
A s  p r e v i o u s l y  d i s c u s s e d ,  m u c h  o f  t h e  s t u d i e s  t o  d a t e  h a v e  f o c u s e d  o n  t h e  
a s s o c i a t i o n  o f  v a r i a n t s  w i t h i n  t h e  3 ’ - U T R  o f  t h e  C O L 5 A 1  g e n e  w i t h  A c h i l l e s  
t e n d i n o p a t h y  a n d  o t h e r  e x e r c i s e - a s s o c i a t e d  p h e n o t y p e s  a n d  s e v e r a l  
p o l y m o r p h i s m s  h a v e  b e e n  a s s o c i a t e d  w i t h  A c h i l l e s  t e n d i n o p a t h y  ( S e e  F i g u r e  
1 . 6 ) .  T h e  v a r i a n t s  r s 1 2 7 2 2  ( C / T ) ,  r s 3 1 9 6 3 7 8  ( A / C ) ,  r s 7 1 7 4 6 7 4 4  ( A G G G ( n ) ) ,  
r s 1 6 3 9 9  ( A T C T ( n ) )  a n d  r s 1 1 3 4 1 7 0  ( A / T )  w e r e  a l l  a s s o c i a t e d  w i t h  A c h i l l e s  
t e n d i n o p a t h y  i n  a t  l e a s t  o n e  C a u c a s i a n  p o p u l a t i o n  [ 1 3 ] ,  [ 1 4 ] ,  [ 2 2 ] .  V a r i a n t s  
r s 1 3 9 4 6  a n d  r s 3 1 2 8 5 7 5  w e r e  a l s o  i n v e s t i g a t e d  b u t  w e r e  n o t  f o u n d  t o  b e  















F i g u r e  1 . 6  V a r i a n t s  w i t h i n  t h e  C O L 5 A 1  3 ’ - U T R  u s e d  t o  d e t e r m i n e  t h e  
a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R .  
V a r i a n t s  r s 1 2 7 2 2 ,  r s 3 1 9 6 3 7 8 ,  r s 7 1 7 4 6 7 4 4 ,  r s 1 6 3 9 9  a n d  r s 1 1 3 4 1 7 0  w e r e  
a s s o c i a t e d  w i t h  A c h i l l e s  t e n d i n o p a t h y  i n  a t  l e a s t  o n e  p o p u l a t i o n .  T h e  5 7  b p  
r e g i o n  c o n t a i n i n g  r s 7 1 7 4 6 7 4 4  a n d  r s 1 1 1 0 3 5 4 4  i s  s h o w n  a l o n g  w i t h  t h e  
p o s i t i o n s  o f  r e s t r i c t i o n  e n z ym e  s i t e s  f o r  X b a I  a n d  A f l I I  [ 1 3 ] ,  [ 1 4 ] ,  [ 2 2 ] . 
 
 
L a g u e t t e  e t  a l .  ( 2 0 1 1 )  a l s o  f o u n d  t h a t  t h e s e  s e v e n  p o l y m o r p h i c  r e g i o n s  
a p p e a r e d  t o  b e  i n  s t r o n g  l i n k a g e  d i s e q u i l i b r i u m ,  g i v i n g  r i s e  t o  t w o  m a j o r  
a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  [ 6 4 ] .  T h e s e  f o r m s  w e r e  a n n o t a t e d  a s  t h e  
C - a l l e l i c  f o r m ,  w h i c h  r e p r e s e n t s  t h e  w i l d - t y p e  s e q u e n c e ,  a n d  t h e  T - a l l e l i c  
f o r m ,  w h i c h  w a s  p r e d o m i n a n t l y  f o u n d  i n  c l o n e s  d e r i v e d  f r o m  s y m p t o m a t i c  
A c h i l l e s  t e n d i n o p a t h i c  i n d i v i d u a l s  a n d  i s  b e l i e v e d  t o  r e p r e s e n t  t h e  “ a t  r i s k ”  
f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R .  I n  f u n c t i o n a l  s t u d i e s ,  i t  w a s  f o u n d  t h a t  t h e  T -
a l l e l e  s h o w e d  a n  o v e r a l l  i n c r e a s e d  l u c i f e r a s e  a c t i v i t y  i n  a  f i b r o s a r c o m a  c e l l  
l i n e .  T h i s  a l l u d e s  t o  i n c r e a s e d  s t a b i l i t y  o f  t h e  T - a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  
m R N A  o v e r  i t s  C - a l l e l i c  c o u n t e r p a r t .  T h i s  d i f f e r e n c e  i n  m R N A  s t a b i l i t y  
b e t w e e n  t h e  a l l e l i c  f o r m s  w a s  a b o l i s h e d  w h e n  a  5 7  b p  r e g i o n  c o n t a i n i n g  t h e  
M b o I I  R F L P  c o n s e r v e d  o c t a m e r  a s  w e l l  a s  t h e  A G G G ( n )  V N T R  ( r s 7 1 7 4 6 7 4 4 ) ,  
w a s  r e m o v e d .   
 
I n  a d d i t i o n ,  t w o  p u t a t i v e  p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e s  w e r e  p r e v i o u s l y  
i d e n t i f i e d  w i t h i n  t h e  3 ’ - U T R  [ 1 4 ]  ( F i g u r e  1 . 6 ) .  T h e  m i R N A  H s a - m i R - 6 0 8  i s  












( C / A )  p o l y m o r p h i s m  i n  t h e  C O L 5 A 1  3 ’ - U T R .  S e p t e m b e r  e t  a l .  ( 2 0 0 9 )  f o u n d  
t h a t  t h e  C A  g e n o t y p e  o f  t h i s  S N P  w a s  s i g n i f i c a n t l y  o v e r - r e p r e s e n t e d  i n  a n  
A u s t r a l i a n  t e n d i n o p a t h y  g r o u p  c o m p a r e d  t o  t h e  A u s t r a l i a n  c o n t r o l  g r o u p  
[ 1 4 ] .  T h e  A - a l l e l e  w a s  a l s o  p r e d o m i n a n t l y  f o u n d  w i t h i n  t h e  t e n d i n o p a t h i c  
c l o n e s  c r e a t e d  b y  L a g u e t t e  e t  a l .  ( 2 0 1 1 )  a n d  i t  w a s  h y p o t h e s i z e d  t h a t  t h i s  
S N P  a l t e r s  t h e  b i n d i n g  a f f i n i t y  o f  H s a - m i R - 6 0 8  i n  t e n d i n o p a t h y  p a t i e n t s  [ 6 4 ] .  
 
T h e  s e c o n d  p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e  o v e r l a p s  w i t h  t h e  M b o I I  R F L P  
p o l y m o r p h i s m  ( r s 1 1 1 0 3 5 4 4 )  a n d  i s  b e l i e v e d  t o  b i n d  a n  u n k n o w n  m i R N A .  T h i s  
s i t e  h a s  a  c o n s e r v e d  o c t a m e r  w h i c h  i s  p r e d i c t e d  t o  b e  a  m i R N A  b i n d i n g  s i t e  
b y  t h e  P a t r o c l e s  m i R N A - b i n d i n g  s i t e  a l g o r i t h m  [ 2 3 ] ,  [ 9 5 ] ,  [ 9 6 ] .  T h e  M b o I I  
R F L P  ( r s 1 1 1 0 3 5 4 4 )  h a s  n o t  b e e n  f o u n d  t o  b e  a s s o c i a t e d  w i t h  A c h i l l e s  
t e n d i n o p a t h y  a n d  d o e s  n o t  c o n t r i b u t e  t o  t h e  i d e n t i f i c a t i o n  o f  t h e  C -  o r  T -
a l l e l i c  f o r m s  [ 1 4 ] .   
 
C o l l i n s  a n d  P o s t h u m u s  ( 2 0 1 1 )  h y p o t h e s i z e  t h a t  o v e r - e x p r e s s i o n  o f  t y p e  V  
c o l l a g e n  w o u l d  d e c r e a s e  t h e  m a x i m u m  l o a d  s t r e s s  o f  t h e  A c h i l l e s  t e n d o n  b y  
d e c r e a s i n g  t h e  a v e r a g e  f i b r i l  d i a m e t e r  a n d  i n c r e a s i n g  t h e  t o t a l  n u m b e r  o f  
f i b r e s  p r e s e n t  ( F i g u r e  1 . 7 )  [ 6 3 ] .  T h i s  m a y  l e a d  t o  m o r e  t i g h t l y  p a c k e d  b u n d l e s  
w h i c h  w o u l d  d e c r e a s e  t h e  f l e x i b i l i t y  o f  t h e  t e n d o n ,  m a k i n g  i t  m o r e  
s u s c e p t i b l e  t o  b o t h  m i c r o -  a n d  m a c r o - i n j u r y .  T h i s  h y p o t h e s i s  i s  s u p p o r t e d  b y  
e x p e r i m e n t s  i n v e s t i g a t i n g  a g e - r e l a t e d  t y p e  V  i n c r e a s e  i n  r a b b i t  p a t e l l a  
t e n d o n  [ 9 7 ] .  A n  i n c r e a s e d  r a t e  o f  d a m a g e  t o  t h e  t e n d o n  m a y  a l t e r  t h e  
p r o d u c t i o n / d e g r a d a t i o n  b a l a n c e  a n d  i n c r e a s e  t h e  t e n d o n ’ s  s u s c e p t i b i l i t y  t o  
d e g e n e r a t i v e  p h e n o t y p e s  s u c h  a s  t e n d i n o p a t h y .  T h e s e  d a t a  m a k e  C O L 5 A 1 ,  
w h i c h  e n c o d e s  a  s u b u n i t  o f  t y p e  V  c o l l a g e n ,  a n  e x c e l l e n t  g e n e  f o r  f u r t h e r  














F i g u r e  1 . 7  S c h e m a t i c  d i a g r a m  s h o w i n g  t h e  n o v e l  h y p o t h e s i s  p r o p o s e d  b y  
C o l l i n s  a n d  P o s t h u m u s  ( 2 0 1 1 ) .  
T h e  l e f t  p a n e l  s h o w s  i r r e g u l a r  f i b r i l  a r c h i t e c t u r e  r e s u l t i n g  f r o m  C O L 5 A 1  g e n e  
h a p l o i n s u f f i c i e n c y .  C l a s s i c a l  E D S  s ym p t o m s  a r e  p r e s e n t  a t  t h e  p h e n o t yp e  
l e v e l .  T h e  c e n t r e  p a n e l  s h o w s  t h e  w i l d - t yp e  p h e n o t yp e  w i t h  n o r m a l  f i b r i l  
a r c h i t e c t u r e .  T h e  r i g h t  p a n e l  s h o w s  t h e  h yp o t h e s i s e d  f i b r i l  a r c h i t e c t u r e  
r e s u l t i n g  f r o m  i n c r e a s e d  m R N A  s t a b i l i t y  o f  t h e  T - a l l e l i c  f r o m  o f  t h e  C O L 5 A 1  
g e n e ;  t h e  c o l l a g e n  f i b r i l s  h a v e  a  d e c r e a s e d  d i a m e t e r  a n d  a r e  m o r e  d e n s e l y  
p a c k e d .  T h i s  a l t e r a t i o n  i s  b e l i e v e d  t o  r e d u c e  r a n g e - o f - m o t i o n  a n d  i n c r e a s e  
r i s k  f o r  s p e c i f i c  m u s c u l o s k e l e t a l  s o f t  t i s s u e  i n j u r i e s  s u c h  a s  A c h i l l e s  















T h e  a i m  o f  t h i s  s t u d y  i s  t o  i n v e s t i g a t e  t h e  m i R N A  r e g u l a t o r y  m e c h a n i s m s  
w i t h i n  t h e  3 ’ - U T R  o f  C O L 5 A 1  a n d  s p e c i f i c a l l y ,  t o  i n v e s t i g a t e  w h e t h e r  t h e  
i d e n t i f i e d  m i R N A s  a r e  m o r e  e f f i c i e n t  a t  r e g u l a t i n g  o n e  o f  t h e  t w o  f u n c t i o n a l  
a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R .  T h i s  w i l l  b e  a c h i e v e d  i n  t h e  f o l l o w i n g  
m a n n e r :  
  
1 .   
a .  T o  i n v e s t i g a t e  t h e  w h e t h e r  t h e  a d d i t i o n  o f  H s a - m i R - 6 0 8  m i m i c  i s  
s u f f i c i e n t  t o  r e d u c e  t h e  l u c i f e r a s e  e x p r e s s i o n  o f  a  l u c i f e r a s e  
c o n s t r u c t  c o n t a i n i n g  t h e  T -  o r  C - a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  3 ’ -
U T R  u s i n g  a  c e l l  c u l t u r e  c o - t r a n s f e c t i o n  a p p r o a c h  
b .  T o  d e t e r m i n e  w h e t h e r  t h e r e  i s  a  s i g n i f i c a n t  d i f f e r e n c e  i n  t h e  
r e g u l a t i o n  o f  t h i s  m i R N A  b i n d i n g  s i t e  b e t w e e n  t h e  C -  a n d  T -
a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  u s i n g  l u c i f e r a s e  a s s a y s .  
  
2 .   
a .  T o  i n v e s t i g a t e  t h e  v a l i d i t y  o f  t h e  p o l y m o r p h i c  M b o I I  R F L P  
o c t a m e r  a s  a  p u t a t i v e  m i R N A  b i n d i n g  s i t e  u s i n g  a  s i t e - d i r e c t e d  
m u t a g e n e s i s  a p p r o a c h  a n d  l u c i f e r a s e  a s s a y s .  
b .  T o  d e t e r m i n e  w h e t h e r  t h e r e  i s  a  s i g n i f i c a n t  d i f f e r e n c e  i n  t h e  
r e g u l a t i o n  o f  t h i s  m i R N A  b i n d i n g  s i t e  b e t w e e n  t h e  C -  a n d  T -
a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  u s i n g  l u c i f e r a s e  a s s a y s .  
 
3 .   
a .  T o  i n v e s t i g a t e  w h e t h e r  t h e  a d d i t i o n  o f  H s a - m i R - 1 2 5 a - 5 p  m i m i c  
i s  s u f f i c i e n t  t o  r e d u c e  t h e  l u c i f e r a s e  e x p r e s s i o n  o f  a  l u c i f e r a s e  
c o n s t r u c t  c o n t a i n i n g  t h e  T -  o r  C - a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  3 ’ -
U T R  u s i n g  a  c e l l  c u l t u r e  c o - t r a n s f e c t i o n  a p p r o a c h   
b .  T o  d e t e r m i n e  w h e t h e r  t h e r e  i s  a  s i g n i f i c a n t  d i f f e r e n c e  i n  t h e  
r e g u l a t i o n  o f  t h i s  m i R N A  b i n d i n g  s i t e  b e t w e e n  t h e  C -  a n d  T -















4 .  
a .  T o  d e t e r m i n e  w h e t h e r  t h e  r s 4 9 1 9 5 1 0  v a r i a n t  w i t h i n  t h e  
M I R 6 0 8  g e n e  i s  a s s o c i a t e d  w i t h  A c h i l l e s  t e n d i n o p a t h y  b y  
g e n o t y p i n g  2  C a u c a s i a n  p o p u l a t i o n s  w i t h  F l u o r e s c e n t  
T a q m a n ®  P C R  i n  a  c a s e - c o n t r o l  s t u d y .  
b .  T o  i n v e s t i g a t e  g e n e - g e n e  i n t e r a c t i o n  b e t w e e n  r s 4 9 1 9 5 1 0  a n d  
t h e  r s 3 1 9 6 3 7 8  v a r i a n t  p r e s e n t  w i t h i n  t h e  p r e d i c t e d  b i n d i n g  
s i t e  f o r  H s a - m i R - 6 0 8  i n  t h e  C O L 5 A 1  3 ’ - U T R .  
 
5 .  
T o  i n v e s t i g a t e  t h e  c o - o p e r a t i v e  e f f e c t s  o f  t h e  v a r i a n t s  w i t h i n  t h e  
C O L 5 A 1  3 ’ - U T R  o n  m R N A  s e c o n d a r y  s t r u c t u r e  b y  c r e a t i n g  a n  i n  
s i l i c o  m o d e l  o f  t h e  3 ’ - U T R  u s i n g  t h e  S f o l d  o n l i n e  f o l d i n g  



























2. Materials and Methods 
 
2.1 Control and tendinopathic participants and DNA extraction 
 
T h r e e  h u n d r e d  a n d  t w e l v e  a s y m p t o m a t i c  c o n t r o l  p a r t i c i p a n t s  ( C O N )  a n d  1 4 3  
p a r t i c i p a n t s  d i a g n o s e d  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  ( T E N )  w e r e  
i n c l u d e d  i n  t h i s  s t u d y .  T h e s e  p a r t i c i p a n t s  w e r e  r e c r u i t e d  f r o m  S o u t h  A f r i c a  
( S A  T E N ,  N  =  7 5  a n d  S A  C O N  =  1 3 5 )  a n d  A u s t r a l i a  ( A U S  T E N ,  N  =  6 8  a n d  A U S  
C O N  =  1 7 7 ) .  A l l  p a r t i c i p a n t s  w e r e  o f  s e l f - r e p o r t e d  E u r o p e a n  C a u c a s i a n  
a n c e s t r y ,  g a v e  w r i t t e n  i n f o r m e d  c o n s e n t  ( A p p e n d i x  A )  p r i o r  t o  p a r t i c i p a t i o n  
i n  t h e  s t u d y ,  p r o v i d e d  p e r s o n a l  p a r t i c u l a r s  a n d  c o m p l e t e d  a  q u e s t i o n n a i r e  
r e g a r d i n g  m e d i c a l  h i s t o r y  a n d  p h y s i c a l  a c t i v i t y  h i s t o r y  ( A p p e n d i x  B ) .  T h e  
r e s e a r c h  p r o j e c t  w a s  a p p r o v e d  b y  t h e  H u m a n  R e s e a r c h  E t h i c s  C o m m i t t e e  o f  
t h e  F a c u l t y  o f  H e a l t h  S c i e n c e  a t  t h e  U n i v e r s i t y  o f  C a p e  T o w n  ( A p p e n d i x  C )  
a n d  t h e  H u m a n  E t h i c s  C o m m i t t e e  o f  L a  T r o b e  U n i v e r s i t y ,  M e l b o u r n e ,  
A u s t r a l i a  ( A p p e n d i x  D ) .  
 
T h e  S o u t h  A f r i c a n  p a r t i c i p a n t s  w i t h  c l i n i c a l l y  d i a g n o s e d  A c h i l l e s  
t e n d i n o p a t h y  w e r e  r e c r u i t e d  f r o m  t h e  S p o r t s  M e d i c i n e  P r a c t i c e  a t  t h e  S p o r t s  
S c i e n c e  I n s t i t u t e  o f  S o u t h  A f r i c a  i n  C a p e  T o w n ,  S o u t h  A f r i c a .  T h e  c l i n i c a l  
d i a g n o s t i c  c r i t e r i a  f o r  A c h i l l e s  t e n d i n o p a t h y  i n c l u d e d  p r o g r e s s i v e  p a i n  i n  t h e  
A c h i l l e s  t e n d o n  a r e a  f o r  a  m i n i m u m  o f  6  m o n t h s  a n d  a t  l e a s t  o n e  o f  t h e  
f o l l o w i n g  s i x  c r i t e r i a :  ( 1 )  E a r l y  m o r n i n g  p a i n  o v e r  t h e  A c h i l l e s  t e n d o n  r e g i o n ;  
( 2 )  e a r l y  m o r n i n g  s t i f f n e s s  o v e r  t h e  A c h i l l e s  t e n d o n  a r e a ;  ( 3 )  a  h i s t o r y  o f  
s w e l l i n g  o f  t h e  A c h i l l e s  t e n d o n  a r e a ;  ( 4 )  t e n d e r n e s s  t o  p a l p a t i o n ;  ( 5 )  n o d u l a r  
t h i c k e n i n g  o v e r  t h e  a f f e c t e d  t e n d o n  o r  ( 6 )  m o v e m e n t  o f  t h e  p a i n f u l  a r e a  i n  
t h e  t e n d o n  d u r i n g  p l a n t a r - d o r s i - f l e x i o n  [ 9 8 ] .  T h e  S A  T E N  d i a g n o s e s  w e r e  
r e v i e w e d  a n d  c o n f i r m e d  b y  a  S p o r t s  P h y s i c i a n ,  u s i n g  a n  i n c l u s i o n  a n d  
e x c l u s i o n  c r i t e r i a  a n d  a  c h e c k l i s t  ( A p p e n d i x  E ) .  T h e  S A  C O N  p a r t i c i p a n t s  
r e p o r t e d  n o  h i s t o r y  o f  t e n d o n  p a t h o l o g y  a n d  w e r e  r e c r u i t e d  f r o m  v a r i o u s  
r e c r e a t i o n a l  s p o r t i n g  c l u b s .  T h e  S A  C O N  g r o u p  w e r e  r e c r u i t e d  s u c h  t h a t  t h e  
s e x  a n d  c o u n t r y  o f  b i r t h  w e r e  s i m i l a r  t o  t h a t  o f  t h e  S A  T E N  g r o u p .  I n  a d d i t i o n ,  
i n  o r d e r  t o  a v o i d  t h e  p o s s i b l e  c o n f o u n d i n g  e f f e c t s  o f  a g e ,  t h e  a g e  o f  t h e  S A  
C O N  g r o u p  w a s  m a t c h e d  t o  t h a t  o f  t h e  a g e  o f  i n i t i a l  i n j u r y  o n s e t  i n  t h e  S A  













T h e  A u s t r a l i a n  t e n d i n o p a t h y  p a r t i c i p a n t s  w e r e  r e c r u i t e d  f r o m  t h e  
M u s c u l o s k e l e t a l  R e s e a r c h  C e n t r e  a t  L a  T r o b e  U n i v e r s i t y  i n  M e l b o u r n e  
A u s t r a l i a  [ 1 4 ] .  A  S p o r t s  P h y s i o t h e r a p i s t  c o n f i r m e d  t h e  A U S  T E N  d i a g n o s e s ,  
u s i n g  t h e  s a m e  c r i t e r i a  a s  t h a t  o f  t h e  S o u t h  A f r i c a n  p a r t i c i p a n t s .  T h e  
p a r t i c i p a n t s  w e r e  r e c r u i t e d  s u c h  t h a t  t h e i r  c o u n t r y  o f  b i r t h  w a s  m a t c h e d  
b e t w e e n  t h e  A U S  C O N  a n d  A U S  T E N  g r o u p s ,  a n d  t h e  a g e  o f  r e c r u i t m e n t  o f  t h e  
A U S  C O N  g r o u p  m a t c h e d  t h a t  o f  i n i t i a l  o n s e t  o f  i n j u r y  o f  t h e  A U S  T E N  g r o u p .   
 
T h e  d i a g n o s i s  o f  a l l  A u s t r a l i a n  t e n d i n o p a t h i c  p a r t i c i p a n t s  w e r e  c o n f i r m e d  
u s i n g  s o f t  t i s s u e  u l t r a s o u n d  i m a g i n g  o f  t h e  a f f e c t e d  t e n d o n .  D i a g n o s i s  w a s  
c o n f i r m e d  b y  s o f t  t i s s u e  u l t r a s o u n d  i m a g i n g  o f  t h e  a f f e c t e d  A c h i l l e s  t e n d o n  
f o r  a  s u b s e t  ( 6 3  o f  2 1 0 )  o f  t h e  S o u t h  A f r i c a n  p a r t i c i p a n t s .  F o r  t h e  S A  
p a r t i c i p a n t s ,  a p p r o x i m a t e l y  4 . 5 m l  o f  v e n o u s  b l o o d  w a s  c o l l e c t e d  v i a  
v e n i p u n c t u r e  o f  a  f o r e a r m  v e i n  i n t o  E D T A  v a c u t a i n e r  t u b e s  a n d  s t o r e d  a t  4 °  
C  u n t i l  t o t a l  D N A  e x t r a c t i o n .  T o t a l  D N A  w a s  e x t r a c t e d  f r o m  b l o o d  u s i n g  a  
m e t h o d  d e s c r i b e d  b y  L a h i r i  a n d  N u r n b e r g e r  ( 1 9 9 1 )  [ 9 9 ]  a n d  m o d i f i e d  b y  
M o k o n e  e t  a l  ( 2 0 0 6 ) .  T h e  D N A  w a s  s t o r e d  a t  - 2 0 °  C  u n t i l  s e q u e n c i n g  o r  
g e n o t y p i n g .  F o r  t h e  A u s t r a l i a n  p a r t i c i p a n t s ,  a p p r o x i m a t e l y  4 . 5 m l  o f  v e n o u s  
b l o o d  w a s  c o l l e c t e d  a n d  D N A  w a s  e x t r a c t e d  u s i n g  a  s e q u e n c e  e x t r a c t i o n  
t e c h n i q u e  ( F l e x i G e n e  D N A  K i t ,  Q i a g e n  P / L ,  V a l e n c i a ,  C a l i f o r n i a ,  U S A )  a s  
d e s c r i b e d  b y  t h e  m a n u f a c t u r e r .  
 
2.2 Cloning of the COL5A1 3’-UTR DNA constructs 
 
T e n  i n d i v i d u a l s  w e r e  s e l e c t e d  f r o m  t h e  T E N  ( n = 5 )  a n d  C O N  ( n = 5 )  p a r t i c i p a n t s  
( T a b l e  2 . 1 ) .  T h e  5  p a r t i c i p a n t s  i n  t h e  t e n d i n o p a t h i c  s u b - g r o u p  r e p r e s e n t e d  a  
“ s e v e r e ”  p h e n o t y p e  w i t h  e a r l y  o n s e t  o f  i n i t i a l  s y m p t o m s  ( 3  o f  5  p a r t i c i p a n t s  
w e r e  ≤ 3 2  y e a r s  o f  a g e ) ,  b i l a t e r a l  A c h i l l e s  t e n d i n o p a t h y  ( 3  o f  5 )  a n d  a  m i d -
t e n d o n  i n j u r y  ( 5  o f  5 ) .  T e n d i n o p a t h i c  p a r t i c i p a n t s  w e r e  a l s o  k n o w n  t o  h a v e  
t h e  “ a t  r i s k ”  T T  g e n o t y p e  f o r  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  a t  t h e  C O L 5 A 1  3 ’ -
u n t r a n s l a t e d  r e g i o n  ( 3 ’ - U T R )  s i n g l e  n u c l e o t i d e  p o l y m o r p h i s m  r s 1 2 7 2 2  
( C / T ) [ 1 3 ] ,  [ 1 4 ] .  T h e  f i v e  C O N  p a r t i c i p a n t s ,  o n  t h e  o t h e r  h a n d ,  h a d  t h e  














F i g u r e  2 . 1  S c h e m a t i c  r e p r e s e n t a t i o n  o f  t h e  2 5 4 6  b p  C O L 5 A 1  3 ′ - U T R  c l o n e d  
d o w n s t r e a m  o f  t h e  f i r e f l y  l u c i f e r a s e  g e n e  ( F i r e f l y  L u c + )  i n t o  t h e  p G L 3 -  
P r o m o t e r  v e c t o r ,  s u b s t i t u t i n g  t h e  S V 4 0  l a t e  p o l y ( A)  s i g n a l  o f  t h e  r e p o r t e r  
g e n e .  
X b a I  a n d  B a m H I  r e s t r i c t i o n  e n z ym e  s i t e s  w e r e  u s e d  t o  c l o n e  t h e  C O L 5 A 1  3 ’ -
U T R  i n t o  t h e  p G L 3 - P r o m o t e r  v e c t o r .  T h e  e x p r e s s i o n  t h e  f i r e f l y  l u c i f e r a s e  g e n e  
i s  d r i v e n  b y  a  S V 4 0  v i r a l  p r o m o t e r .  T h e  p l a s m i d  c o n s t r u c t  i s  c i r c u l a r  b u t  w a s  
l i n e a r i ze d  f o r  s c h e m a t i c  p u r p o s e s  ( A p p e n d i x  F )  
 
 
T h e  p G L 3 - T E N / C O N  l u c i f e r a s e  v e c t o r s  w e r e  c o n s t r u c t e d  b y  a m p l i f y i n g  a  2 5 4 6  
b p  f r a g m e n t  o f  t h e  3 ’ -  U T R  o f  e i t h e r  t e n d i n o p a t h y  o r  c o n t r o l  p a r t i c i p a n t s  
f r o m  t o t a l  g e n o m i c  D N A  v i a  a  n e s t e d  p o l y m e r a s e  c h a i n  r e a c t i o n  ( A p p e n d i x  G  
f o r  p r i m e r s ) .  T h e  a m p l i f i e d  f r a g m e n t  w a s  c l o n e d  i n t o  t h e  p G L 3 - P r o m o t e r  
v e c t o r  ( P r o m e g a  C o r p o r a t i o n ,  M a d i s o n ,  W i s c o n s i n ,  U S A )  d o w n s t r e a m  o f  t h e  
f i r e f l y  l u c i f e r a s e  r e p o r t e r  g e n e  u s i n g  t h e  r e s t r i c t i o n  s i t e s  B a m H I  a n d  X b a I  t o  
r e p l a c e  t h e  n o r m a l  S V 4 0  l a t e  p o l y ( A )  s i g n a l  ( F i g u r e  2 . 1  -  A p p e n d i x  H ) [ 1 0 0 ] .  
 
T h e  p R L - T K  v e c t o r  ( A p p e n d i x  I )  c o n t a i n s  a  c o n s t i t u t i v e  t h y m i d i n e  k i n a s e  3  
p r o m o t e r  w h i c h  d r i v e s  t h e  e x p r e s s i o n  o f  a  r e n i l l a  l u c i f e r a s e  r e p o r t e r  g e n e .  
p R L - T K  w a s  c o - t r a n s f e c t e d  w i t h  e a c h  p G L 3 _ T E N / C O N  v e c t o r  a n d  w a s  u s e d  a s  














Table 2.1 General characteristics of the Achilles tendinopathic (TEN) and control (CON) individuals 
used to clone the 3’-untranslated region of the COL5A1 gene. 
P a r t i c i p a n t  
A g e  a t  
r e c r u i t m e n t  
( y r s . )  
G e n d e r  H e i g h t  ( c m )  
W e i g h t  
( k g )  
B MI  
( k g / m 2 )  
C O L 5 A 1  
r s 1 2 7 2 2  
g e n o t y p e  
T E N - 1  4 9  M a l e  1 8 6  8 7  2 5 . 1  T T  
T E N - 2  2 7  F e m a l e  U n k n o w n  U n k n o w n  U n k n o w n  T T  
T E N - 3  6 2  M a l e  1 7 5  6 4  2 0 . 8  T T  
T E N - 4  4 7  M a l e  1 7 3  7 3  2 4 . 4  T T  
T E N - 5  4 9  M a l e  1 7 9  7 9  2 4 . 7  T T  
M e a n  ±  s . d .  4 6 . 8  ±  1 2 . 6   1 7 8 . 3  ±  5 . 7  7 5 . 8  ±  9 . 7  2 3 . 8  ±  2 . 0   
C O N - 1  U n k n o w n  F e m a l e  1 6 7  5 4  1 9 . 4  C C  
C O N - 2  2 8  M a l e  1 8 3  7 8  2 3 . 3  C C  
C O N - 3  5 1  F e m a l e  1 7 1  5 6  1 9 . 1  C C  
C O N - 4  4 0  F e m a l e  1 7 0  5 8  2 0 . 1  C C  
C O N - 5  U n k n o w n  M a l e  1 8 3  7 9  2 3 . 6  C C  
M e a n  ±  s . d .  3 9 . 7  ±  1 1 . 5   1 7 4 . 8  ±  7 . 6  6 5  ± 1 2 . 4  2 1 . 1  ±  2 . 2  
  
B M I  -  B o d y  m a s s  i n d e x  s . d .  –  s t a n d a r d  d e v i a t i o n   
 
 
D N A  c o n s t r u c t s  w e r e  a m p l i f i e d  u s i n g  c a e s i u m  c h l o r i d e / e t h i d i u m  b r o m i d e  
g r a d i e n t  c e n t r i f u g a t i o n .  T h e  p G L 3 - T E N / C O N  l u c i f e r a s e  c o n s t r u c t s  w e r e  
t r a n s f o r m e d  i n t o  t h e  D H 5 α  s t r a i n  o f  E .  c o l i  a n d  w e r e  s e l e c t e d  f o r  a m p i c i l l i n  
r e s i s t a n c e .  P o s i t i v e  c l o n e s  w e r e  p i c k e d  a n d  g r o w n  i n  a  2  l i t r e  c o n i c a l  f l a s k  
c o n t a i n i n g  4 0 0  m l  o f  1 0 0  μ g / m l  a m p i c i l l i n  L u r i a  b r o t h  a t  3 7 °  C  a n d  s h a k e n  a t  
1 5 0  r p m  f o r  2 0  h o u r s .  T h e  c e l l  c u l t u r e s  w e r e  t h e n  c e n t r i f u g e d  a t  7 0 0 0  r p m  
u s i n g  t h e  J A - 1 0  r o t o r  i n  a  B e c k m a n  C o u l t e r  A v a n t i ®  J - E  c e n t r i f u g e  f o r  1 0  m i n  
a t  4 O C .  T h e  p e l l e t s  w e r e  r e s u s p e n d e d  i n  4 0  m l  o f  m a x i p r e p  s o l u t i o n  I .  T h e  
c e l l s  w e r e  l y s e d  b y  t h e  a d d i t i o n  o f  8 0  m l  o f  m a x i p r e p  s o l u t i o n  I I  c o n t a i n i n g  
1 %  s o d i u m  d o d e c y l  s u l p h a t e .  T h e  a l k a l i n e  l y s a t e s  w e r e  n e u t r a l i z e d  u s i n g  
m a x i p r e p  s o l u t i o n  I I I  a n d  t h e  r e s u l t i n g  m a c r o m o l e c u l e  a g g r e g a t e s  w e r e  
r e m o v e d  b y  c e n t r i f u g a t i o n  a t  7 0 0 0  r p m  u s i n g  t h e  J A - 1 0  r o t o r  i n  a  B e c k m a n  
C o u l t e r  A v a n t i ®  J - E  c e n t r i f u g e  f o r  1 0  m i n  a t  4 O  C .  T h e  s u p e r n a t a n t s  w e r e  
m i x e d  w i t h  9 0  m l  o f  i s o p r o p a n o l  a n d  c e n t r i f u g e d  a t  7 0 0 0  r p m  u s i n g  t h e  J A -
1 0  r o t o r  i n  a  B e c k m a n  C o u l t e r  A v a n t i ®  J - E  c e n t r i f u g e  f o r  1 0  m i n  a t  4 O  C  t o  
p e l l e t  r e m a i n i n g  g e n e t i c  m a t e r i a l .  T h e  s u p e r n a t a n t s  w e r e  d i s c a r d e d  a n d  t h e  
p e l l e t s  r e s u s p e n d e d  i n  2  m l  o f  s t e r i l e  n u c l e a s e  f r e e  w a t e r .  T h e  s o l u t i o n  w a s  












e t h i d i u m  b r o m i d e ,  a  D N A  i n t e r c a l a t i n g  a g e n t .  T h e  s o l u t i o n  w a s  
u l t r a c e n t r i f u g e d  a t  5 3  0 0 0  r p m  u s i n g  t h e  B e c k m a n  V t i  6 5 . 2  V e r t i c a l  t u b e  
r o t o r  f o r  2 0  h o u r s  a t  2 0 O  C  a n d  t h e  r e s u l t i n g  b a n d s  o f  p l a s m i d  D N A  w e r e  
r e m o v e d  w i t h  2 1  g a u g e  n e e d l e  i n t o  a  5  m l  s y r i n g e .  T h e  s o l u t i o n  w a s  w a s h e d  
w i t h  1  v o l u m e  o f  i s o b u t a n o l  a  m i n i m u m  o f  3  t i m e s  t o  r e m o v e  t h e  e t h i d i u m  
b r o m i d e  a n d  1  μ l  o f  1 0  m g / m l  R N A s e  A  w a s  a d d e d  t o  t h e  s o l u t i o n  t o  r e m o v e  
a n y  R N A  c o n t a m i n a t i o n .  T h e  p l a s m i d  D N A  s a m p l e s  w e r e  d i a l y s e d  i n  p H  7 . 5  
T r i s - E D T A  s o l u t i o n  t o  r e d u c e  t h e  c a e s i u m  c h l o r i d e  c o n c e n t r a t i o n .  T h e  
r e m a i n i n g  p r o t e i n  c o m p o n e n t s  w e r e  r e m o v e d  b y  p h e n o l - c h l o r o f o r m  
e x t r a c t i o n  a n d  t h e  a q u e o u s  s u p e r n a t a n t s  w e r e  t r a n s f e r r e d  t o  f r e s h  
e p p e n d o r f  t u b e s .  T h e  s o l u t i o n s  w e r e  c e n t r i f u g e d  a t  1 0  0 0 0  r p m  u s i n g  t h e  
B i o f u g e  F r e s c o  b e n c h  t o p  c e n t r i f u g e  ( H e r a e u s  I n s t r u m e n t s ,  H a n a u ,  G e r m a n y )  
f o r  5  m i n u t e s  a n d  t h e  s u p e r n a t a n t s  r e m o v e d  a n d  d i s c a r d e d .  T h e  p l a s m i d  D N A  
p e l l e t s  w e r e  w a s h e d  w i t h  i n c r e a s i n g  c o n c e n t r a t i o n s  o f  e t h a n o l ,  a i r  d r i e d  f o r  
1 5  m i n  a n d  r e s u s p e n d e d  i n  1 0 0  μ l  o f  n u c l e a s e  f r e e  w a t e r  a n d  n a n o d r o p p e d  
u s i n g  t h e  N a n o D r o p ®  N D - 1 0 0 0  s p e c t r o p h o t o m e t e r  f o r  q u a l i t y  a n d  q u a n t i t y .  
 
T h e  e n t i r e  C O L 5 A 1  3 ’ - U T R  w i t h i n  t h e  p G L 3 - T E N / C O N  l u c i f e r a s e  c o n s t r u c t  
c l o n e s  w e r e  s e q u e n c e d  b y  t h e  t h e  C e n t r a l  A n a l y t i c a l  F a c i l i t y  ( U n i v e r s i t y  o f  
S t e l l e n b o s c h ,  S t e l l e n b o s c h ,  S o u t h  A f r i c a )  a s  p r e v i o u s l y  d e s c r i b e d  [ 6 4 ] .  
B i o E d i t  7 . 0 . 5 . 2  ( w w w . m b i o . n c s u . e d u / b i o e d i t / b i o e d i t . h t m l )  a n d  s e v e r a l  
m i R N A  d a t a b a s e s  ( P a t r o c l e s ,  w w w . p a t r o c l e s . o r g )  [ 9 5 ] ,  m i R B a s e  
( w w w . m i r b a s e . o r g )  [ 1 0 1 ] ,  [ 1 0 2 ]  a n d  M i c r o C o s m  T a r g e t s  
( w w w . e b i . a c . u k / e n r i g h t - s r v / m i c r o c o s m )  w e r e  u s e d  t o  a n a l y z e  t h e  o b t a i n e d  
s e q u e n c e  i n f o r m a t i o n  ( r e f e r  t o  s e c t i o n  2 . 8 ) .  T w o  m a j o r  a l l e l i c  f o r m s  o f  t h e  
C O L 5 A 1  3 ′ - U T R  w e r e  d i s t i n g u i s h e d  f r o m  t h e  s e q u e n c e d  c l o n e s  w h i c h  w e r e  
n a m e d  t h e  C -  ( w h i c h  c o r r e s p o n d s  t o  t h e  p u b l i s h e d  w i l d - t y p e  s e q u e n c e )  a n d  
T - a l l e l e s .  T h e  C - f o r m  w a s  p r e d o m i n a t e l y  i d e n t i f i e d  i n  t h e  C O N  c l o n e s ,  w h i l e  
t h e  T  f o r m  w a s  p r e d o m i n a t e l y  i d e n t i f i e d  i n  t h e  T E N  c l o n e s  [ 6 4 ] .  S e v e n  t i g h t l y  
l i n k e d  p o l y m o r p h i s m s  ( r s 1 3 9 4 6 ,  r s 1 2 7 2 2 ,  r s 3 1 9 6 3 7 8 ,  r s 7 1 7 4 6 7 4 4 ,  r s 1 6 3 9 9 ,  
r s 1 1 3 4 1 7 0  a n d  r s 3 1 2 8 5 7 5 )  d i s t i n g u i s h e d  t h e  t w o  m a j o r  f o r m s  o f  t h e  3 ’ - U T R  
















F i g u r e  2 . 2  S c h e m a t i c  r e p r e s e n t a t i o n  o f  t h e  2 5 4 6  b p  C O L 5 A 1  3 ′ - U T R  c l o n e d  
d o w n s t r e a m  o f  t h e  f i r e f l y  l u c i f e r a s e  g e n e  ( L U C  o f  t h e  p G L 3 - P r o m o t e r  
v e c t o r ) ,  s u b s t i t u t i n g  t h e  S V 4 0  l a t e  p o l y ( A)  s i g n a l  o f  t h e  r e p o r t e r  g e n e  
[ 6 4 ] .  
T h e  s e v e n  t i g h t l y  l i n k e d  p o l ym o r p h i c  s i t e s  w i t h i n  t h e  3 ′ - U T R ,  w h i c h  
d i s t i n g u i s h e d  b e t w e e n  t h e  C -  ( w i l d - t yp e )  a n d  T - a l l e l i c  f o r m s ,  a r e  a n n o t a t e d  
a s  w h i t e  ( t o p )  b l a c k  ( b o t t o m )  b o x e s  r e s p e c t i v e l y .  T h e  a c c e s s i o n  n um b e r s  
a s s o c i a t e d  w i t h  t h e  p o l ym o r p h i c  s i t e s  a r e  i n d i c a t e d  t o g e t h e r  w i t h  t h e  
n u c l e o t i d e  c h a n g e s .  T h e  s e q u e n c e  o f  t h e  s e v e n  p o l ym o r p h i s m s  f o r  t h e  C -  
( w i l d - t yp e )  a n d  T  a l l e l e s  w a s  C - C - C - ( A G G G ) 1 - ( A T C T ) 2 - A - T  a n d  T - T - A -
( A G G G ) 2 - ( A T C T ) 1 - T - C  r e s p e c t i v e l y .  T h e  n u c l e o t i d e  p o s i t i o n  o f  t h e  
p o l ym o r p h i s m s  w i t h i n  w i l d - t yp e  s e q u e n c e  o f  e x o n  6 6  o f  C O L 5 A 1  i s  a l s o  





2.3 Site-directed mutagenesis of constructs 
 
O n e  c o n s t r u c t  o f  e a c h  a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R  ( C o n  5 . 1  a n d  T e n  
1 . 1 . )  w a s  s u b j e c t e d  t o  s i t e - d i r e c t e d  m u t a g e n e s i s  a t  a n  M b o I I  R F L P  s i t e  w h i c h  
o v e r l a p p e d  a  r e g i o n  b e l i e v e d  t o  c o n t a i n  a  p u t a t i v e  m i R N A  b i n d i n g  s i t e  ( F i g u r e  
2 . 3 )  [ 6 4 ] .  A  B g l I I  r e s t r i c t i o n  e n z y m e  s i t e  w a s  i n t r o d u c e d  i n t o  t h e  p u t a t i v e  
m i R N A  b i n d i n g  s i t e  m u t a t i n g  t h e  p r i m a r y  s e q u e n c e  f r o m  5 ’ - T T T  T C T  T T T  T T C  
T A C  A T G  C A C  T T A  A G A  C - 3 ’  t o  5 ’ - T T T  T C T  T A G  A T C  T A C  A T G  C A C  T T A  A G A  C - 3 ’  
( F i g u r e  2 . 3 )  u s i n g  p f u  H i g h  f i d e l i t y  p o l y m e r a s e .  P a r e n t a l  t e m p l a t e  D N A  w a s  
a m p l i f i e d  a n d  m u t a t e d  u s i n g  t h e  f o l l o w i n g  p r i m e r s  ( t h e  p u t a t i v e  m i R N A  












Fwd:  5’-GGG AAA AAA TTT GAT AAT TTT CTT AGA TCT ACA TGC ACT TAA GAC-3’  




F i g u r e  2 . 3  S c h e m a t i c  r e p r e s e n t a t i o n  o f  e x o n  6 6  o f  t h e  C O L 5 A 1  g e n e  
s h o w i n g  p o s i t i o n  o f  t h e  w i l d - t y p e s  s e q u e n c e  a n d  m u t a t e d  n u c l e o t i d e s  
w i t h i n  t h e  M b o I I  c o n s e r v e d  o c t a m e r  a n d  t h e i r  p o s i t i o n  w i t h i n  t h e  2 5 4 6  b p  
s e q u e n c e  o f  t h e  3 ’ - U T R  o f  C O L 5 A 1 .  
 
A  f i n a l  c o n c e n t r a t i o n  o f  8 %  D M S O  w a s  u s e d  t o  f a c i l i t a t e  D N A  s t r a n d  
s e p a r a t i o n .  D p n I  m e t h y l a t i o n - s p e c i f i c  r e s t r i c t i o n  d i g e s t i o n  w a s  u s e d  t o  
r e m o v e  p a r e n t a l  t e m p l a t e  D N A .  S u c c e s s f u l l y  m u t a t e d  c l o n e s  w e r e  c o n f i r m e d  
u s i n g  B g l I I  d i a g n o s t i c  e n z y m e  d i g e s t i o n .  T h e s e  c l o n e s  w e r e  d i g e s t e d  u s i n g  
t h e  B a m H I  a n d  X b a I  r e s t r i c t i o n  e n z y m e s  a n d  t h e  r e s u l t i n g  2  k b  f r a g m e n t  
c o n t a i n i n g  t h e  m u t a t e d  3 ’ - U T R  r e g i o n  w a s  i n s e r t e d  i n t o  t h e  B a m H I - X b a I  s i t e s  













2.4 Plasmid construct sequencing 
 
D i f f e r e n t  p r i m e r  p a i r s  ( A p p e n d i x  J )  w e r e  u s e d  t o  P C R  a m p l i f y  s e l e c t e d  a r e a s  
o f  t h e  2  k b  c l o n e d  B a m H I - X b a I  f r a g m e n t  o f  t h e  C O L 5 A 1  3 ′ - U T R  c o n t a i n i n g  t h e  
M b o I I  R F L P  s i t e - d i r e c t e d  m u t a t i o n .  T h e  P C R  f r a g m e n t s  w e r e  g e l  p u r i f i e d  
u s i n g  t h e  Q I A E X ® I I  G e l  E x t r a c t i o n  k i t  ( Q I A G E N  G m b H ,  H i l d e n ,  G e r m a n y ) ,  a n d  
t h e  s u b s e q u e n t  s e q u e n c i n g  r e a c t i o n s  u s i n g  t h e  a p p r o p r i a t e  p r i m e r s  w e r e  
p e r f o r m e d  b y  t h e  C e n t r a l  A n a l y t i c a l  F a c i l i t y  ( U n i v e r s i t y  o f  S t e l l e n b o s c h ,  
S t e l l e n b o s c h ,  S o u t h  A f r i c a ) .  B i o E d i t  7 . 0 . 5 . 2  
( w w w . m b i o . n c s u . e d u / b i o e d i t / b i o e d i t . h t m l )  w a s  u s e d  t o  a n a l y z e  t h e  o b t a i n e d  
s e q u e n c e  i n f o r m a t i o n .  
 
2.5 Cell culture and propagation of cell lines  
 
T h e  H T 1 0 8 0  h u m a n  f i b r o s a r c o m a  c e l l s  ( A T C C ®  n o .  C C L - 1 2 1 )  a n d  S V W I - 3 8  
i m m o r t a l i s e d  h u m a n  e m b r y o n i c  l u n g  f i b r o b l a s t  c e l l s  ( A T C C ®  n o .  C C L - 7 5 )  [ 1 0 3 ]  
w e r e  c u l t u r e d  f r o m  f r o z e n  s t o c k s  s t o r e d  i n  l i q u i d  n i t r o g e n .  C e l l s  w e r e  
m a i n t a i n e d  i n  1 0  c m  c e l l  c u l t u r e  d i s h e s  a t  3 7 °  C  i n  a n  a t m o s p h e r e  c o m p o s e d  
o f  5 %  C O 2  a n d  9 5 %  a i r  a t  6 5 %  h u m i d i t y .  C e l l s  w e r e  g r o w n  i n  D u l b e c c o ’ s  
M o d i f i e d  E a g l e ’ s  M e d i u m  ( D M E M )  c o n t a i n i n g  1 0 %  f e t a l  b o v i n e  s e r u m  ( F B S )  
( H i g h v e l d  B i o l o g i c a l ,  S o u t h  A f r i c a )  a n d  1 %  P e n i c i l l i n / S t r e p t o m y c i n  a n t i b i o t i c  
s o l u t i o n .  C e l l s  w e r e  m a i n t a i n e d  a t  7 0 - 9 0 %  c o n f l u e n c y  a n d  p a s s a g e d  e v e r y  4 8 -
7 2  h o u r s  b y  t r e a t i n g  w i t h  0 . 0 5 % / 0 . 0 2 %  w / v  t r y p s i n / E D T A  s o l u t i o n .  C e l l s  w e r e  
r e g u l a r l y  t e s t e d  f o r  m y c o p l a s m a  i n f e c t i o n  a n d  v i s u a l l y  m o n i t o r e d  f o r  f u n g a l  
a n d  m i c r o b i a l  i n f e c t i o n s .  
 
2.6 Transient transfections 
 
T w e n t y - f o u r  h o u r s  p r i o r  t o  t r a n s f e c t i o n  H T 1 0 8 0  a n d  S V W I 3 8  c e l l s  w e r e  
s e e d e d  a t  7 . 5  x  1 0 4  a n d  2 . 0  x  1 0 5  c e l l s  p e r  w e l l  r e s p e c t i v e l y ,  i n  a  1 2  w e l l  














2.6.1 DNA transient transfections 
 
C e l l s  w e r e  t r a n s f e c t e d  w i t h  p R L - T K  ( 5 0  n g )  a n d  p G L 3 - C O L 5 A 1 _ T E N / C O N  
( 5 0 0  n g )  p e r  w e l l  u s i n g  X t r e m e g e n e H D  ( R o c h e  D i a g n o s t i c s ,  R o c h e  
A p p l i e d  S c i e n c e ,  M a n n h e i m ,  G e r m a n y ) .  T h e  X t r e m e g e n e H D  
t r a n s f e c t i o n  r e a g e n t  w a s  p r e p a r e d  i n  a  r a t i o  o f  3 : 1 5 0  o f  t r a n s f e c t i o n  
r e a g e n t  t o  s e r u m - f r e e  c u l t u r e  m e d i u m  a n d  a d d e d  t o  n u c l e i c  a c i d  m i x  
i n  a  s o l u t i o n  o f  n u c l e a s e  f r e e  w a t e r .  M i x t u r e  w a s  b r i e f l y  v o r t e x e d  a n d  
c e n t r i f u g e d  a t  1 3  0 0 0  r p m  u s i n g  t h e  B i o f u g e  F r e s c o  b e n c h  t o p  
c e n t r i f u g e  ( H e r a e u s  I n s t r u m e n t s ,  H a n a u ,  G e r m a n y )  f o r  3 0  s e c o n d s  a n d  
i n c u b a t e d  a t  r o o m  t e m p e r a t u r e  f o r  1 5  m i n .  F o r t y - n i n e  μ l  o f  
t r a n s f e c t i o n  c o m p l e x  w a s  a d d e d  d r o p - w i s e  t o  e a c h  w e l l .  
 
2.6.2 RNA:DNA transient co-transfections 
 
C e l l s  w e r e  t r a n s f e c t e d  w i t h  p R L - T K  ( 5 0  n g )  a n d  p G L 3 - C O L 5 A 1 _ T E N / C O N  
( 5 0 0  n g )  p e r  w e l l  u s i n g  A t t r a c t e n e  ( Q I A G E N  G m b H ,  H i l d e n ,  G e r m a n y ) ,  
a  n o n - l i p o s o m a l  r e a g e n t  w h i c h  c a n  b i n d  t o  b o t h  D N A  a n d  R N A .  T h e  
r e a g e n t - n u c l e i c  a c i d  c o m p l e x e s  f u s e  w i t h  t h e  p l a s m a  m e m b r a n e s  o f  t h e  
r e c i p i e n t  c e l l s  a n d  r e l e a s e  t h e i r  n u c l e i c  a c i d  c o n t e n t .  C e l l s  w e r e  a l s o  
t r a n s f e c t e d  w i t h  0 ,  1 ,  1 0  o r  2 0  p m o l  o f  m i R 6 0 8  o r  m i R 1 2 5 a - 5 p  m i S c r i p t  
m i R N A  M i m i c  ( Q I A G E N  G m b H ,  H i l d e n ,  G e r m a n y ) .  T h e  a m o u n t  o f  
t r a n s f e c t e d  R N A  w a s  k e p t  c o n s t a n t  b y  a d d i n g  A l l s t a r s  n e g a t i v e  c o n t r o l  
s i R N A * *  ( Q I A G E N  G m b H ,  H i l d e n ,  G e r m a n y ) .  T h e  m i R N A  m i m i c  i s  a  
s y n t h e t i c  R N A  w h i c h  i m i t a t e s  t h e  m a t u r e  f o r m  o f  t h e  m i R N A s  t e s t e d .  
A l l s t a r s  n e g a t i v e  c o n t r o l  i s  a  s h o r t  s e q u e n c e  o f  s c r a m b l e d  s i R N A  w h i c h  
h a s  b e e n  e x t e n s i v e l y  t e s t e d  t o  c o n f i r m  t h a t  i t  d o e s  n o t  i n f l u e n c e  m R N A  
s t a b i l i t y  o f  a n y  c u r r e n t l y  a n n o t a t e d  h u m a n  g e n e  o r  o f  t h e  t r a n s f e c t e d  
v e c t o r s .  A t t r a c t e n e  t r a n s f e c t i o n  r e a g e n t  w a s  p r e p a r e d  i n  a  r a t i o  o f  
9 : 2 4 0  o f  A t t r a c t e n e  t o  s e r u m - f r e e  c u l t u r e  m e d i u m  a n d  a d d e d  t o  t h e  
n u c l e i c  a c i d  m i x  i n  a  s o l u t i o n  o f  n u c l e a s e  f r e e  w a t e r .  M i x t u r e  w a s  
b r i e f l y  v o r t e x e d  a n d  c e n t r i f u g e d  a t  1 3  0 0 0  r p m  u s i n g  t h e  B i o f u g e  
F r e s c o  b e n c h  t o p  c e n t r i f u g e  ( H e r a e u s  I n s t r u m e n t s ,  H a n a u ,  G e r m a n y )  












s e v e n  µ l  o f  t r a n s f e c t i o n  c o m p l e x  w a s  a d d e d  d r o p - w i s e  t o  e a c h  w e l l  
( A p p e n d i x  K  f o r  c o m p l e t e  p r o t o c o l ) .  
 
T h e  m i R 6 0 8  c o - t r a n s f e c t i o n  i n t o  t h e  h u m a n  f i b r o s a r c o m a  c e l l  l i n e  H T 1 0 8 0  
w a s  c o m p l e t e d  u s i n g  a n  e a r l i e r  p r o t o c o l  i n  w h i c h  c e l l s  w e r e  c o - t r a n s f e c t e d  
w i t h  a  1 ;  1 0 ;  5 0  o r  1 0 0  p m o l  m i R N A  m i m i c  O R  A l l s t a r s  n e g a t i v e  c o n t r o l .  T h i s  
p r o t o c o l  h o w e v e r ,  s h o w e d  s i g n i f i c a n t  l e v e l s  o f  c e l l  c y t o t o x i c i t y  a n d  w a s  
a l t e r e d  f o r  a l l  f u t u r e  e x p e r i m e n t s  ( A p p e n d i x  L ) .  
 
2.7 Luciferase assay 
 
A f t e r  a  t o t a l  o f  4 5  h o u r s  o f  t r a n s f e c t i o n ,  t h e  a c t i v i t y  o f  f i r e f l y  l u c i f e r a s e  b y  
p G L 3 - C O N / T E N  a n d  r e n i l l a  l u c i f e r a s e  e x p r e s s e d  b y  p R L - T K  w a s  m e a s u r e d  
i n d e p e n d e n t l y  u s i n g  t h e  D u a l  L u c i f e r a s e  R e p o r t e r  A s s a y  s y s t e m  ( P r o m e g a  
C o r p o r a t i o n ,  M a d i s o n ,  W i s c o n s i n ,  U S A )  a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ’ s  
i n s t r u c t i o n s .  C e l l s  w e r e  w a s h e d  t w i c e  w i t h  1  m l  o f  c h i l l e d  1 X  P h o s p h a t e  
B u f f e r e d  S a l i n e  ( P B S )  a n d  l y s e d  w i t h  1 0 0  μ l  o f  1 X  P a s s i v e  L y s i s  P u f f e r  ( P L B )  
( P r o m e g a  C o r p o r a t i o n ,  M a d i s o n ,  W i s c o n s i n ,  U S A )  f o r  t w e n t y  m i n u t e s  o n  a  
s h a k e r  a t  r o o m  t e m p e r a t u r e .  L y s a t e s  w e r e  c o l l e c t e d  a n d  s t o r e d  o v e r n i g h t  a t  
- 8 0 °  C ,  t h e n  t h a w e d  a n d  b r i e f l y  v o r t e x e d  a n d  c e n t r i f u g e d  a t  1 3  0 0 0  r p m  u s i n g  
t h e  B i o f u g e  F r e s c o  b e n c h  t o p  c e n t r i f u g e  ( H e r a e u s  I n s t r u m e n t s ,  H a n a u ,  
G e r m a n y )  f o r  3 0  s e c o n d s .  T e n  µ l  o f  s u p e r n a t a n t  o f  e a c h  s a m p l e  w a s  p l a t e d  
i n t o  a  9 6 - w e l l  p l a t e  a n d  i n c u b a t e d  i n  a  1 X  L u c i f e r a s e  A s s a y  B u f f e r  c o n t a i n i n g  
5 0  μ l  o f  f i r e f l y  l u c i f e r a s e  s u b s t r a t e ,  b e e t l e  l u c i f e r i n .  U p o n  e x p o s u r e  t o  t h e  
s u b s t r a t e ,  f i r e f l y  l u c i f e r a s e  e x p r e s s e d  b y  p G L - 3 - T E N / C O N  D N A  c o n s t r u c t s  w i l l  
c a t a l y s e  t h e  b e e t l e  l u c i f e r i n  t o  p r o d u c e  o x y l u c i f e r i n  a n d  l i g h t .  T h e  e m i t t e d  
l i g h t  d i r e c t l y  c o r r e l a t e s  w i t h  t h e  a m o u n t  o f  l u c i f e r a s e  p r e s e n t  a n d  i s  u s e d  a s  
a n  i n d i r e c t  m e a s u r e  o f  m R N A  s t a b i l i t y .  L i g h t  e m i s s i o n  ( l u m i n e s c e n c e )  w a s  
q u a n t i f i e d  w i t h  a  L u m i n o s k a n  A s c e n t  l u m i n o m e t e r  ( T h e r m o  L a b s y s t e m s ,  
C h e s h i r e ,  U K ) .  F i f t y  m i c r o l i t e r s  o f  1 X  S t o p  &  G l o  B u f f e r  ( P r o m e g a  
C o r p o r a t i o n ,  M a d i s o n ,  W i s c o n s i n ,  U S A )  w a s  t h e n  a d d e d  t o  t h e  s a m p l e s .  T h i s  
r e a g e n t  c o n t a i n s  r e n i l l a  l u c i f e r a s e  s u b s t r a t e  w h i c h  i n t e r a c t s  w i t h  r e n i l l a  
l u c i f e r a s e  t o  p r o d u c e  l u m i n e s c e n c e .  T h e s e  r e a d i n g s  w e r e  a n a l y s e d  w i t h  
A s c e n t  S o f t w a r e  2 . 6  ( T h e r m o  L a b s y s t e m s ,  C h e s h i r e ,  U K ) .  F i r e f l y  l u c i f e r a s e  












i n  e a c h  s a m p l e .  T h e  d a t a  o b t a i n e d  f r o m  r e n i l l a  l u c i f e r a s e  r e a d i n g s  w e r e  u s e d  
t o  n o r m a l i z e  f i r e f l y  l u c i f e r a s e  r e s u l t s .   
 
2.8 Bioinformatic analyses 
 
S e v e r a l  b i o i n f o r m a t i c s  d a t a b a s e s  i n c l u d i n g  E n s e m b l ,  N C B I ,  H a p m a p ,  d b S N P ,  
1 0 0 0 g e n o m e s  a n d  U C S C  w e r e  i n v e s t i g a t e d  p r i o r  t o  i n i t i a t i o n  o f  b i o c h e m i c a l  
a s s a y s .  H i g h l y  c o n s e r v e d  r e g i o n s  w e r e  i d e n t i f i e d  a n d  i n v e s t i g a t e d  i n  g r e a t e r  
d e t a i l .  T h e  C O L 5 A 1  3 ’ - U T R  w a s  a n n o t a t e d  w i t h  s i n g l e  n u c l e o t i d e  
p o l y m o r p h i s m s  a n d  v a r i a b l e  n u c l e o t i d e  t a n d e m  r e p e a t s  u s i n g  t h e  H a p m a p  
( h t t p : / / h a p m a p . n c b i . n l m . n i h . g o v  -  A c c e s s e d  N o v e m b e r  1 s t  2 0 1 2 )  d b S N P  
( h t t p : / / w w w . n c b i . n l m . n i h . g o v / p r o j e c t s / S N P / )  a n d  E n s e m b l  
( h t t p : / / w w w . e n s e m b l . o r g )  d a t a b a s e s .  R N A  b i n d i n g  p r o t e i n  m o t i f s  w e r e  
i d e n t i f i e d  u s i n g  t h e  R N A  b i n d i n g  p r o t e i n  d a t a b a s e  R B P D B  
( h t t p : / / r b p d b . c c b r . u t o r o n t o . c a /  -  A c c e s s e d  N o v e m b e r  1 s t  2 0 1 2 )  
 
2.8.1 Identification of putative miRNA binding sites 
 
P o l y m o r p h i c  m i R N A  b i n d i n g  s i t e s  p r e s e n t  w i t h i n  t h e  3 ’ - U T R  w e r e  i d e n t i f i e d  
u s i n g  t h e  P a t r o c l e s  p o l y m o r p h i c  m i R N A - t a r g e t  d a t a b a s e  
( h t t p : / / w w w . p a t r o c l e s . o r g ) .  T h e  P a t r o c l e s  p r e d i c t i o n  a l g o r i t h m  r e l i e s  o n  t h e  
e v o l u t i o n a r i l y  c o n s e r v e d  h e p t a m e r  a n d  o c t a m e r  s e e d  r e g i o n s  t o  i d e n t i f y  
p o t e n t i a l  s i t e s  ( A p p e n d i c e s  M  a n d  N ) .  m i c r o C O S M  T a r g e t s ,  a  d a t a b a s e  
c u r a t e d  b y  t h e  E u r o p e a n  B i o i n f o r m a t i c  I n s t i t u t e  ( E B I )  ( a  s u b s i d i a r y  o f  t h e  
E u r o p e a n  M o l e c u l a r  B i o l o g y  L a b o r a t o r y  -  E M B L )  w a s  u s e d  t o  i d e n t i f y  
p o t e n t i a l  n o n - p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e s  ( A p p e n d i x  O ) .  A l l  c h o s e n  
m i R N A s  w e r e  i n v e s t i g a t e d  u s i n g  t h e  m i R B a s e  d a t a b a s e  
( w w w . m i R B a s e . o r g ) [ 1 0 1 ] ,  [ 1 0 2 ]   
 
2.8.2 Identification of conserved sequences between species 
 
T h e  D N A  s e q u e n c e  o f  t h e  e x o n  6 6  o f  C O L 5 A 1  w a s  a l i g n e d  t o  t h e  c o r r e s p o n d i n g  
r e g i o n  i n  s e v e r a l  a n i m a l s  i n c l u d i n g  m o u s e ,  r a t ,  c h i m p a n z e e  a n d  g o r i l l a  u s i n g  
E C R  b r o w s e r  ( h t t p : / / e c r b r o w s e r . d c o d e . o r g /  A c c e s s e d  N o v e m b e r  1 s t  2 0 1 2 -  













2.8.3 mRNA secondary structures 
 
A l l  s e c o n d a r y  s t r u c t u r e s  o f  t h e  w i l d - t y p e  a n d  m u t a t e d  C  a n d  T  f u n c t i o n a l  
f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  w e r e  g e n e r a t e d  u s i n g  t h e  S f o l d  o n l i n e  R N A  
f o l d i n g  t o o l  ( h t t p : / / s f o l d . w a d s w o r t h . o r g )  [ 1 0 4 ] ,  [ 1 0 5 ] .  T h e  S f o l d  R N A  f o l d i n g  
a l g o r i t h m  g e n e r a t e s  R N A  s e c o n d a r y  s t r u c t u r e s  u s i n g  a  s t a t i s t i c a l  s a m p l e  f r o m  
t h e  B o l t z m a n n  e n s e m b l e  o f  s e c o n d a r y  s t r u c t u r e s .  A l l  s t r u c t u r e s  w e r e  f o l d e d  
a t  3 7 °  C  a n d  1  M  N a C l  i n  t h e  a b s e n c e  o f  d i v a l e n t  i o n s .   
 
2.9 MIR608 genotyping 
 
T h e  p a r t i c i p a n t s  ( 1 4 3  T E N  a n d  3 1 2  C O N )  w e r e  g e n o t y p e d  f o r  t h e  G > C  S N P  
( r s 4 9 1 9 5 1 0 )  p r e s e n t  i n  t h e  M I R 6 0 8  g e n e  u s i n g  a  c u s t o m  d e s i g n e d  
F l u o r e s c e n c e - b a s e d  T a q m a n  P C R  a s s a y  ( A p p l i e d  B i o s y s t e m s ,  F o s t e r  C i t y ,  C A ,  
U S A ) .  A l l e l e - s p e c i f i c  p r o b e s  a n d  f l a n k i n g  p r i m e r  s e t s  ( s e q u e n c e s  a v a i l a b l e  o n  
r e q u e s t )  w e r e  u s e d  a l o n g  w i t h  a  p r e m a d e  P C R  m a s t e r m i x  c o n t a i n i n g  a m p l i T a q  
D N A  p o l y m e r a s e  G o l d  ( A p p l i e d  B i o s y s t e m s )  i n  a  f i n a l  r e a c t i o n  v o l u m e  o f  8  μ l .  
T h e  t w o - s t e p  P C R  c o n s i s t e d  o f  a  1 0 - m i n  h e a t  a c t i v a t i o n  s t e p  ( 9 5 ◦ C )  f o l l o w e d  
b y  4 0  c y c l e s  o f  1 5  s  a t  9 2 ◦  C  a n d  1  m i n  a t  6 0 ◦ C  u s i n g  t h e  X P  T h e r m a l  C y c l e r ,  
B l o c k  m o d e l  X P - G  ( B i o e r  T e c h n o l o g y  C o . ,  L t d ,  T o k y o ,  J a p a n ) .  E n d - p o i n t  
f l u o r e s c e n c e  u s i n g  a  7 9 0 0  H T  F a s t  R e a l - T i m e  P C R  S y s t e m  a n d  t h e  S D S  
S o f t w a r e  v e r s i o n  2 . 3  ( A p p l i e d  B i o s y s t e m s )  w a s  u s e d  t o  d e t e r m i n e  t h e  
g e n o t y p e s  o f  e a c h  p o l y m o r p h i s m .  D u p l i c a t e s  o f  t h r e e  t o  n i n e  D N A  s a m p l e s  
w e r e  i n c l u d e d  i n  e a c h  g e n o t y p i n g  r u n  a s  p o s i t i v e  c o n t r o l s .  T h e  m a t u r e  m i R N A  
m i R 6 0 8  h a s  t h e  f o l l o w i n g  s e q u e n c e :   
 














2.10 Statistical analyses 
 
A l l  d a t a  w a s  a n a l y s e d  w i t h  S T A T I S T I C A  V 1 0 . 0  ( S t a t s o f t  I n c . ,  T u l s a ,  O K ,  U S A )  
a n d  G r a p h P a d  P r i s m  v e r s i o n  5 . 0 d  f o r  M a c  O S  X  ( G r a p h P a d  S o f t w a r e ,  S a n  
D i e g o ,  C A ,  U S A ,  h t t p : / / w w w . g r a p h p a d . c o m )  p r o g r a m s .   
 
N o r m a l l y  d i s t r i b u t e d  d a t a  w e r e  a n a l y z e d  u s i n g  a n  i n d e p e n d e n t  t - t e s t  o r  a  
o n e - w a y  a n a l y s i s  o f  v a r i a n c e  ( A N O V A ) ,  f o l l o w e d  b y ,  i f  a p p r o p r i a t e ,  a  T u k e y  
H S D  p o s t - h o c  a n a l y s i s .  D a t a  w h i c h  d e v i a t e d  f r o m  n o r m a l  d i s t r i b u t i o n  w e r e  
a n a l y s e d  u s i n g  t h e  n o n - p a r a m e t r i c  M a n n - W h i t n e y  t e s t .   
 
A  o n e - w a y  a n a l y s i s  o f  v a r i a n c e  w a s  u s e d  t o  d e t e r m i n e  a n y  s i g n i f i c a n t  
d i f f e r e n c e s  b e t w e e n  t h e  c h a r a c t e r i s t i c s  o f  t h e  T E N  a n d  C O N  g r o u p s  w i t h i n  
t h e  A U S  a n d  S A  c o h o r t s .  A  C h i - s q u a r e d  a n a l y s i s  o r  F i s h e r ’ s  e x a c t  t e s t  w a s  
u s e d  t o  a n a l y s e  a n y  d i f f e r e n c e s  i n  t h e  g e n o t y p e  f r e q u e n c i e s  a n d  o t h e r  
c a t e g o r i c a l  d a t a  b e t w e e n  t h e  g r o u p s .  S t a t i s t i c a l  s i g n i f i c a n t  d i f f e r e n c e s  w e r e  
a c c e p t e d  w h e n  P < 0 . 0 5 .  H a r d y - W e i n b e r g  e q u i l i b r i u m  ( H W E )  w a s  e s t a b l i s h e d  
u s i n g  t h e  p r o g r a m  G e n e p o p  w e b  v e r s i o n  3 . 4  ( h t t p : / / g e n e p o p . c u r t i n . e d u . a u / ) .  
D a t a  w e r e  p r e s e n t e d  a s  m e a n  ±  s t a n d a r d  d e v i a t i o n  o r  a  f r e q u e n c y  a n d  r e s u l t s  
w e r e  c o n s i d e r e d  s i g n i f i c a n t  a t  p < 0 . 0 5 .   
C o m b i n e d  g e n o t y p e  f r e q u e n c i e s  w e r e  a l s o  a n a l y z e d  u s i n g  t h e  M o n t e  C a r l o  
t e s t  ( C L U M P  p r o g r a m ,  v e r s i o n  2 . 0 )  ( S h a m  &  C u r t i s ,  1 9 9 5 ) .  W h e n  c o m b i n e d  
g e n e - g e n e  i n t e r a c t i o n s  a n d  e f f e c t s  w e r e  a n a l y z e d ,  s t a t i s t i c a l l y  s i g n i f i c a n t  














3.1 Identification of putative miRNA binding sites 
 
T o  i d e n t i f y  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w i t h i n  t h e  C O L 5 A 1  3 ’ - U T R ,  a n  
e x t e n s i v e  b i o i n f o r m a t i c  i n v e s t i g a t i o n  o f  2 . 5  k b  o f  t h e  w i l d - t y p e  s e q u e n c e  
( e q u i v a l e n t  t o  t h e  C - f u n c t i o n a l  f o r m ) ( A p p e n d i x  Q )  w a s  u n d e r t a k e n  [ 6 4 ] .  
T h r e e  m a j o r  m i R N A  d a t a b a s e s  w e r e  u s e d  i n  t h e  i n v e s t i g a t i o n :  ( 1 )  t h e  
P a t r o c l e s  d a t a b a s e  w a s  u s e d  t o  i d e n t i f y  p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e s ;  
( 2 )  m i c r o C O S M  T a r g e t s  w a s  u s e d  t o  i d e n t i f y  p o t e n t i a l  m i R N A  b i n d i n g  s i t e s  
u s i n g  a  l e s s  s t r i n g e n t  p r e d i c t i o n  a l g o r i t h m  a n d  ( 3 )  m i R B a s e  w a s  u s e d  t o  
c o n f i r m  p o t e n t i a l  m i R N A  r e g u l a t o r s  a n d  t o  i d e n t i f y  r e l a t e d  m i R N A s .   
 
I n v e s t i g a t i o n  o f  t h e  P a t r o c l e s  d a t a b a s e  r e t u r n e d  t h r e e  p u t a t i v e  h e p t a m e r i c  
o r  o c t a m e r i c  p o l y m o r p h i c  m i R N A  s i t e s  f o r  H s a - m i R 8 8 6 - 5 p ,  H s a - m i R - 6 9 8  a n d  
a n  u n k n o w n  m i R N A  ( h e r e a f t e r  r e f e r r e d  t o  a s  t h e  M b o I I  o c t a m e r )  ( T a b l e  3 . 1  
a n d  F i g u r e  3 . 1 ) .  A l l  3  s i t e s  w e r e  i d e n t i f i e d  b y  t h e i r  s e q u e n c e  c o n s e r v a t i o n  
a c r o s s  s p e c i e s  a n d  w e r e  c o n f i r m e d  b y  g e n e t i c  c o - e x p r e s s i o n  s t u d i e s  o r  g e n e  
e x p r e s s i o n  a n a l y s e s .   
 
Table 3.1 Three putative polymorphic miRNA binding sites within the 2.5 kb COL5A1 3’-untranslated 
region (UTR) identified using the Patrocles algorithm 
miRNA ID SNP ID Description 
Target 
Heptamer/Octamer 
Position a Confirmation b 
Hsa-miR886-
5p 
rs1134114 C/T CCGACCCA 327-335 Co-expression 
Hsa-miR-608 rs3196378 C/A CCACCCA 744-751 Co-expression 
MboII RFLP 
octamer 




a Nucleotide position within the COL5A1 3’-UTR (Appendix Q) 
b All sites were confirmed by co-expression or gene expression experiments (Appendices M and N). 
Polymorphic nucleotides are underlined.  


















F i g u r e  3 . 1  S c h e m a t i c  d i a g r a m  s h o w i n g  p o s i t i o n s  o f  t h e  t h r e e  
e v o l u t i o n a r i l y  c o n s e r v e d  h e p t a m e r i c  o r  o c t a m e r i c  p o l ym o r p h i c  m i R N A 
b i n d i n g  s i t e s  w i t h i n  t h e  3 ’ - U T R  o f  C O L 5 A 1 .  
T h e  s e v e n  p o l ym o r p h i s m s  w h i c h  d e t e r m i n e  t h e  C -  ( w i l d - t yp e )  a n d  t h e  T - a l l e l i c  
f o r m s  o f  t h e  3 ’ - U T R  a r e  s h o w n  i n  t h e  w h i t e  a n d  b l a c k  s q u a r e s  r e s p e c t i v e l y .  
T h e  p o s i t i o n s  o f  t h e  t h r e e  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  a r e  i n d i c a t e d .  T h e  
H s a - m i R - 6 0 8  b i n d i n g  s i t e  c o n t a i n s  s i n g l e  n u c l e o t i d e  p o l ym o r p h i s m  ( S N P )  
r s 3 1 9 6 3 7 8 .  T h e  H s a - m i R - 8 8 6 - 5 p  a n d  M b o I I  o c t a m e r  b i n d i n g  s i t e s  c o n t a i n  
S N P s  r s 1 1 3 4 1 1 4  a n d  r s 1 1 1 0 3 5 4 4  r e s p e c t i v e l y .  T h e  C  o r  T  a l l e l e s  o f  t h e s e  
t w o  S N P s  a r e  a s s o c i a t e d  e i t h e r  f o r m  o f  t h e  3 ’ - U T R .  T h e  n u c l e o t i d e  p o s i t i o n s  
a n d  t h e  r s  n u m b e r s  o f  e a c h  o f  t h e  p o l ym o r p h i s m s  a r e  a n n o t a t e d  a b o v e  o r  
b e l o w  t h e  b o x e s  r e s p e c t i v e l y .  Y  -  C  o r  T ;  1  -  ( A G G G ) 1  o r  ( A T C T ) 1 ;  2  -  ( A G G G ) 2  
o r  ( A T C T ) 2 .  
 
T h e  m i c r o C O S M  a l g o r i t h m  i d e n t i f i e d  3 3  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w i t h i n  
t h e  3 ’ - U T R  o f  t h e  h u m a n  C O L 5 A 1  g e n e  ( A p p e n d i x  O ) .  T h e  1 0  p u t a t i v e  m i R N A  
b i n d i n g  s i t e s  w i t h  t h e  h i g h e s t  b i n d i n g  p r o b a b i l i t y  b a s e d  o n  a  c o m b i n a t i o n  o f  
t h e  m i R A N D A  b i n d i n g ,  P o i s s o n  b i n d i n g  a n d  O r t h o l o g o u s  m i R N A  b i n d i n g  
s t a t i s t i c a l  t e s t s  a r e  l i s t e d  i n  T a b l e  3 . 2 .  T h e  m i R A N D A  b i n d i n g  s c o r e  i s  a  
m e a s u r e  o f  t h e  b i n d i n g  p r o b a b i l i t y  o f  t h e  m i R N A  t o  i t s  t a r g e t ,  t h e  P o i s s o n  
s c o r e  d e n o t e s  t h e  p r o b a b i l i t y  o f  a  s i n g l e  t r a n s c r i p t  h a v i n g  m u l t i p l e  m i R N A  
h i t s  w h i l e  t h e  o r t h o l o g o u s  m i R N A  b i n d i n g  s c o r e  i s  a  m e a s u r e  o f  t h e  
p r o b a b i l i t y  o f  a  m i R N A  f a m i l y  b i n d i n g  t o  t h e  s a m e  c o n s e r v e d  s i t e  i n  c l o s e l y  
r e l a t e d  s p e c i e s  f r o m  t h e  s a m e  o r t h o l o g o u s  g r o u p  [ 1 0 6 ] .  A n y  p r e d i c t e d  m i R N A  
b i n d i n g  s i t e  w h i c h  s c o r e d  a  p - v a l u e  g r e a t e r  t h a n  0 . 0 5 1  f o r  a n y  o f  t h e  a b o v e -
s t a t e d  t e s t s  w a s  o m i t t e d  f r o m  f u r t h e r  a n a l y s i s .  E x c e p t  f o r  m i R - 3 7 7 *  a n d  m i R -
3 3 0 - 5 p ,  t h e  r e m a i n i n g  e i g h t  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w e r e  l o c a t e d  
w i t h i n  t h e  8 5 8  b p  r e g i o n  o f  t h e  C O L 5 A 1  3 ’ - U T R  p r e v i o u s l y  a s s o c i a t e d  w i t h  












Table 3.2 The ten putative miRNA binding sites with the greatest binding probability within the 3’-UTR 
of COL5A1 as predicted by the MicroCOSM Targets database 
Rfam ID Score Energy Base P Poisson P Org P Position a 
hsa-miR-768-5p 18.261 -29.09 8.08E-03 8.05E-03 8.05E-03 592 to 615 
hsa-miR-377* 17.738 -26.18 1.16E-02 1.16E-02 1.16E-02 31 to 52 
hsa-miR-125a-5p 17.577 -23.67 1.32E-02 1.32E-02 4.71E-04 346 to 361 
hsa-miR-150 17.316 -32.17 2.33E-02 2.30E-02 2.30E-02 357 to 369 
hsa-miR-499-5p 17.189 -11.35 2.14E-02 2.11E-02 3.03E-04 577 to 595 
hsa-miR-330-5p 17.105 -26.56 4.74E-02 4.63E-02 2.75E-03 176 to 187 
hsa-miR-124 17.065 -17.22 1.79E-02 1.77E-02 3.01E-05 537 to 556 
hsa-miR-125b 16.999 -24.99 2.19E-02 2.16E-02 4.71E-04 344 to 361 
hsa-miR-331-3p 16.871 -25.46 3.93E-02 3.86E-02 3.86E-02 345 to 362 
hsa-miR-570 16.788 -17.88 5.05E-02 4.93E-02 1.13E-02 577 to 596 
a Nucleotide position within the COL5A1 3’-UTR (Appendix Q) 
Score – calculated using the miRanda algorithm as a measure of base-pair complementarity.  
Energy – calculated using Vienna RNA folding routines as a measure of thermodynamic stability. 
Base P – a measure of the binding probability calculated using the miRanda score. 
Poisson P – a measure of the probability that a single transcript has more than one statistically 
significant hit according to a Poisson distribution 
Org P - an estimation of the probability of the same miRNA family hitting multiple transcripts for different 
species in an orthologous group  
Base P and Poisson P values are calculated using the model proposed by Rehmsmeier et al. (2004) 
[106]  
 
T h e  m i R N A s  H s a - m i R - 6 0 8  a n d  t h e  c o n s e r v e d  M b o I I  R F L P  o c t a m e r  w e r e  c h o s e n  
f o r  f u r t h e r  i n v e s t i g a t i o n  ( s e c t i o n  3 . 2 )  d u e  t o  t h e  p o l y m o r p h i c  n a t u r e  o f  t h e i r  
b i n d i n g  s i t e s  a n d  t h e i r  s t r a t e g i c  p o s i t i o n s  w i t h i n  t h e  r e g i o n  o f  t h e  C O L 5 A 1  
3 ’ - U T R  s h o w n  t o  b e  p r e v i o u s l y  a s s o c i a t e d  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  
[ 1 3 ] ,  [ 1 4 ] ,  [ 2 2 ] .  T h e  M I R 6 0 8  g e n e  a l s o  c o n t a i n s  a  C > G  S N P  ( r s 4 9 1 9 5 1 0 )  w i t h i n  
t h e  m a t u r e  m i R N A  s e q u e n c e .  T h e  a s s o c i a t i o n  o f  t h i s  p o l y m o r p h i s m  w i t h  
A c h i l l e s  t e n d i n o p a t h y  w a s  t h e r e f o r e  i n v e s t i g a t e d  ( s e c t i o n  3 . 3 ) .  I n  a d d i t i o n  
t o  t h e s e  m i R N A  b i n d i n g  s i t e s ,  t h e  H s a - m i R - 1 2 5 a - 5 p  b i n d i n g  s i t e  w a s  a l s o  












( C / T )  [ 1 3 ] ,  [ 1 4 ]  a n d  t h e  c o m m e r c i a l  a v a i l a b i l i t y  o f  i t s  m i R N A  m i m i c .  F i g u r e  
3 . 2  i s  s c h e m a t i c  d i a g r a m  s h o w i n g  t h e  p o s i t i o n s  o f  t h e  1 3  m i R N A  b i n d i n g s  
s i t e s  i d e n t i f i e d  i n  a b o v e  a n a l y s e s  i n  r e l a t i o n  t o  t h e  7  a l l e l e  d i f f e r e n t i a t i n g  
v a r i a n t s .   
 
 
F i g u r e  3 . 2  S c h e m a t i c  d i a g r a m  s h o w i n g  p o s i t i o n s  o f  t h e  1 3  p u t a t i v e  m i R N A 
b i n d i n g  s i t e s  w i t h i n  t h e  3 ’ - U T R  o f  C O L 5 A 1  i n  r e l a t i o n  t o  t h e  s e v e n  
p o l y m o r p h i s m s  ( n u m b e r e d  r e c t a n g l e s )  t h a t  d e t e r m i n e  t h e  C -  a n d  T - a l l e l i c  
f o r m s .  
T h e  t h r e e  p u t a t i v e  p o l ym o r p h i c  m i R N A  s i t e s  p r e d i c t e d  b y  t h e  P a t r o c l e s  
d a t a b a s e  a r e  u n d e r l i n e d .  ( 1 )  r s 1 3 9 4 6  ( C / T ) ,  ( 2 )  r s 1 2 7 2 2  ( C / T ) ,  ( 3 )  r s 3 1 9 6 3 7 8  
( A / C ) ,  ( 4 )  r s 7 1 7 4 6 7 4 4  ( A G G G ( n ) ) ,  ( 5 )  r s 1 6 3 9 9  ( A T C T ( n ) ) ,  ( 6 )  r s 1 1 3 4 1 7 0  ( A / T )  
a n d  ( 7 )  r s 3 1 2 8 5 7 5  ( C / T )  
 
 
3.2 miRNA analyses 
 
T h e  n e x t  a i m  o f  t h i s  p r o j e c t  w a s  t o  t e s t  w h e t h e r  t h e  m i R N A  m i m i c s  f o r  H s a -
m i R - 6 0 8  a n d  h s a - m i R 1 2 5 a - 5 p  w e r e  c a p a b l e  o f  r e p r e s s i n g  t h e  l u c i f e r a s e  
e x p r e s s i o n  o f  t h e  C O L 5 A 1  3 ’ - U T R  c o n s t r u c t s  a n d  w h e t h e r  t h e s e  m i m i c s  w e r e  
a b l e  t o  r e p r e s s  t h e  l u c i f e r a s e  e x p r e s s i o n  o f  t h e  C -  a n d  T - a l l e l i c  f o r m s  t o  
d i f f e r e n t  d e g r e e s  [ 6 4 ] .  T o  t h i s  e n d  s e v e r a l  r e p o r t e r  c o n s t r u c t s  c o n t a i n i n g  
t h e  f u l l  l e n g t h  C O L 5 A 1 - 3 ′ U T R  w e r e  t r a n s f e c t e d  w i t h  m i R N A  m i m i c  a n d  
a s s a y e d  f o r  l u c i f e r a s e  a c t i v i t y  i n  H T 1 0 8 0  f i b r o s a r c o m a  a n d / o r  S V W I - 3 8  c e l l s .  
T h e  s e q u e n c e  o f  t h e  C O L 5 A 1  3 ’ - U T R  w i t h i n  a l l  c o n t r o l  ( C O N  5 . 1 ,  C O N  3 . 2  a n d  












u s e d  i n  t h i s  s t u d y  w a s  p r e v i o u s l y  c o n f i r m e d  t o  c o r r e s p o n d  t o  t h e  C -  a n d  T -
a l l e l i c  f o r m s  r e s p e c t i v e l y  [ 6 4 ] .  A s  n o  m i R N A  m i m i c  w a s  c o m m e r c i a l l y  
a v a i l a b l e  f o r  t h e  M b o I I  o c t a m e r ,  a  s i t e - d i r e c t e d  m u t a g e n e s i s  a p p r o a c h  w a s  
u n d e r t a k e n  t o  i n v e s t i g a t e  w h e t h e r  t h i s  s i t e  w a s  a  v a l i d  b i n d i n g  s i t e  f o r  a  
n e g a t i v e  r e g u l a t o r  o f  t h e  C O L 5 A 1  3 ’ - U T R .  
 
3.2.1 The co-transfection of Hsa-miR-608 mimic reduces luciferase expression by binding to the 
polymorphic binding site within in the COL5A1 3’-UTR in the HT1080 fibrosarcoma cell line with 
greater repression observed with the T-allele. 
 
A  s t a t i s t i c a l l y  s i g n i f i c a n t  r e d u c t i o n  i n  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  w a s  
n o t e d  f o r  b o t h  t h e  C O N  ( C l o n e  C O N  2 . 1 ,  F i g u r e  3 . 3 )  a n d  T E N  ( C l o n e  T E N  2 . 2 ,  
F i g u r e  3 . 3 )  c o n s t r u c t s  a t  a l l  d o s e s  ( 1 ;  1 0 ;  5 0  a n d  1 0 0  p m o l )  o f  m i R N A  m i m i c  
t e s t e d .  I n t e r e s t i n g l y ,  t h e r e  w a s  n o  d o s e - d e p e n d e n t  r e d u c t i o n  i n  l u c i f e r a s e  
a c t i v i t y  o b s e r v e d  f o r  e i t h e r  C O N  o r  T E N  c o n s t r u c t s .   
 
F i g u r e  3 . 3  H i s t o g r a m s  s h o w i n g  n o r m a l i z e d  l u c i f e r a s e  a c t i v i t y  f o r  
a s y m p t o m a t i c  C - a l l e l e  a n d  s y m p t o m a t i c  T - a l l e l e  c o n s t r u c t s  w i t h  
i n c r e a s i n g  c o n c e n t r a t i o n s  o f  H s a - m i R - 6 0 8  m i m i c  o r  s i C o n t r o l .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n  c o n t r o l .  A l l  g r a p h e d  d a t a  p o i n t s  
r e p r e s e n t  t h e  a v e r a g e  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  a s  a  p e r c e n t a g e  o f  p G L 3 -
C O N  2 . 1  ( r e f e r e n c e )  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y .  N u m b e r  o f  b i o l o g i c a l  
r e p l i c a t e s  ( N )  i s  d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  b a r s  r e p r e s e n t  













T w o  a d d i t i o n a l  c l o n e s  c o n t a i n i n g  t h e  C -  ( c l o n e s  C O N  5 . 1  a n d  C O N  3 . 2 )  a n d  T -
a l l e l i c  ( c l o n e s  T E N  5 . 1  a n d  T E N  3 . 2 )  f o r m s  w e r e  a s s a y e d  w i t h  1  p m o l  o f  H s a -
m i R - 6 0 8  m i m i c  o r  s i C o n t r o l  t o  c o n f i r m  t h e s e  f i n d i n g s  ( F i g u r e  3 . 4 ) .  A  
s i g n i f i c a n t  r e d u c t i o n  i n  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  w a s  n o t e d  w h e n  1  p m o l  
o f  m i R N A  m i m i c  w a s  t e s t e d  w i t h  b o t h  t h e  C - a l l e l i c  c o n s t r u c t s  ( p < 0 . 0 0 1 ;  
F i g u r e  3 . 4  A )  a n d  T - a l l e l i c  c o n s t r u c t s  ( T E N  5 . 1  -  p < 0 . 0 0 1 ;  T E N  3 . 2  –  p = 0 . 0 0 2 ;  




F i g u r e  3 . 4  H i s t o g r a m s  s h o w i n g  n o r m a l i z e d  l u c i f e r a s e  a c t i v i t y  f o r  t w o  
m o r e  a s y m p t o m a t i c  C - a l l e l e  ( A)  a n d  s y m p t o m a t i c  T - a l l e l e  c o n s t r u c t s  ( B )  
t r a n s f e c t e d  w i t h  1  p m o l  o f  H s a - m i R - 6 0 8  m i m i c  o r  s i C o n t r o l .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n  c o n t r o l .  T h e  n o r m a l i s e d  
l u c i f e r a s e  a c t i v i t y  o f  t h e  H T 1 0 8 0  c e l l s  t r a n s f e c t e d  w i t h  1 p m o l  m i R N A  m i m i c  
i s  e x p r e s s e d  r e l a t i v e  t o  t h e  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  o f  t h e  c e l l s  
t r a n s f e c t e d  w i t h  1  p m o l  s i C o n t r o l .  N u m b e r  o f  b i o l o g i c a l  r e p l i c a t e s  ( N )  i s  
d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  b a r s  r e p r e s e n t  s t a n d a r d  d e v i a t i o n .  
S i g n i f i c a n c e  w a s  a c c e p t e d  a t  p < 0 . 0 5 .  
 
 
T o  i n v e s t i g a t e  w h e t h e r  t h e r e  w a s  a  s i g n i f i c a n t  d i f f e r e n c e  i n  H s a - m i R - 6 0 8 ’ s  
a b i l i t y  t o  r e g u l a t e  t h e  d i f f e r e n t  a l l e l i c  f o r m s  o f  t h e  3 ’ - U T R ,  t h e  l e v e l  o f  
r e d u c t i o n  i n  l u c i f e r a s e  a c t i v i t y  a t  1  p m o l  t r a n s f e c t i o n  w a s  p o o l e d  f o r  t h e  T -
a l l e l e  c o n s t r u c t s  ( T E N  2 . 2 :  6 0 . 8  ±  2 5 . 1 % ,  N = 3 ;  T E N  3 . 2 :  5 3 . 0  ±  1 2 . 2 % ,  N = 3  a n d  
T E N  5 . 1 :  7 7 . 1  ±  0 . 9 % ,  N = 3 )  a n d  C – a l l e l e  c o n s t r u c t s  ( C O N  2 . 1 :  8 0 . 1  ±  8 . 7 % ,  












w e i g h t  t h e  c o n t r i b u t i o n  o f  e a c h  c o n s t r u c t ,  o n l y  t h e  h i g h e s t ,  l o w e s t  a n d  
m e d i a n  v a l u e s  o f  C O N  2 . 1  ( N = 1 2 )  a n d  T E N  2 . 2  ( N = 9 )  a t  t h e  1  p m o l  m i R N A  
m i m i c  t r a n s f e c t i o n  w e r e  u s e d .  
 
T h e  p o o l e d  l u c i f e r a s e  a c t i v i t y  o f  t h e  T - a l l e l i c  c o n s t r u c t s  w a s  s i g n i f i c a n t l y  
l o w e r  ( p = 0 . 0 0 3 )  i n  c o m p a r i s o n  t o  t h e  p o o l e d  C - a l l e l e  c o n s t r u c t s .  T h e r e  w a s ,  
o n  a v e r a g e ,  a  1 3 . 7  ±  7 . 6 %  a n d  3 6 . 4  ±  1 5 . 6 %  r e d u c t i o n  i n  l u c i f e r a s e  a c t i v i t y  
f o r  t h e  C -  a n d  T - a l l e l e  c o n s t r u c t s  r e s p e c t i v e l y  a f t e r  t r a n s f e c t i o n  w i t h  1  p m o l  
o f  m i R N A  m i m i c  ( F i g u r e  3 . 5 ) .  T h e s e  o b s e r v a t i o n s  s u g g e s t  t h a t  t h e  c o -
t r a n s f e c t e d  H s a - m i R - 6 0 8  m i m i c  r e p r e s s e s  t h e  T - a l l e l i c  f o r m  o f  C O L 5 A 1  t o  a  
g r e a t e r  e x t e n t  t h a n  t h e  w i l d  t y p e  C - a l l e l i c  f o r m  i n  t h e  H T 1 0 8 0  f i b r o s a r c o m a  






F i g u r e  3 . 5  H i s t o g r a m  s h o w i n g  a v e r a g e d  l u c i f e r a s e  a c t i v i t y  o f  p o o l e d  T -  
a n d  C - a l l e l i c  c o n s t r u c t s  c o - t r a n s f e c t e d  w i t h  1  p m o l  o f  m i R N A m i m i c .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n  c o n t r o l .  N u m b e r  o f  b i o l o g i c a l  
r e p l i c a t e s  ( N )  i s  d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  b a r s  r e p r e s e n t  
















3.2.2 The addition of Hsa-miR-608 mimic is also capable of repressing luciferase activity in another 
fibroblast cell line. 
 
T h e  H s a - m i R - 6 0 8  c o - t r a n s f e c t i o n  w a s  r e p e a t e d  i n  a  s e c o n d  f i b r o b l a s t - l i k e  c e l l  
l i n e ,  S V W I - 3 8 ,  w h i c h  w a s  o b t a i n e d  b y  i m m o r t a l i s a t i o n  o f  t h e  n o r m a l  W i - 3 8  
f i b r o b l a s t s  w i t h  t h e  S i m i a n  V i r u s  4 0  ( S V 4 0 ) .  T o  r e d u c e  s o u r c e s  o f  e r r o r  a n d  
t h e  l e v e l  o f  c y t o t o x i c i t y  o b s e r v e d  d u r i n g  H T 1 0 8 0  t r a n s f e c t i o n ,  t h e  
t r a n s f e c t i o n  p r o t o c o l  w a s  m o d i f i e d .  T h e  t o t a l  t r a n s f e c t e d  R N A  w a s  
m a i n t a i n e d  a t  2 0  p m o l  a n d  a l l  l u c i f e r a s e  v a l u e s  w e r e  n o r m a l i s e d  w i t h  t h e  
c o r r e s p o n d i n g  2 0  p m o l  s i C o n t r o l  l u c i f e r a s e  a c t i v i t y  ( 1 0 0 % ) .  
 
A  s i g n i f i c a n t  r e d u c t i o n  i n  l u c i f e r a s e  a c t i v i t y  w a s  n o t e d  f o r  b o t h  t h e  C -  ( F i g u r e  
3 . 6  A ,  p < 0 . 0 0 1 )  a n d  T - a l l e l i c  ( F i g u r e  3 . 6  B ,  p = 0 . 0 1 6 )  c o n s t r u c t s .  S p e c i f i c a l l y ,  
w h e n  t h e  S V W I - 3 8  f i b r o b l a s t s  w e r e  c o - t r a n s f e c t e d  w i t h  C O N  5 . 1  a n d  m i R - 6 0 8  
m i m i c ,  t h e r e  w a s  a  s t a t i s t i c a l l y  s i g n i f i c a n t  r e d u c t i o n  i n  n o r m a l i s e d  l u c i f e r a s e  
a c t i v i t y  b e t w e e n  t h e  0  p m o l  ( 1 0 0  ±  0 . 0 % ,  n = 1 8 )  a n d  2 0  p m o l  ( 8 5 . 8  ±  1 4 . 0 % ,  
n = 1 8 )  m i R - 6 0 8  m i m i c  g r o u p s  ( p = 0 . 0 0 7 ) ,  a s  w e l l  a s  b e t w e e n  t h e  1  p m o l  ( 1 0 6 . 2  
±  1 6 . 2 % ,  n = 1 8 )  a n d  2 0  p m o l  g r o u p s  ( p < 0 . 0 0 1 ) .  S i m i l a r l y  w i t h i n  t h e  T E N  1 . 1  
t r a n s f e c t e d  c e l l s ,  t h e r e  w a s  a  s i g n i f i c a n t  d e c r e a s e  i n  n o r m a l i s e d  l u c i f e r a s e  
a c t i v i t y  b e t w e e n  t h e  0  p m o l  ( 1 0 0  ±  0 . 0 % ,  n = 1 5 )  a n d  2 0  p m o l  ( 8 4 . 2  ±  1 7 . 7 % ,  



















F i g u r e  3 . 6  H i s t o g r a m s  s h o w i n g  a v e r a g e d  l u c i f e r a s e  a c t i v i t y  o f  i n c r e a s i n g  
a m o u n t s  o f  H s a - m i R - 6 0 8  m i m i c  c o - t r a n s f e c t e d  w i t h  ( A)  C - a l l e l i c  a n d  ( B )  
T - a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  i n  S V W I - 3 8  f i b r o b l a s t s .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n  c o n t r o l .  N o r m a l i s e d  l u c i f e r a s e  
a c t i v i t i e s  a r e  s h o w n  a s  a  p e r c e n t a g e  o f  2 0  p m o l  s i C o n t r o l  a c t i v i t y  ( 1 0 0 % ) .  
N u m b e r  o f  b i o l o g i c a l  r e p l i c a t e s  ( N )  i s  d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  
b a r s  r e p r e s e n t  s t a n d a r d  d e v i a t i o n .  S i g n i f i c a n c e  w a s  a c c e p t e d  a t  p < 0 . 0 5 .   
 
 
S i n c e  H s a - m i R - 6 0 8  h a d  a  h i g h e r  a f f i n i t y  f o r  i t s  b i n d i n g  s i t e  i n  t h e  T  a l l e l i c  
f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R  i n  H T 1 0 8 0  f i b r o s a r c o m a  c e l l s  ( F i g u r e  3 . 5 ) ,  t h e  
r e l a t i v e  l u c i f e r a s e  a c t i v i t i e s  o f  t h e  C -  a n d  T - a l l e l i c  c o n s t r u c t s  w e r e  c o m p a r e d  
a t  t h e  1 ;  1 0  a n d  2 0  p m o l  H s a - m i R - 6 0 8  m i m i c  t r a n s f e c t i o n s  i n  t h e  S V W I - 3 8  
c e l l s .  T h e r e  w a s  h o w e v e r  n o  s i g n i f i c a n t  d i f f e r e n c e  i n  l u c i f e r a s e  a c t i v i t y  
b e t w e e n  t h e  a l l e l i c  f o r m s  a t  t h e  1  p m o l  ( C O N  5 . 1 :  1 0 6 . 2  ±  1 6 . 2 %  v s  T E N  1 . 1 :  
9 7 . 5  ±  1 2 . 6 % ;  p =  0 . 1 0 1 ) ,  1 0  p m o l  ( C O N  5 . 1 :  9 5 . 7  ±  1 3 . 7 %  v s  T E N  1 . 1 :  9 5 . 4  ±  
1 8 . 2 % ;  p =  0 . 9 6 2 )  o r  2 0  p m o l  l e v e l  o f  m i R N A  m i m i c  ( C O N  5 . 1 :  8 5 . 8  ±  1 4 . 0 %  v s  
















3.2.3 The MboII RFLP conserved octamer is a valid binding site for a negative regulator of the 
COL5A1 gene in HT1080 fibrosarcoma cells. 
 
A s  p r e v i o u s l y  m e n t i o n e d  t h e r e  w a s  n o  m i R N A  m i m i c  c o m m e r c i a l l y  a v a i l a b l e  
f o r  t h e  M b o I I  o c t a m e r  a n d  t h e r e f o r e  t o  d e t e r m i n e  w h e t h e r  t h i s  s i t e  w a s  
f u n c t i o n a l  i t  w a s  m u t a t e d  b y  s i t e - d i r e c t e d  m u t a g e n e s i s  a n d  t h e  i m p a c t  o f  
t h i s  i n v e s t i g a t e d  i n  l u c i f e r a s e  a s s a y s  a s  d e s c r i b e d  e a r l i e r .  E x c e p t  f o r  t h e  C O N  
5 . 1  m u t a n t  c l o n e  1  ( M u t  1 ) ,  t h e r e  w a s  a  s i g n i f i c a n t  i n c r e a s e  i n  l u c i f e r a s e  
a c t i v i t y  w h e n  C O N  5 . 1  m u t a n t  c l o n e s  2  a n d  3 ,  a s  w e l l  a s  T E N  m u t a n t  c l o n e s  
1 ,  2  a n d  3  w e r e  a n a l y s e d  a n d  c o m p a r e d  t o  t h e i r  r e s p e c t i v e  p a r e n t a l  c o n t r o l s  
( F i g u r e  3 . 7  A  a n d  B ) .  T o  d e t e r m i n e  t h e  a n o m a l o u s  r e s u l t s  o b t a i n e d  f o r  C O N  
5 . 1  M u t  1  a p p r o x i m a t e l y  9 4 %  o f  t h e  C O L 5 A 1  3 ’ - U T R  i n s e r t  w i t h i n  t h i s  
c o n s t r u c t  w a s  s e q u e n c e d  a n d  n o  s p u r i o u s  m u t a t i o n s  w e r e  f o u n d .  A s  i t  w a s  
t h e  o n l y  m u t a t e d  c o n s t r u c t  t o  s h o w  a  s i g n i f i c a n t  r e d u c t i o n  i n  l u c i f e r a s e  
a c t i v i t y  ( 1  o f  6 ) ,  i t  w a s  c o n s i d e r e d  a n  o u t l i e r  a n d  r e m o v e d  f r o m  f u r t h e r  





F i g u r e  3 . 7  H i s t o g r a m s  s h o w i n g  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  o f  C - a l l e l i c  
( A)  a n d  T - a l l e l i c  ( B )  c o n s t r u c t s  w i t h  m u t a t e d  Mb o I I  R F L P  o c t a m e r  s i t e s  
t r a n s f e c t e d  i n  t h e  H T 1 0 8 0  f i b r o s a r c o m a  c e l l s .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n  c o n t r o l .  L u c i f e r a s e  a c t i v i t y  w a s  
e x p r e s s e d  r e l a t i v e  t o  t h e  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  o f  c e l l s  t r a n s f e c t e d  
w i t h  t h e  p a r e n t a l  v e c t o r s  ( s e t  t o  1 . 0 ) .  N u m b e r  o f  b i o l o g i c a l  r e p l i c a t e s  ( N )  i s  
d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  b a r s  r e p r e s e n t  s t a n d a r d  d e v i a t i o n .  












3.2.4 The MboII RFLP conserved octamer is also a valid binding site in SVWI-38 cells. 
 
T o  c o n f i r m  t h a t  t h e  r e s u l t s  o b t a i n e d  a b o v e  c o u l d  b e  r e p r o d u c e d  i n  a n o t h e r  
f i b r o b l a s t  c e l l  l i n e ,  t h e  e x p e r i m e n t s  p e r f o r m e d  i n  t h e  p r e v i o u s  s e c t i o n  w e r e  
r e p e a t e d  i n  t h e  S V W I - 3 8  c e l l  l i n e .  I n d e e d ,  a  c o m p a r a b l e  t r e n d  w a s  o b s e r v e d  
i n  t h e  H T 1 0 8 0  a n d  S V W i - 3 8  c e l l  l i n e s .  E x c e p t  f o r  t h e  C O N  5 . 1  m u t a n t  c l o n e  
1 ,  t h e r e  w a s  a  s i g n i f i c a n t  i n c r e a s e  i n  l u c i f e r a s e  a c t i v i t y  w h e n  C O N  5 . 1  m u t a n t  
c l o n e s  2  a n d  3 ,  a s  w e l l  a s  t h e  T E N  m u t a n t  c l o n e s  1 ;  2  a n d  3  w e r e  a n a l y s e d  
a n d  c o m p a r e d  t o  t h e i r  r e s p e c t i v e  p a r e n t a l  c o n t r o l s  ( F i g u r e  3 . 8  A  a n d  B ) .  C O N  






F i g u r e  3 . 8  H i s t o g r a m s  s h o w i n g  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  o f  C - a l l e l i c  
( A)  a n d  T - a l l e l i c  ( B )  c o n s t r u c t s  w i t h  m u t a t e d  M b o I I  R F L P  o c t a m e r  s i t e s  
t r a n s f e c t e d  i n  t h e  S V W I - 3 8  c e l l s .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n .  L u c i f e r a s e  a c t i v i t y  w a s  
e x p r e s s e d  r e l a t i v e  t o  t h e  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  o f  c e l l s  t r a n s f e c t e d  
w i t h  t h e  p a r e n t a l  v e c t o r s  ( s e t  t o  1 . 0 ) .  N u m b e r  o f  b i o l o g i c a l  r e p l i c a t e s  ( N )  i s  
d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  b a r s  r e p r e s e n t  s t a n d a r d  d e v i a t i o n .  














3.2.5 The co-transfection of miR-125a-5p mimic reduces luciferase expression by binding to the 
non-polymorphic binding site within the COL5A1 3’-UTR in the HT1080 fibrosarcoma cell line with 
greater repression observed with the T-allele. 
 
T o  d e t e r m i n e  w h e t h e r  m i R - 1 2 5 a - 5 p  m i m i c  i s  c a p a b l e  o f  r e p r e s s i n g  t h e  
a c t i v i t y  o f  t h e  C O L 5 A 1  3 ’ - U T R ,  C - a l l e l i c  a n d  T - a l l e l i c  c o n s t r u c t s  w e r e  c o -
t r a n s f e c t e d  w i t h  m i R - 1 2 5 a - 5 p  m i m i c  i n  H T 1 0 8 0  c e l l s .  A  s i g n i f i c a n t  r e d u c t i o n  
i n  l u c i f e r a s e  a c t i v i t y  w a s  n o t e d  f o r  b o t h  t h e  C -  ( F i g u r e  3 . 9  A ,  p = 0 . 0 0 5 )  a n d  
T - a l l e l i c  ( F i g u r e  3 . 9  B ,  p < 0 . 0 0 1 )  c o n s t r u c t s .  S p e c i f i c a l l y ,  w h e n  t h e  H T 1 0 8 0  
c e l l s  w e r e  c o - t r a n s f e c t e d  w i t h  C O N  5 . 1  a n d  m i R - 1 2 5 a - 5 p  m i m i c ,  t h e r e  w a s  a  
s t a t i s t i c a l l y  s i g n i f i c a n t  r e d u c t i o n  i n  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  b e t w e e n  
t h e  1  p m o l  ( 1 1 9 . 3  ±  2 2 . 2 % ,  N = 6 )  a n d  2 0  p m o l  ( 8 7 . 7  ±  1 2 . 0 % ,  N = 6 )  m i R - 6 0 8  
m i m i c  g r o u p s  ( p = 0 . 0 0 4 ) ,  a s  w e l l  a s  b e t w e e n  t h e  1 0  p m o l  ( 1 1 5 . 8  ±  2 . 9 % ,  N = 3 )  
a n d  2 0  p m o l  g r o u p s  ( p = 0 . 0 4 5 ) .  S i m i l a r l y  w i t h i n  t h e  T E N  1 . 1  t r a n s f e c t e d  c e l l s ,  
t h e r e  w a s  a  s i g n i f i c a n t  d e c r e a s e  i n  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t y  b e t w e e n  
t h e  0  p m o l  ( 1 0 0  ±  0 . 0 % ,  n = 1 5 )  a n d  2 0  p m o l  ( 6 5 . 0  ±  6 . 4 % ,  N = 6 )  m i R - 1 2 5 a - 5 p  
m i m i c  g r o u p s  ( p < 0 . 0 0 1 ) ,  a s  w e l l  a s  b e t w e e n  t h e  1  p m o l  ( 1 2 1 . 4  ±  1 1 . 5 % ,  N = 6 )  
a n d  2 0  p m o l  ( p < 0 . 0 0 1 )  a n d  1 0  p m o l  ( 8 1 . 6  ±  4 . 0 % ,  N = 3 )  a n d  2 0  p m o l  m i R - 1 2 5 a -
5 p  m i m i c  g r o u p s  ( p = 0 . 0 2 2 ) .  
 
F i g u r e  3 . 9  H i s t o g r a m  s h o w i n g  a v e r a g e d  l u c i f e r a s e  a c t i v i t y  o f  i n c r e a s i n g  
a m o u n t s  o f  H s a - m i R - 1 2 5 a - 5 p  m i m i c  c o - t r a n s f e c t e d  i n  H T 1 0 8 0  c e l l s  w i t h  
( A)  C -  a n d  ( B )  T - a l l e l i c  C O L 5 A1  3 ’ - U T R  c o n s t r u c t s .  
A l l  f i r e f l y  l u c i f e r a s e  a c t i v i t i e s  w e r e  n o r m a l i s e d  t o  r e n i l l a  l u c i f e r a s e  a c t i v i t y ,  
w h i c h  w a s  i n c l u d e d  a s  a n  i n t e r n a l  t r a n s f e c t i o n  c o n t r o l .  N o r m a l i s e d  l u c i f e r a s e  
a c t i v i t i e s  a r e  s h o w n  a s  a  p e r c e n t a g e  o f  2 0  p m o l  s i C o n t r o l  a c t i v i t y  ( 1 0 0 % ) .  
N u m b e r  o f  b i o l o g i c a l  r e p l i c a t e s  ( N )  i s  d e n o t e d  a b o v e  c o r r e s p o n d i n g  b a r .  E r r o r  












T h e  n o r m a l i s e d  l u c i f e r a s e  a c t i v i t i e s  o f  t h e  C -  a n d  T - a l l e l i c  w e r e  c o m p a r e d  a t  
1 ;  1 0  a n d  2 0  p m o l  H s a - m i R - 1 2 5 a - 5 p  m i m i c  t r a n s f e c t i o n s .  T h e r e  w a s  n o  
s i g n i f i c a n t  d i f f e r e n c e  b e t w e e n  t h e  a l l e l i c  f o r m s  a t  t h e  1  p m o l  m i R - 1 2 5 a - 5 p  
m i m i c  t r a n s f e c t i o n  ( C O N  5 . 1 :  1 1 9 . 3  ±  2 2 . 2 %  v s  T E N  2 . 2 :  1 2 1 . 4  ±  1 1 . 5 % ;  
p = 0 . 9 9 9 ) .  T h e  T - a l l e l i c  f o r m  h o w e v e r ,  s h o w e d  a  s i g n i f i c a n t l y  g r e a t e r  
r e d u c t i o n  i n  l u c i f e r a s e  a c t i v i t y  a t  1 0  p m o l  ( C O N  5 . 1 :  1 1 5 . 8  ±  3 . 0 %  v s  T E N  2 . 2 :  
8 1 . 6  ±  4 . 0 % ;  p = 0 . 0 1 1 )  a n d  2 0  p m o l  m i R - 1 2 5 a - 5 p  m i m i c  t r a n s f e c t i o n  ( C O N  5 . 1 :  
8 7 . 7  ±  1 2 . 0 %  v s  T E N  2 . 2 :  6 5 . 0  ±  6 . 4 % ;  p = 0 . 0 2 1 )   
 
3.3 The CC genotype of MIR608 rs4919510 (C/G) is associated with Achilles tendinopathy 
 
A s  p r e v i o u s l y  r e p o r t e d  i n  s e c t i o n  3 . 1  t h e  H s a - m i R - 6 0 8  b i n d i n g  s i t e ,  w h i c h  
c o n t a i n s  a  s i n g l e  n u c l e o t i d e  p o l y m o r p h i s m  ( S N P )  r s 3 1 9 6 3 7 8  ( A c i I  R F L P ,  C / A ) ,  
i s  v a l i d .  T w o  f o r m s  o f  t h e  m a t u r e  H s a - m i R - 6 0 8 ,  w h i c h  a r e  p r o d u c e d  f r o m  t h e  
p o l y m o r p h i c  M I R 6 0 8  g e n e  ( S N P  r s 4 9 1 9 5 1 0 ,  C / G )  o n  c h r o m o s o m e  1 0 q 2 4 ,  c a n  
p o t e n t i a l l y  b i n d  t o  t h i s  s i t e  ( h t t p : / / w w w . n c b i . n l m . n i h . g o v ) .  T h e  M I R 6 0 8  g e n e  
e n c o d e s  a  2 5  b p  m a t u r e  m i R N A  w i t h  S N P  r s 4 9 1 9 5 1 0  o c c u r r i n g  o u t s i d e  o f  t h e  
t a r g e t  r e c o g n i t i o n  o c t a m e r  a t  n u c l e o t i d e  p o s i t i o n  2 2 .  T h e  a i m s  o f  t h i s  s e c t i o n  
w e r e  t h e r e f o r e  t o  d e t e r m i n e  ( i )  w h e t h e r  S N P  r s 4 9 1 9 5 1 0  ( C / G )  w i t h i n  t h e  
M I R 6 0 8  g e n e  i s  a s s o c i a t e d  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  a n d  ( i i )  t o  
i n v e s t i g a t e  t h e  g e n e - g e n e  i n t e r a c t i o n s  b e t w e e n  r s 4 9 1 9 5 1 0  a n d  t h e  S N P  
( r s 3 1 9 6 3 7 8 )  i n  i t s  C O L 5 A 1  b i n d i n g  s i t e .  
 
3.3.1 Participant characteristics 
 
3.3.1.1 South African participants  
 
P a r t i c i p a n t s  w i t h  A c h i l l e s  t e n d i n o p a t h y  ( S A  T E N )  a n d  c o n t r o l  ( S A  C O N )  
p a r t i c i p a n t s  i n  t h e  S o u t h  A f r i c a n  p o p u l a t i o n  w e r e  m a t c h e d  f o r  h e i g h t ,  g e n d e r  
a n d  b o d y  m a s s  i n d e x  ( B M I )  ( T a b l e  3 . 3 ) .  T h e  S A  T E N  g r o u p  w a s  s i g n i f i c a n t l y  
o l d e r  ( p < 0 . 0 0 1 )  a t  t h e  a g e  o f  r e c r u i t m e n t  w i t h  a n  a v e r a g e  a g e  o f  4 8 . 2  ±  1 1 . 3  
y e a r s  ( N = 7 1 )  c o m p a r e d  t o  t h e  S A  C O N  g r o u p  a t  3 7 . 0  ±  1 0 . 7  y e a r s  ( N = 1 2 8 ) .  
T h e  S A  T E N  p a r t i c i p a n t s  w e r e  h o w e v e r ,  s i m i l a r l y  m a t c h e d  ( p = 0 . 1 9 1 )  t o  t h e  
S A  C O N  g r o u p  a t  t h e  a g e  o f  i n i t i a l  i n j u r y  ( T a b l e  3 . 3 ) .  T h e  S A  T E N  g r o u p  w e r e  












w e i g h t  o f  7 7 . 5  ±  1 3 . 7  k g  ( N = 6 8 )  c o m p a r e d  t o  7 2 . 9  ±  1 2 . 1  k g  ( N = 1 3 4 )  f o r  t h e  
S A  C O N  g r o u p .  W h e n  c o - v a r i e d  f o r  a g e  a n d  g e n d e r ,  a  s i g n i f i c a n t  d i f f e r e n c e  
b e t w e e n  t h e  S A  T E N  a n d  S A  C O N  g r o u p s  w a s  o b s e r v e d  ( p = 0 . 0 2 3 ) .  
 





SA TEN Group 
(75) 





Gender    
(% Male) 
67.62 (142) 71.62 (53) 66.42 (89) 0.534 N.D. 
Age (yrs) a 37.9 ± 14.8 (198) 39.4 ± 10.7 (70) 37.0 ± 10.7 (128) 0.191 N.D. 
Weight (kg) 74.4 ± 12.8 (202) 77.5 ± 13.7 (68) 72.9 ± 12.1 (134) 0.015 0.023 b 
Height (cm) 175.8 ± 9.2 (195) 176.7 ± 8.7 (65) 175.3 ± 9.4 (130) 0.327 N.D. 
BMI (kg/m2) 24.0 ± 3.0 (191) 24.6 ± 3.2 (65) 23.7 ± 2.9 (126) 0.051 N.D. 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age of the TEN participants is at their initial injury, while the age of the CON participants is at 
recruitment. 
b co-varied for age and gender. 
yrs, years; kg, kilogram; cm, centimetre, N.D. not determined.  
 
3.3.1.2 Australian participants 
 
T h e r e  w a s  a  s i g n i f i c a n t l y  g r e a t e r  p e r c e n t a g e  o f  m a l e s  ( p < 0 . 0 0 1 )  i n  t h e  
A u s t r a l i a n  ( A U S )  T E N  g r o u p  ( 7 2 . 1 % ;  N = 4 9 )  t h a n  i n  t h e  A U S  C O N  g r o u p  ( 4 1 . 5 % ;  
N = 7 3 )  ( T a b l e  3 . 4 ) .  A s  a  r e s u l t ,  t h e  A U S  T E N  g r o u p  w a s ,  o n  a v e r a g e ,  h e a v i e r  
( A U S  T E N :  8 0 . 6  ±  1 3 . 9  k g ,  N = 6 8  v s  A U S  C O N :  7 3 . 3  ±  1 4 . 6  k g ,  N = 1 7 5 ;  p < 0 . 0 0 1 ) ,  
t a l l e r  ( A U S  T E N :  1 7 4 . 7  ±  1 0 . 4  c m ,  N = 6 5  v s  A U S  C O N :  1 7 1 . 7  ±  9 . 2  c m ,  N = 1 7 4 ,  
p = 0 . 0 3 6 )  a n d  h a d  a  h i g h e r  B M I  ( A U S  T E N :  2 6 . 4  ±  3 . 8  k g / m 2 ,  N = 6 5  v s  A U S  C O N :  
2 4 . 8  ±  4 . 1  k g / m 2 ,  N = 1 2 6 ,  p = 0 . 0 0 7 )  t h a n  t h e  A U S  C O N  g r o u p .  W h e n  c o - v a r i e d  
f o r  a g e  a n d  g e n d e r ,  n o  s i g n i f i c a n t  d i f f e r e n c e s  i n  w e i g h t  ( p = 0 . 3 5 8 ) ,  h e i g h t  
( p = 0 . 3 0 2 )  o r  B M I  ( p = 0 . 1 5 4 )  w e r e  n o t e d .  F u r t h e r m o r e ,  t h e  A U S  T E N  g r o u p  w a s  
s i g n i f i c a n t l y  o l d e r  ( 4 8 . 0  ±  1 2 . 9  y e a r s ,  N = 6 8 )  a t  t h e  a g e  o f  r e c r u i t m e n t  w h e n  
c o m p a r e d  t o  t h e  A U S  C O N  g r o u p  ( 3 8 . 2  ±  1 2 . 1  y e a r s ,  N = 1 7 3  p < 0 . 0 0 1 )  b u t  w e r e  
s i m i l a r l y  m a t c h e d  ( p = 0 . 7 0 3 )  a t  t h e  a g e  o f  i n i t i a l  i n j u r y  ( T a b l e  3 . 4 ) .   
















AUS TEN Group    
(68) 







49.80 (122) 72.06 (49) 41.48 (73) <0.001 N.D. 
Age (yrs) a 38.4 ± 12.6 (240) 38.9 ± 13.9 (67) 38.2 ± 12.1 (173) 0.703 N.D. 
Weight (kg) 75.3 ± 14.8 (243) 80.6 ± 13.9 (68) 73.3 ± 14.6 (175) <0.001 0.358 b 
Height (cm) 172.5 ± 9.6 (239) 174.7 ± 10.4 (65) 171.7 ± 9.2 (174) 0.036 0.302 b 
BMI (kg/m2) 25.2 ± 4.1 (239) 26.4 ± 3.8 (65) 24.8 ± 4.1 (126) 0.007 0.154 b 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age of the TEN participants is at their initial injury, while the age of the CON participants is at 
recruitment. 
b co-varied for age and gender. 
yrs, years; kg, kilogram; cm, centimetre, N.D., not determined.  
 
3.3.1.3 Combined South African and Australian participants 
 
T h e r e  w a s  a  s i g n i f i c a n t l y  g r e a t e r  p e r c e n t a g e  o f  m a l e s  ( p < 0 . 0 0 1 )  i n  t h e  
c o m b i n e d  S A + A U S  T E N  g r o u p  ( 7 1 . 8 % ;  N = 1 0 2 )  t h a n  i n  t h e  c o m b i n e d  S A + A U S  
C O N  g r o u p  ( 5 2 . 3 % ;  N = 1 6 2 )  ( T a b l e  3 . 5 ) .  A s  a  r e s u l t ,  t h e  S A + A U S  T E N  g r o u p  
w a s  h e a v i e r  ( S A + A U S  T E N :  7 9 . 1  ±  7 3 . 1  k g ,  N = 1 0 2  v s  S A + A U S  C O N :  7 3 . 1  ±  1 3 . 6  
k g ,  N = 3 0 9 ;  p = 0 . 0 0 1 )  a n d  h a d  a  h i g h e r  B M I  ( S A + A U S  T E N :  2 5 . 5  ±  3 . 6  k g / m 2 ,  
N = 1 3 0  v s  S A + A U S  C O N :  2 4 . 3  ±  3 . 7  k g / m 2 ,  N = 3 0 4 ,  p = 0 . 0 4 7 )  t h a n  t h e  S A + A U S  
C O N  g r o u p .  T h e  T E N  a n d  C O N  g r o u p s  w e r e  h o w e v e r ,  s i m i l a r l y  m a t c h e d  f o r  
h e i g h t  ( u n a d j u s t e d  p = 0 . 0 5 6 ;  g e n d e r  a d j u s t e d  p = 0 . 7 2 4 ) .  T h e  S A + A U S  T E N  
g r o u p  w a s  s i g n i f i c a n t l y  o l d e r  ( 4 8 . 1  ±  1 1 . 8  y e a r s ,  N = 1 4 3 )  a t  t h e  a g e  o f  
r e c r u i t m e n t  w h e n  c o m p a r e d  t o  t h e  S A + A U S  C O N  g r o u p  ( 3 7 . 7  ±  1 1 . 5  y e a r s ,  
N = 3 0 1  p < 0 . 0 0 1 ) ,  b u t  w e r e  s i m i l a r l y  m a t c h e d  ( p = 0 . 2 5 5 )  t o  t h e  A U S  C O N  g r o u p  
a t  t h e  a g e  o f  i n i t i a l  i n j u r y  ( T a b l e  3 . 5 ) .  W h e n  c o - v a r i e d  f o r  g e n d e r  a n d  a g e  a t  
r e c r u i t m e n t  a  s i g n i f i c a n t  d i f f e r e n c e  w a s  n o t e d  f o r  w e i g h t  ( p = 0 . 0 0 4 )  b u t  n o t  












Table 3.5 Descriptive characteristics of the combined South African and Australian Achilles 










 p-value  
Gender    
(% Male) 
54.07 (246) 71.83 (102) 52.26 (162) <0.001 N.D. 
Age (yrs) a 38.2 ± 12.5 (438) 
39.2 ± 14.4 
(137) 
37.7 ± 11.5 (301) 0.255 N.D. 
Weight (kg) 74.9 ± 13.9 (445) 
79.1 ± 13.9 
(136) 
73.1 ± 13.6 (309) 0.001 0.004 b 
Height (cm) 174.0 ± 9.5 (434) 
175.7 ± 9.6 
(130) 
173.3 ± 9.4 (304) 0.056 N.D 
BMI (kg/m2) 24.7 ± 3.7 (430) 25.5 ± 3.6 (130) 24.3 ± 3.7 (304) 0.047 0.069 b 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age of the TEN participants is at their initial injury, while the age of the CON participants is at 
recruitment. 
b co-varied for age and gender. 
yrs, years; kg, kilogram; cm, centimetre, N.D., not determined.  
 
3.3.1.4 Genotype effects on physiological variables 
 
T h e r e  w e r e  n o  s i g n i f i c a n t  g e n o t y p e  e f f e c t s  o n  g e n d e r  ( p = 0 . 5 4 1 ) ,  a g e  
( p = 0 . 0 9 3 ) ,  w e i g h t  ( p = 0 . 9 8 1 ) ,  h e i g h t  ( p = 0 . 1 9 7 )  o r  B M I  ( p = 0 . 6 0 4 )  f o r  
r s 4 9 1 9 5 1 0  i n  t h e  c o m b i n e d  S A + A U S  p o p u l a t i o n  ( T a b l e  3 . 6 ) .  A s  t h e r e  w a s  n o  
s i g n i f i c a n t  g e n e t i c  a s s o c i a t i o n  w i t h  e a c h  i n d i v i d u a l  p o p u l a t i o n ,  o n l y  
g e n o t y p e  e f f e c t  i n  t h e  c o m b i n e d  p o p u l a t i o n  w a s  c o n s i d e r e d .   
 
Table 3.6 Physiological characteristics of the three MIR608 rs4919510 (G/C) genotype groups of the 
combined Australian and South African participants. 
 CC CG GG p-value 
Gender   
(% Male) 
56.36 (155) 61.39 (97) 63.16 (12) 0.541 
Age (yrs) a 42.0 ± 12.9 (269) 39.4 ± 12.0 (154) 39.1 ± 11.0 (17) 0.093 
Weight (kg) 75.0 ± 14.6 (272) 74.8 ± 13.0 (155) 75.3 ± 10.3 (18) 0.981 
Height (cm) 173.5 ± 9.4 (264) 174.5 ± 9.8 (152) 177.1 ± 10.0 (18) 0.197 
BMI (kg/m2) 24.8 ± 3.9 (260) 24.6 ± 3.4 (152) 24.0 ± 2.8 (18) 0.604 
 
Except for gender, which is presented as a frequency, values are presented as mean ± standard 
deviations. The number of participants with non-missing data is in parenthesis. 
a Age at recruitment. 













3.3.2 Genotype Distributions 
 
T h e r e  w a s  n o  s i g n i f i c a n t  d i f f e r e n c e  i n  g e n o t y p e  f r e q u e n c i e s  i n  t h e  g e n o t y p e  
g r o u p s  b e t w e e n  t h e  T E N  a n d  C O N  p a r t i c i p a n t s  w h e n  t h e  S A  ( p = 0 . 1 8 6 )  a n d  
A U S  ( p = 0 . 0 8 1 )  p o p u l a t i o n s  w e r e  a n a l y s e d  s e p a r a t e l y  ( F i g u r e  3 . 1 0 ) .  S i n c e  t h e  
g e n o t y p e  f r e q u e n c i e s  o f  t h e  T E N  a n d  C O N  g r o u p s  b e t w e e n  t h e  S A  a n d  A U S  
p o p u l a t i o n s  w e r e  s i m i l a r ,  t h e  t w o  p o p u l a t i o n s  w e r e  c o m b i n e d  f o r  f u r t h e r  
a n a l y s i s  t o  i n c r e a s e  s t a t i s t i c a l  p o w e r .  A s  i l l u s t r a t e d  i n  F i g u r e  3 . 1 1 ,  t h e  C C  
g e n o t y p e  f r e q u e n c y  o f  t h e  c o m b i n e d  S A  a n d  A U S  T E N  g r o u p s  ( T E N  C C  
g e n o t y p e :  6 8 . 5 % )  w a s  s i g n i f i c a n t l y  o v e r - r e p r e s e n t e d  ( C C  v s  C G + C G ,  p = 0 . 0 2 3 ,  
o d d s  r a t i o  ( O R ) = 1 . 6 ,  9 5 %  c o n f i d e n c e  i n t e r v a l  ( C I ) :  1 . 1  –  2 . 5 )  w h e n  c o m p a r e d  
t o  t h e  c o m b i n e d  C O N  g r o u p  ( C O N  C C  g e n o t y p e :  5 7 . 1 % ) .  T h e  g e n o t y p e  
d i s t r i b u t i o n s  o f  r s 4 9 1 9 5 1 0  w e r e  i n  H a r d y - W e i n b e r g  e q u i l i b r i u m  i n  a l l  g r o u p s  
( S A  C O N :  p = 0 . 8 1 5 ;  S A  T E N :  p = 1 . 0 0 0 ;  A U S  C O N :  p =  0 . 1 4 7 ;  A U S  T E N :  p = 0 . 4 1 3 ;  




F i g u r e  3 . 1 0  G e n o t y p e  f r e q u e n c y  d i s t r i b u t i o n s  o f  MI R 6 0 8  r s 4 9 1 9 5 1 0  ( C / G )  
i n  t h e  ( A)  S o u t h  Af r i c a n  a n d  ( B )  Au s t r a l i a n  p o p u l a t i o n s  Ac h i l l e s  
t e n d i n o p a t h y  ( T E N )  a n d  a s y m p t o m a t i c  c o n t r o l  ( C O N )  p a r t i c i p a n t s .  
T h e  g e n o t yp e  f r e q u e n c y  f o r  t h e  C O N  a n d  T E N  g r o u p s  a r e  d e n o t e d  b y  b l a c k  
a n d  w h i t e  b a r s  r e s p e c t i v e l y .  ( A )  S A :  C C  v s .  G  a l l e l e ,  p =  0 . 1 8 6 .  ( B )  A U S :  C C  
v s .  G  a l l e l e ,  p =  0 . 0 8 1 .  T h e  n u m b e r  o f  p a r t i c i p a n t s  ( N )  i n  e a c h  g e n o t yp e  g r o u p  

















F i g u r e  3 . 1 1  G e n o t y p e  f r e q u e n c y  d i s t r i b u t i o n s  o f  M I R 6 0 8  r s 4 9 1 9 5 1 0  ( C / G )  
i n  t h e  c o m b i n e d  S o u t h  Af r i c a n  a n d  Au s t r a l i a n  p o p u l a t i o n s  Ac h i l l e s  
t e n d i n o p a t h y  ( T E N )  a n d  a s y m p t o m a t i c  c o n t r o l  ( C O N )  g r o u p s .  
T h e  g e n o t yp e  f r e q u e n c y  f o r  t h e  C O N  a n d  T E N  g r o u p s  a r e  d e n o t e d  b y  b l a c k  
a n d  w h i t e  b a r s  r e s p e c t i v e l y .  A s  i n d i c a t e d ,  t h e  C C  g e n o t yp e  i s  s i g n i f i c a n t l y  
o v e r - r e p r e s e n t e d  i n  t h e  C O N  g r o u p  w h e n  c o m p a r e d  t o  t h e  G  a l l e l e  ( G C  +  G G  
g e n o t yp e ) .  T h e  n u m b e r  o f  p a r t i c i p a n t s  ( N )  i n  e a c h  g e n o t yp e  g r o u p  i s  d e n o t e d  
a b o v e  c o r r e s p o n d i n g  b a r .  S i g n i f i c a n c e  w a s  a c c e p t e d  a t  p < 0 . 0 5 .  
 
 
3.3.3 Genotype-Genotype Interactions 
 
A s  p r e v i o u s l y  m e n t i o n e d ,  t h e  H s a - m i R - 6 0 8  b i n d i n g  s i t e  w i t h i n  t h e  C O L 5 A 1  3 ′ -
U T R  i s  a l s o  p o l y m o r p h i c  [ 1 4 ] .  T h e  c o m b i n e d  g e n o t y p e  f r e q u e n c i e s  o f  M I R 6 0 8  
S N P  r s 4 9 1 9 5 1 0  a n d  i t s  c o r r e s p o n d i n g  C O L 5 A 1  b i n d i n g  s i t e  S N P  r s 3 1 9 6 3 7 8  
( C / A ,  A c i I  R F L P )  w e r e  t h e r e f o r e  i n v e s t i g a t e d .  T h e  A  n u c l e o t i d e  o f  r s 3 1 9 6 3 7 8  
w a s  i d e n t i f i e d  w i t h i n  t h e  T - f u n c t i o n a l  f o r m  o f  t h e  C O L 5 A 1  3 ′ - U T R ,  w h i c h  w a s  
p r e d o m i n a t e l y  c l o n e d  f r o m  T E N  s u b j e c t s  [ 6 4 ] .  T h e r e  w e r e  n o  s i g n i f i c a n t  
d i f f e r e n c e s  b e t w e e n  t h e  g l o b a l  P  v a l u e s  ( M o n t e  C a r l o  t e s t s )  w h e n  t h e  
c o m b i n e d  r s 4 9 1 9 5 1 0  a n d  r s 3 1 9 6 3 7 8  g e n o t y p e  f r e q u e n c i e s  w e r e  c o m p a r e d  
b e t w e e n  t h e  p o o l e d  T E N  a n d  C O N  g r o u p s  ( T a b l e  3 . 7 ) .  T h e  c o m b i n e d  M I R 6 0 8  
C C  a n d  C O L 5 A 1  r s 3 1 9 6 3 7 8  C A  g e n o t y p e s  w e r e  h o w e v e r  s i g n i f i c a n t l y  o v e r -
r e p r e s e n t e d  i n  T E N  ( 4 2 . 3 % )  w h e n  c o m p a r e d  t o  t h e  C O N  ( 3 0 . 9 % )  g r o u p s  












A A  c o m b i n e d  g e n o t y p e  d i s t r i b u t i o n s  w e r e ,  h o w e v e r ,  s i m i l a r  b e t w e e n  t h e  T E N  
( 1 0 . 9 % )  a n d  C O N  ( 9 . 5 % )  g r o u p s .  T h i s  s i m i l a r i t y  w a s  d u e  t o  t h e  c o m b i n e d  
M I R 6 0 8  C C  a n d  C O L 5 A 1  C C  g e n o t y p e s  b e i n g  u n d e r - r e p r e s e n t e d  w i t h i n  t h e  A U S  
T E N  c o h o r t ,  b u t  n o t  t h e  S A  T E N  c o h o r t  ( T a b l e  3 . 7 ) .  T h e  c o m b i n e d  M I R 6 0 8  C C  
g e n o t y p e  a n d  C O L 5 A 1  r s 3 1 9 6 3 7 8  A  a l l e l e  ( C A  a n d  A A  g e n o t y p e s )  w a s  
s i g n i f i c a n t l y  o v e r - r e p r e s e n t e d  i n  t h e  T E N  g r o u p  ( 5 3 . 2 % ,  N  =  7 3 )  w h e n  
c o m p a r e d  t o  t h e  C O N  g r o u p s  ( 4 0 . 4 % ,  N  =  1 1 1 )  ( P = 0 . 0 1 6 ,  O R = 1 . 7 ,  9 5 %  C I  =  1 . 1  
t o  2 . 5 ) .  
 
Table 3.7 Combined genotype frequency distributions of the MIR608 gene rs4919510 (C/G) single 
nucleotide polymorphism (SNP) and the COL5A1 3’-UTR SNP rs3196378 (C/A) within the Hsa-miR-
608 binding site in control (CON) and chronic Achilles tendinopathy (TEN) groups of South African (SA) 



















CC CC 13.0 (13) 12.2 (9) 15.4 (27) 15.9 (10) 14.5 (40) 13.9 (19) 0.96 
CC CA 28.0 (28) a 40.5 (30) a 32.6 (57) c 44.4 (28) c 30.9 (85) d,e 42.3 (58) d,e 1.37 
CC AA 11.0 (11) b 14.9 (11) b 8.6 (15) 6.4 (4) 9.5 (26) e 10.9 (15) e 1.15 
CG CC 12.0 (12) 6.8 (5) 8.0 (14) 0.0 (0) 9.5 (26) 3.6 (5) 0.38 
CG CA 20.0 (20) 14.9 (11) 25.7 (45) 23.8 (15) 23.6 (65) 19.0 (26) 0.81 
CG AA 10.0 (10) 8.1 (6) 6.9 (12) 4.8 (3) 8.0 (22) 6.6 (9) 0.83 
GG CC 2.0 (2) 1.4 (1) 0.6 (1) 0.0 (0) 1.1 (3) 0.7 (1) 0.64 
GG CA 2.0 (2) 1.4 (1) 1.7 (3) 4.7 (3) 1.8 (5) 2.9 (4) 1.61 
GG AA 2.0 (2) 0.0 (0) 0.6 (1) 0.0 (0) 1.1 (3) 0.0 (0) 0.00 
Genotype pairs are expressed as percentages with numbers (N) in parenthesis. TEN/CON, SA+AUS 
TEN/SA+AUS CON. 
a SA TEN/SA CON = 1.45 
b SA TEN/SA CON = 1.35 
c AUS TEN/AUS CON = 1.36 
d SA+AUS TEN vs SA+AUS CON (MIR608 CC genotype + COL5A1 CA genotype), P=0.022, odds ratio 
= 1.6, 95% confidence interval = 1.1 to 2.5. 
e SA+AUS TEN vs SA+AUS CON (MIR608 CC genotype + COL5A1 A allele), P=0.016, odds ratio = 




















3.4 mRNA secondary structure 
 
3.4.1 The secondary structures of the T- and C-allelic forms of the COL5A1 3’-UTR differ 
significantly across an 858 bp region associated with AT 
 
T h e  s e c o n d a r y  s t r u c t u r e s  o f  t h e  T -  a n d  C - a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R  
w e r e  g e n e r a t e d  u s i n g  t h e  s t a t i s t i c a l  R N A  f o l d i n g  a l g o r i t h m  ( S f o l d )  t o  i d e n t i f y  
r e g i o n s  o f  h i g h  a n d  l o w  R N A  s t a b i l i t y .  T h e  p o s i t i o n  o f  s t a b l e  r e g i o n s  d i f f e r e d  
s i g n i f i c a n t l y  b e t w e e n  t h e  t w o  a l l e l i c  f o r m s  ( F i g u r e  3 . 1 2 ) .  T h e  m o s t  s t r i k i n g  
d i f f e r e n c e s  e x i s t  i n  a n  8 5 8  b p  r e g i o n  c o n t a i n i n g  f i v e  o f  t h e  s e v e n  a l l e l e  
d e t e r m i n i n g  v a r i a n t s ,  n a m e l y  r s 1 2 7 2 2 ;  r s 3 1 9 6 3 7 8 ;  r s 7 1 7 4 6 7 4 4 ;  r s 1 6 3 9 9  a n d  
r s 1 1 6 3 4 1 7 0  a s  w e l l  a s  t h e  t h r e e  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  i n v e s t i g a t e d  i n  
t h i s  s t u d y  ( I n s e r t s  A  a n d  B ) .  T h e  A G G G ( n )  s h o r t  t a n d e m  r e p e a t  p o l y m o r p h i s m  
( S T R P )  ( r s 7 1 7 4 6 7 4 4 ) ,  w h i c h  h a s  b e e n  a s s o c i a t e d  w i t h  A T ,  a p p e a r s  t o  b e  
d i r e c t l y  i n v o l v e d  i n  t h e  s e c o n d a r y  s t r u c t u r e  o f  t h e  M b o I I  o c t a m e r  b i n d i n g  
s i t e  ( F i g u r e  3 . 1 3 ,  t o p  i n s e r t s ) .  A  s i g n i f i c a n t  r e - o r i e n t a t i o n  o f  t h e  p o s i t i o n s  
o f  u n s t a b l e  r e g i o n s  o c c u r  i n  t h e  r e g i o n  c o n t a i n i n g  t h e  m i R - 6 0 8  b i n d i n g  s i t e ,  
t h e  A G G G ( n )  S T R P  a n d  t h e  M b o I I  o c t a m e r  ( i n s e r t  A ) .  T h i s  r e g i o n  m a i n t a i n s  a  
s i m i l a r  o r i e n t a t i o n  i n  a l l  1 0  o f  t h e  m o s t  s t a b l e  i t e r a t i o n s  o f  t h e  C - a l l e l i c  f o r m  
( C C C 1 2 A T ) ,  b u t  i s  o n l y  p r e s e n t  i n  2  o f  t h e  1 0  s t r u c t u r e s  ( 4 t h  a n d  5 t h  m o s t  













F i g u r e  3 . 1 2  T h e  m o s t  s t a b l e  p r e d i c t e d  s e c o n d a r y  s t r u c t u r e s  o f  t h e  C  ( l e f t  
p a n e l )  a n d  T  ( r i g h t  p a n e l )  f u n c t i o n a l  f o r m s  o f  t h e  C O L 5 A1  3 ’ - U T R .  
T h e  r e g i o n ,  w h i c h  c o n t a i n s  t h e  p u t a t i ve  m i R - 6 0 8  b i n d i n g  s i t e ,  t h e  M b o I I  
o c t am e r  a n d  t h e  A G G G  s h o r t  t a n d e m  r e p e a t  p o l ym o r p h i s m  ( S T R P )  
( r s 7 1 7 4 6 7 4 4 ) ,  i s  i n d i c a t e d  w i t h  b o x  A .  B o x  B  i n d i c a t e d  t h e  r e g i o n  w h i c h  
c o n t a i n s  t h e  p r e d i c t e d  b i n d i n g  s i t e  f o r  H s a - m i R - 1 2 5 a - 5 p .  R e g i o n s  A  a n d  B  o f  
t h e  C  ( l e f t  i n s e r t )  a n d  T  ( r i g h t  i n s e r t )  f u n c t i o n a l  f o r m s  o f  C O L 5 A 1  3 ’ - U T R  i s  
e x p a n d e d  i n  t h e  i n s e r t s .  P r e d i c t e d  b i n d i n g  s i t e s  a n d  s e q u e n c e  v a r i a t i o n s  a r e  
h i g h l i g h t e d  i n  t h e  i n s e r t s .  N u c l e o t i d e  p o s i t i o n s  w i t h i n  t h e  3 ’ - U T R  a r e  a l s o  
















F i g u r e  3 . 1 3  T h e  m o s t  s t a b l e  p r e d i c t e d  s e c o n d a r y  s t r u c t u r e s  o f  r e g i o n  A  
( r e f e r  t o  F i g u r e  3 . 1 2 )  o f  t h e  C  ( l e f t  p a n e l )  a n d  T  ( r i g h t  p a n e l )  f u n c t i o n a l  
f o r m s  o f  t h e  C O L 5 A1  3 ’ - U T R .  
T h i s  r e g i o n  c o n t a i n s  b o t h  p o l ym o r p h i c  m i R N A  b i n d i n g  s i t e s ,  t h e  A G G G  
v a r i a b l e  n u c l e o t i d e  t a n d e m  r e p e a t  ( S T R P )  ( r s 7 1 7 4 6 7 4 4 ) ,  s i n g l e  n u c l e o t i d e  
p o l ym o r p h i s m  ( S N P )  r s 1 1 1 0 3 5 4 4  ( T / C )  a n d  S N P  r s 3 1 9 6 3 7 8  ( C / A ) .  T h e  r e g i o n  
t o  w h i c h  H s a - m i R - 6 0 8  ( b o t t o m  i n s e r t s )  a n d  t h e  M b o I I  o c t a m e r  ( t o p  i n s e r t s )  
b i n d s  a r e  e x p a n d e d  i n  t h e  b o x e d  i n s e r t s .  T h e  o n e  a n d  t w o  c o p i e s  o f  t h e  A G G G  
S T R P  a r e  h i g h l i g h t e d  w i t h  g r e y  d i a m o n d s  i n  t h e  t o p  i n s e r t s .  T h e  m i R N A  
b i n d i n g  s i t e s  a r e  h i g h l i g h t e d  w i t h  g r e y  c i r c l e s .  T h e  S N P s  w i t h i n  t h e s e  b i n d i n g  
s i t e s  a r e  i n d i c a t e d  w i t h  g r e y  d i a m o n d s .  N u c l e o t i d e  p o s i t i o n s  w i t h i n  t h e  3 ’ -
U T R  a r e  a l s o  i n d i c a t e d .  
 
W h e n  t h e  C O L 5 A 1  3 ’ - U T R  w a s  s u b j e c t e d  t o  i n  s i l i c o  m u t a g e n e s i s ,  a n a l y s i s  o f  
t h e  s e c o n d a r y  s t r u c t u r e  o f  t h e  r e g i o n  p r e s e n t  i n  i n s e r t  A  p r o d u c e d  3  d i s t i n c t  
g r o u p s .  T h e  f i r s t  g r o u p  c o m p o s e d  o f  m u t a t i o n s  w h i c h  p r o d u c e d  7  o r  m o r e  C -
f o r m  s t r u c t u r e s  p r e d o m i n a n t l y  h a d  a  C  a t  r s 3 1 9 6 3 7 8  ( 6  o f  8 )  a n d  a  s i n g l e  
c o p y  o f  t h e  A G G G ( n )  S T R P  a t  r s 7 1 7 4 6 7 4 4  ( 7  o f  8 ) .  T h e  s e c o n d  g r o u p  w h i c h  
p r o d u c e d  a n  i n t e r m e d i a t e  n u m b e r  o f  C  f o r m s  ( 5  a n d  6 )  h a d  v a r i e d  
c o m b i n a t i o n s  o f  m u t a t i o n s  b e t w e e n  t h e  T -  a n d  C - a l l e l i c  s e q u e n c e s .  T h e  f i n a l  
g r o u p  w h i c h  p r o d u c e d  4  o r  l e s s  C  f o r m  s t r u c t u r e s  w e r e  p r e d o m i n a n t l y  h a d  
a n  A  a t  r s 3 1 9 6 3 7 8  ( 6  o f  8 ) ,  2  c o p i e s  o f  t h e  A G G G ( n )  S T R P  a t  r s 7 1 7 4 6 7 4 4  ( 7  o f  
8 ) ,  a  s i n g l e  c o p y  o f  t h e  A T C T ( n )  a t  r s 1 6 3 9 9  ( 6  o f  8 )  a n d  a  T  a t  r s 1 1 3 4 1 7 0  ( 6  o f  













F i g u r e  3 . 1 4  T h e  n u m b e r  o f  p r e d i c t e d  s e c o n d a r y  s t r u c t u r e s  s i m i l a r  t o  t h e  
C - f o r m  f o r  e a c h  o f  t h e  C O L 5 A1  3 ’ - U T R  h a p l o t y p e s  g e n e r a t e d  d u r i n g  i n  
s i l i c o  s i t e - d i r e c t e d  m u t a g e n e s i s .  
T h e  h a p l o t yp e s  c o n s i s t  o f  t h e  s e v e n  p o l ym o r p h i c  s i t e s ;  r s 1 3 9 4 6  ( C / T ) ,  
r s 1 2 7 2 2  ( C / T ) ,  r s 3 1 9 6 3 7 8  ( C / A ) ,  r s 7 1 7 4 6 7 4 4  ( - / A G G G ) ,  r s 1 6 3 9 9  ( A T C T / - ) ,  
r s 1 1 3 4 1 7 0  ( A / T )  a n d  r s 3 1 2 8 5 7 5  ( T / C ) ;  t h a t  d e t e r m i n e  t h e  d i s t i n c t  C  a n d  T  
f u n c t i o n a l  f o r m s .  T h e  n u c l e o t i d e  s e q u e n c e  a s s o c i a t e d  w i t h  t h e  C  f o r m  ( C - C -
C - 1 A G G G - 2 A T C T - A - T )  i s  h i g h l i g h t e d  i n  w h i t e ,  w h i l e  t h e  s e q u e n c e  a s s o c i a t e d  
w i t h  t h e  T  f o r m  ( T - T -A - 2 A G G G - 1 A T C T - T - C )  i s  h i g h l i g h t e d  i n  g r e y .  T h e  a l g o r i t h m  
g e n e r a t e s  R N A  s e c o n d a r y  s t r u c t u r e s  u s i n g  a  s t a t i s t i c a l  s a m p l e  f r o m  t h e  
B o l t zm a n n  e n s e m b l e  o f  s e c o n d a r y  s t r u c t u r e s .  A l l  s t r u c t u r e s  w e r e  f o l d e d  a t  
3 7 ° C  a n d  1 M  N a C l  i n  t h e  a b s e n c e  o f  d i va l e n t  i o n s .  T h e  ∆G  va l u e s  f o r  t h e  1 0  
m o s t  s t a b l e  s t r u c t u r e s  a r e  i n d i c a t e d .  T h e  s e c o n d a r y  s t r u c t u r e s  w h i c h  a r e  
s i m i l a r  t o  t h e  C  f u n c t i o n a l  f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R  w e r e  i d e n t i f i e d  f o r  e a c h  
h a p l o t yp e  a n d  i n d i c a t e d .  T h e  p r e f e r r e d  s e q u e n c e s  w i t h i n  t h e  C O L 5 A 1  3 ’ - U T R  
p o l ym o r p h i s m s  t h a t  p r o d u c e d  7  o r  m o r e  C - f o r m  s t r u c t u r e s  ( a b o v e  t h e  t o p  
d a s h e d  l i n e )  i s  i n d i c a t e d  a b o v e  t h e  h i s t o g r a m ,  w h i l e  t h e  p r e f e r r e d  s e q u e n c e s  
w i t h i n  t h e  C O L 5 A 1  3 ’ - U T R  p o l ym o r p h i s m s  t h a t  p r o d u c e d  4  o r  l e s s  C - f o r m  
s t r u c t u r e s  ( b e l o w  t h e  b o t t o m  d a s h e d  l i n e )  i s  i n d i c a t e d  b e l o w  t h e  h i s t o g r a m .  
A  s i n g l e  s e q u e n c e  w a s  i n d i c a t e d  a t  a  va r i a n t  o n l y  i f  i t  w a s  p r e s e n t  i n  6  o r  













O f  i n t e r e s t  w a s  t h a t  a  s i n g l e  c o p y  o f  t h e  A G G G ( n )  S T R P  ( T T A 1 1 T C )  w a s  
s u f f i c i e n t  t o  a l t e r  t h e  s t r u c t u r e  o f  i n s e r t  A  t o  t h e  C  f o r m  i n  8  o f  t h e  1 0  m o s t  
s t a b l e  s t r u c t u r e s  ( F i g u r e  3 . 1 4 ) .  
 
A n a l y s i s  o f  t h e  s e c o n d a r y  s t r u c t u r e  o f  t h e  m i R - 1 2 5 a - 5 p  b i n d i n g  s i t e  ( i n s e r t  
B )  s h o w e d  t h a t  t h e  h a i r p i n  s t r u c t u r e  a n d  p o s i t i o n  o f  t h e  i n t e r n a l  b u l g e  w a s  
m a i n t a i n e d  i n  a l l  1 0  o f  t h e  m o s t  s t a b l e  s e c o n d a r y  s t r u c t u r e s  f o r  b o t h  t h e  C -  





F i g u r e  3 . 1 5  T h e  m o s t  s t a b l e  p r e d i c t e d  s e c o n d a r y  s t r u c t u r e s  o f  r e g i o n  B  
( r e f e r  t o  F i g u r e  3 . 1 2 )  o f  t h e  C  ( l e f t  p a n e l )  a n d  T  ( r i g h t  p a n e l )  f u n c t i o n a l  
f o r m s  o f  t h e  C O L 5 A 1  3 ’ - U T R .  
T h i s  r e g i o n  c o n t a i n s  t h e  p u t a t i v e  n o n - p o l ym o r p h i c  b i n d i n g  s i t e  f o r  H s a - m i R -
1 2 5 a - 5 p .  T h e  b a s e s  t o  w h i c h  H s a - m i R - 1 2 5 a - 5 p  b i n d s  a r e  h i g h l i g h t e d  w i t h  g r e y  
d i a m o n d s .  T h e  s e e d  b i n d i n g  b a s e s  ( u G G G G A C )  f o r  m i R 1 2 5 a - 5 p  a r e  p r e s e n t  
w i t h i n  a n  u n s t a b l e  i n t e r n a l  b u l g e  r e g i o n .  N u c l e o t i d e  p o s i t i o n s  w i t h i n  t h e  3 ’ -


















A  c o m m o n  C / T  p o l y m o r p h i s m  ( S N P  r s 1 2 7 2 2 )  w i t h i n  t h e  C O L 5 A 1  3 ′ - U T R  h a s  
p r e v i o u s l y  b e e n  a s s o c i a t e d  w i t h  s e v e r a l  c o m p l e x  e x e r c i s e - r e l a t e d  
p h e n o t y p e s ,  i n c l u d i n g  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  [ 1 3 ] ,  [ 1 4 ] ,  A C L  i n j u r i e s  
i n  f e m a l e s  [ 1 5 ] ,  r a n g e  o f  m o t i o n  m e a s u r e m e n t s  [ 1 6 ] ,  [ 1 7 ] ,  r u n n i n g  e n d u r a n c e  
p e r f o r m a n c e  [ 1 0 7 ] ,  [ 1 0 8 ]  a n d  e x e r c i s e  a s s o c i a t e d  m u s c l e  c r a m p s  [ 1 0 9 ] .  T h r e e  
a d d i t i o n a l  p o l y m o r p h i s m s  w i t h i n  t h e  C O L 5 A 1  3 ’ - U T R ,  n a m e l y  r s 7 1 7 4 6 7 4 4  ( -
/ A G G G ) ,  r s 1 6 3 9 9  ( A T C T / - )  a n d  r s 1 1 3 4 1 7 0  ( T / A ) ,  h a v e  a l s o  b e e n  r e p o r t e d  t o  
i n d e p e n d e n t l y  a s s o c i a t e  w i t h  c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  [ 2 2 ] .  A n o t h e r  
s t u d y  r e p o r t e d  t w o  m a j o r  f u n c t i o n a l  f o r m s  o f  t h e  C O L 5 A 1  3 ′ - U T R ,  n a m e l y  t h e  
C -  a n d  T - f o r m s ,  w h i c h  w e r e  p r e d o m i n a n t l y  f o u n d  i n  A c h i l l e s  t e n d i n o p a t h y  
a n d  a s y m p t o m a t i c  c o n t r o l  p a r t i c i p a n t s ,  r e s p e c t i v e l y  [ 6 4 ] .  I m p o r t a n t l y ,  t h e  
a u t h o r s  s h o w e d  t h a t  t h e  C -  a n d  T - f o r m s  e x h i b i t e d  s i g n i f i c a n t  d i f f e r e n c e s  i n  
t h e i r  m R N A  s t a b i l i t y .  T h e  a i m  o f  t h i s  d i s s e r t a t i o n  w a s  t h e r e f o r e  t o  
i n v e s t i g a t e  t h e  b a s i s  f o r  t h e s e  d i f f e r e n c e s  b y  e x p l o r i n g  t h e  r o l e  o f  p u t a t i v e  
m i R N A  b i n d i n g  s i t e s  w i t h i n  t h e  3 ’ - U T R  o f  C O L 5 A 1  o n  m R N A  s t a b i l i t y .  I n  
p a r t i c u l a r ,  a  r e g i o n  o f  t h e  C O L 5 A 1  3 ′ - U T R  p r e v i o u s l y  a s s o c i a t e d  w i t h  A c h i l l e s  
t e n d i n o p a t h y ,  c o n t a i n i n g  t h r e e  m i R N A  b i n d i n g  s i t e s  w a s  i n v e s t i g a t e d  u s i n g  
l u c i f e r a s e  a c t i v i t y  a s  a n  i n d i r e c t  m e a s u r e  o f  m R N A  s t a b i l i t y .  B r i e f l y ,  i n  o r d e r  
t o  t e s t  w h e t h e r  t h e  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w e r e  v a l i d  n e g a t i v e  
r e g u l a t o r y  e l e m e n t s ,  t h e  T -  a n d  C - a l l e l i c  3 ’ - U T R s  w h i c h  w e r e  p r e v i o u s l y  
c l o n e d  d o w n s t r e a m  o f  a  l u c i f e r a s e  r e p o r t e r  g e n e ,  w e r e  t r a n s f e c t e d  i n t o  
f i b r o s a r c o m a  o r  f i b r o b l a s t - l i k e  c e l l s  [ 6 4 ] .  T h i s  a p p r o a c h  w a s  s i m i l a r  t o  t h a t  
u s e d  b y  T h i e l e  e t  a l .  ( 2 0 0 4 )  t o  i n d i r e c t l y  m e a s u r e  t h e  m R N A  s t a b i l i t y  o f  t h e  
f i b r i l l a r  c o l l a g e n  t y p e s  I  a n d  I I I  i n  a  p G L 3 - P r o m o t e r  c o n s t r u c t  [ 1 1 0 ] .  T h e  f i r s t  
m a i n  n o v e l  f i n d i n g s  o f  t h i s  d i s s e r t a t i o n  w e r e :  ( i )  t h e  c o - t r a n s f e c t i o n  o f  H s a -
m i R - 6 0 8  m i m i c  r e p r e s s e s  l u c i f e r a s e  a c t i v i t y  o f  t h e  C - a n d  T - a l l e l i c  c o n s t r u c t s  
o f  t h e  3 ’ - U T R  o f  C O L 5 A 1  a n d  p r e f e r e n t i a l l y  r e p r e s s e s  t h e  T - a l l e l i c  f o r m  i n  t h e  
H T 1 0 8 0  f i b r o s a r c o m a  c e l l  l i n e  b u t  n o t  i n  t h e  S V W I - 3 8  t r a n s f o r m e d  f i b r o b l a s t  
l i n e ;  ( i i )  t h e  r e g i o n  c o n t a i n i n g  t h e  p r e d i c t e d  p o l y m o r p h i c  m i R N A  b i n d i n g  s i t e  
w h i c h  o v e r l a p s  w i t h  t h e  M b o I I  R F L P  i s  a l s o  v a l i d  a n d  c o n t a i n s  a  n e g a t i v e  
r e g u l a t o r y  e l e m e n t  w h i c h  r e p r e s s e s  t h e  C O L 5 A 1  3 ’ - U T R  i n  b o t h  H T 1 0 8 0  a n d  












r e p r e s s e s  l u c i f e r a s e  a c t i v i t y  o f  b o t h  C -  a n d  T - a l l e l i c  c o n s t r u c t s  o f  t h e  C O L 5 A 1  
3 ’ - U T R  b u t  p r e f e r e n t i a l l y  r e p r e s s e s  t h e  T - a l l e l e  i n  t h e  H T 1 0 8 0  c e l l  l i n e .   
 
T h e  a d d i t i o n  o f  H s a - m i R - 6 0 8  m i m i c  w a s  s u f f i c i e n t  t o  c a u s e  a  s i g n i f i c a n t  
d e c r e a s e  i n  t h e  l u c i f e r a s e  a c t i v i t y  o f  t h e  C -  a n d  T - a l l e l i c  c o n s t r u c t s  i n  t h e  
H T 1 0 8 0  c e l l  l i n e .  T h e r e  w a s  h o w e v e r ,  n o  d o s e - d e p e n d e n t  r e d u c t i o n  i n  
l u c i f e r a s e  a c t i v i t y  w i t h  i n c r e a s i n g  a m o u n t s  o f  t r a n s f e c t e d  H s a - m i R - 6 0 8  
m i m i c .  T h i s  m a y  b e  d u e  t o  i n c r e a s e d  c y t o t o x i c i t y  o f  t r a n s f e c t i n g  l a r g e  
a m o u n t s  o f  m i R N A  m i m i c  w h i c h  m a y  h a v e  n e g a t i v e l y  a f f e c t e d  o t h e r  p r o t e i n  
t a r g e t s  a s  w e l l  a s  d e p l e t i n g  t h e  R N A - i n d u c e d  s i l e n c i n g  c o m p l e x e s  ( R I S C )  
m a c h i n e r y  w i t h i n  t h e  c e l l s .  A d d i t i o n a l l y ,  t h e  c e l l s  m a y  b e c o m e  s a t u r a t e d  
w i t h  m i R N A  m i m i c ,  o b s c u r i n g  a n y  d o s e - d e p e n d e n t  f e a t u r e s  i n  t h e  d a t a  s e t .  
T o  a d d r e s s  t h i s ,  t w o  C - a l l e l i c  a n d  t w o  T - a l l e l i c  c o n s t r u c t s  c o n t a i n i n g  t h e  
C O L 5 A 1  3 ’ - U T R  d e r i v e d  f r o m  d i f f e r e n t  i n d i v i d u a l s  w e r e  t e s t e d  a t  t h e  l o w e s t  
f u n c t i o n a l  c o n c e n t r a t i o n  o f  m i R N A  m i m i c .  I t  i s  i m p o r t a n t  t o  n o t e  t h a t  w h i l e  
t h e  t w o  C - a l l e l i c  c o n s t r u c t s  h a v e  t h e  s a m e  D N A  s e q u e n c e s  t h e y  h a v e  b e e n  
r e p o r t e d  t o  d i s p l a y  m i n o r  v a r i a t i o n s  i n  t h e i r  l u c i f e r a s e  a c t i v i t y  a n d  t h i s  w a s  
a l s o  f o u n d  t o  b e  t r u e  f o r  t h e  t w o  T - a l l e l i c  c o n s t r u c t s  [ 6 4 ] .  T o  p r e v e n t  s k e w i n g  
o f  t h e  d a t a ,  t h e  l u c i f e r a s e  a c t i v i t y  o b t a i n e d  f o r  t h e  s i C o n t r o l  o n  e a c h  
c o n s t r u c t  w a s  s e t  t o  1 0 0 %  a n d  t h e  l u c i f e r a s e  a c t i v i t y  o b t a i n e d  f o r  t h e  m i R N A  
m i m i c  w a s  t h e n  c a l c u l a t e d  a s  a  p e r c e n t a g e  o f  t h e i r  i n d i v i d u a l  s i C o n t r o l  
b e f o r e  p o o l i n g .  T h e  r e s u l t s  f r o m  t h e  c u r r e n t  s t u d y  s h o w  t h a t  t h e  H s a - m i R -
6 0 8  m i m i c  r e p r e s s e d  t h e  T - a l l e l e  t o  a  g r e a t e r  e x t e n t  r e s u l t i n g  i n  a  
c o r r e s p o n d i n g  d e c r e a s e d  e x p r e s s i o n  o f  l u c i f e r a s e .  T h e s e  r e s u l t s  s u g g e s t  t h a t  
H s a - m i R - 6 0 8  m a y  p r e f e r e n t i a l l y  b i n d  t h e  T - a l l e l e  d u e  t o  t h e  A  n u c l e o t i d e  o f  
r s 3 1 9 6 3 7 8  w i t h i n  t h e  H s a - m i R - 6 0 8  b i n d i n g  s i t e  o r  a s  a  r e s u l t  o f  a  c h a n g e  i n  
m R N A  s e c o n d a r y  s t r u c t u r e  d u e  t o  o t h e r  v a r i a n t s  p r e s e n t  w i t h i n  t h e  3 ’ - U T R .  
T h i s  e x p e r i m e n t  w a s  r e p e a t e d  i n  t h e  S V 4 0  t r a n s f o r m e d  f i b r o b l a s t  c e l l  l i n e ,  
S V W I - 3 8 ,  u s i n g  a  m o d i f i e d  p r o t o c o l  t o  p r e v e n t  d e p l e t i o n  o f  t h e  R I S -
c o m p l e x e s .  H s a - m i R - 6 0 8  m i m i c  w a s  o n c e  a g a i n  f o u n d  t o  b e  c a p a b l e  o f  
r e d u c i n g  l u c i f e r a s e  a c t i v i t y ,  i n  a  d o s e - d e p e n d e n t  m a n n e r .  T h e r e  w a s  
h o w e v e r ,  n o  p r e f e r e n t i a l  r e p r e s s i o n  o f  t h e  T - a l l e l e  a t  a n y  o f  t h e  t e s t e d  












p r e f e r e n t i a l  r e p r e s s i o n  o f  t h e  T - a l l e l e  a r e  c u r r e n t l y  u n k n o w n  a n d  r e q u i r e  
f u r t h e r  r e s e a r c h .  
 
I n v e s t i g a t i o n s  i n t o  t h e  i m p a c t  o f  t h e  M b o I I  o c t a m e r  r e g u l a t o r y  e l e m e n t  
r e v e a l e d  t h a t  i t  m a y  p l a y  a n  i m p o r t a n t  r o l e  i n  m R N A  s t a b i l i t y  s i n c e  m u t a t i n g  
t h i s  e l e m e n t  s i g n i f i c a n t l y  i n c r e a s e d  l u c i f e r a s e  a c t i v i t y  i n  b o t h  H T 1 0 8 0  a n d  
S V W I - 3 8  c e l l  l i n e s .  A n  e x c e p t i o n  w a s  t h e  r e s u l t s  o b t a i n e d  f o r  t h e  C O N  5 . 1  
M u t  1  c o n s t r u c t  w h i c h  s h o w e d  a  s t a t i s t i c a l l y  s i g n i f i c a n t  d e c r e a s e  i n  
l u c i f e r a s e  a c t i v i t y .  W h e n  a p p r o x i m a t e l y  9 4  p e r c e n t  o f  t h e  2 . 5  k b  3 ’ - U T R  
i n s e r t  o f  t h i s  c o n s t r u c t  w a s  s e q u e n c e d  n o  s p u r i o u s  m u t a t i o n s  w e r e  
i d e n t i f i e d .  A s  t h i s  c l o n e  w a s  t h e  o n l y  o n e  t o  s h o w  a  s i g n i f i c a n t  r e d u c t i o n  i n  
l u c i f e r a s e  a c t i v i t y  a n d  m u t a t i o n s  i n  t h e  p r o m o t e r  o r  l u c i f e r a s e  g e n e  r e g i o n s  
o f  t h e  v e c t o r  c o u l d  n o t  b e  r u l e d  o u t ,  i t  w a s  o m i t t e d  f r o m  a l l  f u r t h e r  a n a l y s e s .  
I n t e r e s t i n g l y ,  t h e  M b o I I  o c t a m e r  i s  l o c a t e d  w i t h i n  a  5 7  b p  r e g i o n  w h i c h ,  w h e n  
d e l e t e d ,  w a s  p r e v i o u s l y  s h o w n  t o  a b o l i s h  t h e  d i f f e r e n c e  i n  m R N A  s t a b i l i t y  
b e t w e e n  t h e  T -  a n d  C - f o r m s  [ 6 4 ] .  I t  w a s  n o t ,  h o w e v e r ,  p o s s i b l e  t o  c o n c l u d e  
t h a t  t h e  M b o I I  o c t a m e r  i s  t h e  s o l e  r e g u l a t o r y  e l e m e n t  r e s p o n s i b l e  f o r  t h e  
a b o l i s h m e n t  o f  t h e  d i f f e r e n c e  i n  m R N A  s t a b i l i t y  o b s e r v e d  i n  t h e  5 7 b p  
d e l e t i o n  c o n s t r u c t s .  B i o i n f o r m a t i c  a n a l y s e s  w e r e  t h e r e f o r e  p e r f o r m e d  t o  
i d e n t i f y  p u t a t i v e  R N A - b i n d i n g  p r o t e i n  m o t i f s  p r e s e n t  w i t h i n  a n d  a r o u n d  t h e  
M b o I I  o c t a m e r  a s  w e l l  a s  i n  t h e  s u r r o u n d i n g  5 7  b p  r e g i o n  t h a t  m a y  a f f e c t  














Table 4.1 RNA-binding protein binding sites within the ∆57 bp region of the COL5A1 3’-UTR 
 
T h e  K H D D R B S 3 ,  P T B P 1  a n d  h n R N P A 1  g e n e s  e n c o d e  h e t e r o g e n e o u s  n u c l e a r  
r i b o n u c l e o p r o t e i n s  w h i c h  b i n d  t o  p r e - m R N A s  i n  t h e  n u c l e u s .  T h e  h n R N P A 1  
a n d  N O N O  p r o t e i n s  h a v e  p r e v i o u s l y  b e e n  s h o w n  t o  a c t  a s  n u c l e a r - c y t o p l a s m i c  
s h u t t l e  p r o t e i n s ,  s p l i c i n g  f a c t o r s  a n d  r e g u l a t o r s  o f  g e n e  e x p r e s s i o n  [ 7 2 ] ,  
[ 1 1 1 ] ,  [ 1 1 2 ] ,  [ 1 1 3 ] ,  [ 1 1 4 ] ,  [ 1 1 5 ] ,  [ 1 1 6 ] .  E u k a r y o t i c  i n i t i a t i o n  f a c t o r  4 B  ( e I F 4 B )  
f a c i l i t a t e s  t h e  b i n d i n g  o f  m R N A  t o  t h e  p r e - i n i t i a t i o n  c o m p l e x  a n d  a c t s  i n  
c o n c e r t  w i t h  e I F 4 F  t o  b i n d  t o  a n d  u n w i n d  t h e  s e c o n d a r y  s t r u c t u r e  o f  t h e  
m R N A  c a p  s t r u c t u r e  i n  t h e  5 ’ - U T R .  I t  h a s  a l s o  b e e n  s h o w n  t o  s t i m u l a t e  t h e  
A T P a s e  a n d  R N A  h e l i c a s e  a c t i v i t i e s  o f  e I F 4 A  [ 1 1 7 ] ,  [ 1 1 8 ] .  M e m b e r s  o f  t h e  
E L A V L  p r o t e i n  f a m i l y  h a v e  a l s o  b e e n  f o u n d  t o  b i n d  t o  A U  r i c h  e l e m e n t s  t o  
d e s t a b i l i z e  m R N A s  a n d  i n f l u e n c e  g e n e  e x p r e s s i o n  [ 1 1 9 ] ,  [ 1 2 0 ] ,  [ 1 2 1 ] .  T h e  
r e g u l a t o r y  a b i l i t i e s  o f  R N A - b i n d i n g  p r o t e i n s  v a r y  t o  a  g r e a t  e x t e n t  a n d  t h e i r  
r o l e  i n  t h e  r e g u l a t i o n  o f  t h e  C O L 5 A 1  g e n e  s h o u l d  b e  i n v e s t i g a t e d  i n  g r e a t e r  
d e t a i l  ( A p p e n d i x  R ) .  I t  i s  w o r t h  n o t i n g  t h a t  i n  a d d i t i o n  t o  t h e  a b o v e  R N A -
b i n d i n g  p r o t e i n  m o t i f s ,  s e v e r a l  o t h e r  p u t a t i v e  m i R N A  b i n d i n g  s i t e s  w i t h i n  t h e  
C O L 5 A 1  3 ’ - U T R  w e r e  i d e n t i f i e d  b y  t h e  b i o i n f o r m a t i c  a n a l y s e s .  S i n c e  t h e s e  
m a y  b e  i n v o l v e d  i n  t h e  r e g u l a t i o n  o f  t h e  C O L 5 A 1  m R N A  s t a b i l i t y  f u r t h e r  
RN A 
b i nd i ng  
p rot e in :  
Ge ne  
Sym bol  
RN A b ind ing  
p rot e in :  Nam e 
B ind ing  
e l eme nt :  
De scr i p t ion  
Re l a t i ve  
Sc ore  
( %)  




Po lyp yr im id i ne  t r ac t  
b i nd ing  p ro t e i n  1 /  
He t e rog e ne ous  
R ib on uc le opr o te i n  
p o l ype p t i de  I  
AG ACUUUUUU
UUUUU 
9 6  9 96  1 01 0  
HNRNPA
1 
Het e rog e ne ous  
R ib on uc le opr o te i n  
A1  
UAGGGA 1 00  1 01 5  1 02 0  
NONO 
No n-PO U d oma in  
c on t a in ing  o c tam er  
b i nd ing  p ro t e i n  
AGGG A 1 00  1 01 6  1 02 0  
EIF4B 
Euk ar yo t i c  
t r a ns la t ion  i n i t i a t i on  
f ac to r  4B  
GGAA 1 00  1 01 8  1 02 1  
KHDRBS
3 
Het e rog e ne ous  
R ib on uc le opr o te i n  G  
UUUAAU 
9 3  1 01 0  1 01 5  
9 5  1 02 9  1 03 4  
ELAVL1 
Embr yon i c  l e th a l ,  
a bn orma l  v i s io n ,  
D ro so ph i la - l i k e  1  
AUUU 
8 6  1 02 5  1 02 8  












r e s e a r c h  i s  n e e d e d  t o  t e s t  t h e  v a l i d i t y  o f  t h e s e  s i t e s  a n d  t h e i r  r e l a t i o n  t o  
A c h i l l e s  t e n d i n o p a t h y  a n d  o t h e r  e x e r c i s e - r e l a t e d  p h e n o t y p e s .  
 
I n  t h i s  d i s s e r t a t i o n ,  t h e  c o - t r a n s f e c t i o n  o f  H s a - m i R - 1 2 5 a - 5 p  m i m i c  i s  
s u f f i c i e n t  t o  r e d u c e  t h e  l u c i f e r a s e  e x p r e s s i o n  o f  t h e  C -  a n d  T - a l l e l i c  
c o n s t r u c t s  i n  t h e  H T 1 0 8 0  c e l l  l i n e .  A  d o s e - d e p e n d e n t  r e d u c t i o n  i n  m R N A  
s t a b i l i t y  w a s  n o t e d  f o r  b o t h  t h e  C -  a n d  T - a l l e l i c  c o n s t r u c t s ,  w i t h  t h e  T - a l l e l i c  
c o n s t r u c t  s h o w i n g  s t a t i s t i c a l l y  g r e a t e r  r e d u c t i o n  i n  m R N A  s t a b i l i t y  a t  t h e  1 0  
a n d  2 0  p m o l  c o n c e n t r a t i o n s  o f  H s a - m i R - 1 2 5 a - 5 p  m i m i c .  T h i s  d a t a  i s  c o n t r a r y  
t o  e x p e c t a t i o n  a s  t h e  s e q u e n c e  f o r  t h e  m i R - 1 2 5 a - 5 p  b i n d i n g  s i t e  i s  i d e n t i c a l  
i n  b o t h  a l l e l i c  f o r m s .  A d d i t i o n a l l y ,  t h e  e f f e c t s  o f  t h e  o t h e r  v a r i a n t s  p r e s e n t  
w i t h i n  t h e  3 ’ - U T R  o f  C O L 5 A 1  m a y  a l t e r  t h e  a c c e s s i b i l i t y  o f  t h e  t a r g e t  s i t e  a n d  
c a u s e  t h e  T - a l l e l i c  f o r m  t o  b e  m o r e  s u s c e p t i b l e  t o  r e p r e s s i o n  b y  H s a - m i R -
1 2 5 a - 5 p .  I t  i s  a l s o  p o s s i b l e  t h a t  a n  e x t e r n a l  f a c t o r  s u c h  a s  R N A - b i n d i n g  
p r o t e i n s  a r e  a c t i n g  o n  t h e  C O L 5 A 1  3 ’ - U T R  t o  c h a n g e  l o c a l  s e c o n d a r y  
s t r u c t u r e s  a n d  a l t e r  i t s  s u s c e p t i b i l i t y  t o  m i R N A  r e g u l a t i o n ,  i n d e p e n d e n t  o f  
t h e  s e q u e n c e  o f  t h e  m i R - 1 2 5 a - 5 p  b i n d i n g  s i t e .   
.   
 
I n  s u m m a r y ,  c o n t r a r y  t o  e x p e c t a t i o n s ,  a t  l e a s t  2  o f  t h e  3  r e g u l a t o r y  s i t e s  
t e s t e d  i n  t h i s  d i s s e r t a t i o n  s h o w e d  a  p r e f e r e n t i a l  r e d u c t i o n  i n  m R N A  s t a b i l i t y  
i n  t h e  m o r e  s t a b l e  T - a l l e l i c  f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R  i n  t h e  H T 1 0 8 0  c e l l  
l i n e .  T h e s e  r e s u l t s  c o u l d  n o t  h o w e v e r  b e  r e p r o d u c e d  i n  t h e  S V W I - 3 8  c e l l s  
s i n c e  n o  s t a t i s t i c a l  d i f f e r e n c e s  b e t w e e n  t h e  t w o  a l l e l i c  f o r m s  o f  t h e  C O L 5 A 1  
3 ’ - U T R  w e r e  o b s e r v e d .  I t  i s  w o r t h  n o t i n g  t h a t  w h i l e  t h e r e  a r e  o b v i o u s  
l i m i t a t i o n s  t o  u s i n g  a  n o n - t e n d o n  c e l l  l i n e  s u c h  a s  t h e  H T 1 0 8 0 ,  i t  i s  a n  
e s t a b l i s h e d  f i b r o b l a s t  c e l l  l i n e  w h i c h  i s  g e n e r a l l y  a g r e e d  t o  r e p r e s e n t  o n e  o f  
t h e  b e s t  m o d e l s  f o r  o u r  i n i t i a l  s t u d y .  F u r t h e r m o r e ,  H T 1 0 8 0  c e l l s  a r e  
c o m m o n l y  u s e d  f o r  t r a n s f e c t i o n  a s s a y s  w i t h  r e p o r t e r  g e n e s  a n d  h a v e  
p r e v i o u s l y  b e e n  u s e d  t o  s t u d y  t h e  e x p r e s s i o n  o f  o t h e r  p G L 3  p r o m o t e r -  
c o l l a g e n  3 ′ - U T R  c o n s t r u c t s  [ 1 1 0 ] .  O u r  r e s e a r c h  g r o u p  i s ,  h o w e v e r ,  p l a n n i n g  
t o  c o n f i r m  t h e  f i n d i n g s  o f  t h i s  s t u d y  i n  o t h e r  f i b r o b l a s t  c e l l  l i n e s  i n c l u d i n g  
p r i m a r y  f i b r o b l a s t s  d e r i v e d  f r o m  c o n t r o l  a n d  t e n d i n o p a t h i c  p a r t i c i p a n t s .  












t i s s u e  b i o p s i e s  f r o m  a s y m p t o m a t i c  c o n t r o l  s u b j e c t s  a n d  p a t i e n t s  w i t h  c h r o n i c  
A c h i l l e s  t e n d i n o p a t h y  i n  o r d e r  t o  c o m p a r e  C O L 5 A 1  3 ′ - U T R  g e n o t y p e s  a n d  
C O L 5 A 1  m R N A  a n d  t y p e  V  c o l l a g e n  p r o t e i n  l e v e l s .  
 
F u r t h e r m o r e ,  t h i s  d i s s e r t a t i o n  h a s  i d e n t i f i e d  s e v e r a l  o t h e r  p u t a t i v e  m i R N A  
b i n d i n g  s i t e s  w i t h i n  t h e  C O L 5 A 1  3 ’ - U T R  w h i c h  m a y  r e g u l a t e  t h e  m R N A  
s t a b i l i t y  o f  t h e  C O L 5 A 1  m R N A  a n d  f u r t h e r  r e s e a r c h  i s  n e e d e d  t o  t e s t  t h e  
v a l i d i t y  o f  t h e s e  s i t e s  a n d  t h e i r  r e l a t i o n  t o  A c h i l l e s  t e n d i n o p a t h y  a n d  o t h e r  
e x e r c i s e - r e l a t e d  p h e n o t y p e s .  
 
T h e  s e c o n d  m a i n  n o v e l  f i n d i n g  o f  t h i s  d i s s e r t a t i o n  w a s  t h a t  t h e  p o l y m o r p h i c  
M I R 6 0 8  g e n e  ( r s 4 9 1 9 5 1 0 ,  C / G )  w a s  a l s o  a s s o c i a t e d  w i t h  c h r o n i c  A c h i l l e s  
t e n d i n o p a t h y .  T h e  C C  g e n o t y p e  o f  t h i s  p o l y m o r p h i s m  w a s  s i g n i f i c a n t l y  o v e r -
r e p r e s e n t e d  w i t h i n  t h e  t e n d i n o p a t h i c  p a r t i c i p a n t s .  E a c h  a l l e l e  o f  t h e  M I R 6 0 8  
g e n e  e n c o d e s  f o r  a  d i s t i n c t  m a t u r e  m i R N A ,  H s a - m i R - 6 0 8 ,  w h i c h  b i n d s  t o  a  
p o l y m o r p h i c  ( r s 3 1 9 6 3 7 8 ,  A c i I  R F L P ,  C / A )  c i s - a c t i n g  e l e m e n t  w i t h i n  t h e  
C O L 5 A 1  3 ′ - U T R  [ 1 4 ] ,  [ 6 4 ] .  S i n c e  t h e  A  a l l e l e  o f  r s 3 1 9 6 3 7 8  w i t h i n  t h e  H s a - m i R -
6 0 8  b i n d i n g  s i t e  w a s  i d e n t i f i e d  w i t h i n  t h e  T - f u n c t i o n a l  f o r m  o f  t h e  C O L 5 A 1  
3 ′ - U T R  [ 6 4 ] ,  t h e  c o m b i n e d  g e n o t y p e  f r e q u e n c i e s  o f  M I R 6 0 8  r s 4 9 1 9 5 1 0  a n d  
r s 3 1 9 6 3 7 8  w i t h i n  t h e  m i R N A  b i n d i n g  s i t e  w a s  i n v e s t i g a t e d .  I t  w a s  
h y p o t h e s i z e d  t h a t  t h e  c o m b i n e d  M I R 6 0 8  r s 4 9 1 9 5 1 0  C C  a n d  C O L 5 A 1  m i R N A  
b i n d i n g  s i t e  r s 3 1 9 6 3 7 8  A A  g e n o t y p e s  s h o u l d  b e  o v e r - r e p r e s e n t e d  i n  t h e  
c h r o n i c  A c h i l l e s  t e n d i n o p a t h y  g r o u p .  A l t h o u g h  t h e  c o m b i n e d  M I R 6 0 8  C C  a n d  
C O L 5 A 1  r s 3 1 9 6 3 7 8  A A  g e n o t y p e  d i s t r i b u t i o n s  w e r e  s i m i l a r  b e t w e e n  t h e  A U S  
T E N  a n d  A U S  C O N  g r o u p s ,  t h e  c o m b i n e d  M I R 6 0 8  C C  g e n o t y p e  a n d  C O L 5 A 1  
r s 3 1 9 6 3 7 8  A  a l l e l e  ( C A  a n d  A A  g e n o t y p e s )  w e r e  s i g n i f i c a n t l y  o v e r -
r e p r e s e n t e d  i n  a l l  t h e  T E N  p a r t i c i p a n t s  w h e n  c o m p a r e d  t o  a l l  t h e  C O N  
p a r t i c i p a n t s .  O v e r a l l ,  a n  o d d s  r a t i o  o f  1 . 6  ( 9 5 %  C I =  1 . 1  –  2 . 5 )  w a s  f o u n d  f o r  
r s 4 9 1 9 5 1 0  a n d  A c h i l l e s  t e n d i n o p a t h y ,  w h i c h  i n c r e a s e d  t o  1 . 7  ( 9 5 %  C I =  1 . 1  –  
2 . 5 )  w h e n  a  C A  o r  A A  g e n o t y p e  w a s  p r e s e n t  a t  t h e  r s 3 1 9 6 3 7 8  C O L 5 A 1  m i R N A  
b i n d i n g  l o c u s .  
 
T h e  g e n e t i c  c o m p o n e n t  o f  m u l t i f a c t o r i a l  c o n d i t i o n s  s u c h  a s  A c h i l l e s  












s u c h  a s  m e m b e r s  o f  t h e  T G F - β  s u p e r f a m i l y  ( G D F 5  a n d  T G F - β ) ,  [ 2 8 ] ,  [ 1 2 2 ] ,  
i n f l a m m a t o r y  c y t o k i n e s  a n d  r e c e p t o r s  ( I L - 1 β ,  I L - 6  a n d  I L - 1 R )  [ 2 9 ] ,  m e m b e r s  
o f  t h e  a p o p t o t i c  p a t h w a y  ( C A S P 8 )  [ 9 4 ] ,  e x t r a c e l l u l a r  m a t r i x  d e g r a d a t i o n  
p a t h w a y  ( M M P - 3  a n d  T I M P - 2 )  [ 2 6 ] ,  [ 2 7 ]  a n d  t h e  f i b r i l l a r  c o l l a g e n  f a m i l y  
( C O L 5 A 1 )  [ 1 3 ] ,  [ 1 4 ] .  T h i s  m a k e s  e l u c i d a t i n g  t h e  m a j o r  e t i o l o g i c a l  m e c h a n i s m s  
d i f f i c u l t  a n d  r e q u i r e s  m u l t i - g e n i c  a n a l y s e s  t o  a c c u r a t e l y  d e t e r m i n e  r i s k .      
 
T h e  t h i r d  m a i n  n o v e l  f i n d i n g  o f  t h i s  d i s s e r t a t i o n  w a s  t h e  c l e a r  s t r u c t u r a l  
d i f f e r e n c e s  i n  t h e  m o s t  s t a b l e  C -  a n d  T - f u n c t i o n a l  f o r m s  o f  t h e  C O L 5 A 1  3 ′ -
U T R .  T h e  p r e d i c t e d  s e c o n d a r y  s t r u c t u r e  o f  t h e  r e g i o n  c o n t a i n i n g  t h e  m i R N A  
b i n d i n g  s i t e s  o f  i n t e r e s t  w a s  d i s t i n c t l y  d i f f e r e n t  i n  t h e s e  t w o  f o r m s .  S f o l d  
a n a l y s e s  r e v e a l e d  t h a t  s e q u e n c e  d i f f e r e n c e s  w i t h i n  o n l y  s e v e n  p o l y m o r p h i c  
s i t e s  s p a n n i n g  t h e  e n t i r e  2 . 5  k b  C O L 5 A 1  3 ′ - U T R  d e t e r m i n e d  t h e  d i s t i n c t  
p r e d i c t e d  s e c o n d a r y  s t r u c t u r e s  o f  t h e  C -  a n d  T - f u n c t i o n a l  f o r m s .  A l l  s e v e n  o f  
t h e s e  p o l y m o r p h i c  s i t e s  c o n t r i b u t e  t o  t h e  p r e d i c t e d  s t r u c t u r e s  a s s o c i a t e d  
w i t h  t h e  C -  a n d  T - f u n c t i o n a l  f o r m s  a l t h o u g h  t h e  w e i g h t  o f  t h e i r  c o n t r i b u t i o n s  
v a r i e s .  T h e  s e c o n d a r y  s t r u c t u r e  o f  t h e  H s a - m i R 1 2 5 a - 5 p  b i n d i n g  s i t e  w a s  
m a i n t a i n e d  i n  a l l  t h e  i n v e s t i g a t e d  s t r u c t u r e s  o f  b o t h  t h e  C -  a n d  T - a l l e l i c  
f o r m s .  T h i s  w a s  o f  p a r t i c u l a r  i n t e r e s t  b e c a u s e  t h e  T - a l l e l i c  f o r m  s h o w e d  
s i g n i f i c a n t l y  g r e a t e r  r e p r e s s i o n  b y  t h e  H s a - m i R 1 2 5 a - 5 p  m i m i c  i n  v i t r o  
( F i g u r e s  3 . 1 1  a n d  3 . 1 7 ) .  I n  t h i s  s t u d y ,  a l l  s e c o n d a r y  s t r u c t u r e s  w e r e  f o l d e d  
a t  3 7 ° C  a n d  1  M  N a C l  a s  p r e v i o u s l y  d e s c r i b e d  [ 1 2 3 ] .  D i v a l e n t  c a t i o n  ( M g 2 + )  
c o n c e n t r a t i o n s  a r e  o n l y  c o n s i d e r e d  r e l e v a n t  f o r  t h e  t e r t i a r y  f o l d i n g  o f  R N A  
a n d  w e r e  i g n o r e d  f o r  t h e  p u r p o s e  o f  t h i s  s t u d y  [ 1 2 4 ] .  O n e  l i m i t a t i o n  o f  t h i s  
s t u d y  i s  t h e  u s e  o f  a n  i n  s i l i c o  p r e d i c t i o n  o f  t h e  s e c o n d a r y  s t r u c t u r e s  o f  t h e  
3 ′ - U T R .  F o r  e x a m p l e ,  S f o l d  w h i c h  w a s  u s e d  i n  t h i s  s t u d y ,  i s  u n a b l e  t o  p r e d i c t  
p s e u d o k n o t s  a n d  t h e  a c c u r a c y  o f  t h e  p r e d i c t i o n  a l s o  d i m i n i s h e s  a s  t h e  s i z e  
o f  t h e  R N A  i n c r e a s e s  [ 8 9 ] .  T o  a d d r e s s  t h i s  i s s u e ,  t h e  8 5 8  b p  s u b s e c t i o n  o f  
t h e  m R N A  c o n t a i n i n g  t h e  v a r i a n t s  r s 1 2 7 2 2 ,  r s 3 1 9 6 3 7 8 ,  r s 7 1 7 4 6 7 4 4 ,  r s 1 6 3 9 9  
a n d  r s 1 1 3 4 1 7 0  a n d  t h e  3  m i R N A  b i n d i n g  s i t e s  w a s  f o l d e d  a n d  a n a l y s e d  f o r  
u n s t a b l e  r e g i o n s  i n  e a c h  a l l e l i c  f o r m .  T h e  s e e d - b i n d i n g  o c t a m e r s  o f  a l l  3  
m i R N A  b i n d i n g  s i t e s  w e r e  f o u n d  t o  b e  p a r t i a l l y  o r  c o m p l e t e l y  w i t h i n  u n s t a b l e  
s i n g l e  s t r a n d e d  r e g i o n s  o f  t h e  m R N A  ( A p p e n d i x  S ) .  F o r  b o t h  a l l e l i c  f o r m s ,  t h e  












5 7  b p  r e g i o n .  T h e  a l g o r i t h m s  u s e d  i n  t h e  p r e d i c t i o n  o f  R N A  s e c o n d a r y  
s t r u c t u r e s  a r e  i m p e r f e c t  a n d  s e v e r a l  o b s t a c l e s  m u s t  b e  o v e r c o m e  t o  
a c c u r a t e l y  p r e d i c t  t h e  s t r u c t u r e  o f  R N A  i n  v i v o .  A  s i g n i f i c a n t  a m o u n t  o f  
r e s e a r c h  h a s  h o w e v e r  b e e n  c o n d u c t e d  t o  a c c u r a t e l y  d e t e r m i n e  t h e  e n e r g i e s  
t h a t  s t a b i l i z e  h e l i c e s  a n d  h e n c e  i n  s i l i c o  s e c o n d a r y  s t r u c t u r e  p r e d i c t i o n  
r e m a i n s  a  p o w e r f u l  t o o l  [ 8 8 ] ,  [ 1 2 3 ] ,  [ 1 2 5 ] .  
 
I n  c o n c l u s i o n ,  L a g u e t t e  e t  a l .  ( 2 0 1 1 )  f o u n d  t h a t  t h e  T - a l l e l i c  f o r m  o f  t h e  
C O L 5 A 1  g e n e  s h o w e d  a n  i n c r e a s e d  m R N A  s t a b i l i t y  r e l a t i v e  t o  t h e  w i l d - t y p e  
C - a l l e l i c  f o r m .  C o l l i n s  a n d  P o s t h u m u s  ( 2 0 1 1 )  h y p o t h e s i z e d  t h a t  t h i s  i n c r e a s e  
i n  m R N A  s t a b i l i t y  m a y  a l t e r  t h e  r e l a t i v e  l e v e l s  o f  t y p e  V  c o l l a g e n  i n  l i g a m e n t s  
a n d  t e n d o n s  t h e r e b y  a l t e r i n g  t h e  f i b r i l  a r c h i t e c t u r e  a n d  i n c r e a s i n g  t h e  r i s k  
o f  i n j u r y  [ 6 3 ] ,  [ 6 4 ] .  T h i s  d i s s e r t a t i o n  a i m e d  t o  i n v e s t i g a t e  w h e t h e r  3  m i R N A  
b i n d i n g  s i t e s  i n  t h e  C O L 5 A 1  3 ’ - U T R  c o u l d  c o n t r i b u t e  t o  t h e  d i f f e r e n c e  i n  
m R N A  s t a b i l i t y  o b s e r v e d  b e t w e e n  t h e  t w o  a l l e l i c  f o r m s .  T h e  r e s u l t s  h o w e v e r  
i n d i c a t e  t h a t  t h e y  d o  n o t  c o n t r i b u t e  t o  i n c r e a s e d  s t a b i l i t y  o f  t h e  T - a l l e l i c  
f o r m  o f  t h e  C O L 5 A 1  3 ’ - U T R .  T h i s  d i s s e r t a t i o n  h a s  h o w e v e r ,  r a i s e d  i n t e r e s t i n g  
q u e s t i o n s  a b o u t  t h e  r e g u l a t i o n  o f  t h e  C O L 5 A 1  g e n e  a t  t h e  m R N A  l e v e l ,  w h i c h  
m a y  h a v e  i m p o r t a n t  i m p l i c a t i o n s  i n  t h e  p r e v e n t i o n  a n d  t r e a t m e n t  o f  A c h i l l e s  
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Appendix A : Achilles tendinopathy informed consent form 
 
Department of Human Biology 
UCT/MRC RESEARCH U NIT FOR EXERCISE SCIENCE & S PORTS MEDICINE 
Faculty of Health Sciences , University of Cape Town 
Private Bag, Rondebosch 7700 , South Africa 
Tel: + 27-21-650-4561 Fax: + 27-21-686-7530 
IDENTIFICATION OF GENETIC RISK FACTORS UNDERLYING ACHILLES 
TENDON INJURIES: A REPEAT STUDY 
INFORMED CONSENT 
I, (the participant), have been full y informed about this study on the genetic basis of Achilles 
lend in apathy to be conducted by the UCTiMRC Research Unit for Exercise Science and Sports 
Medicine at the University of Cape. I have agreed to donate five millili tres of venous blood or a Buccal 
mouthwash/swab sample, which w ill be used for the extraction and analysis of genetic material (DNA). 
I agree that the blood sample w ill be taken by a nurse, physician or phlebotomist. I agree to perform a 
range of motion test (sit-and-reach test or a single leg raise test) to determine my flexibili ty. I have also 
agreed to complete personal particulars, sporting participation, personal and famil y medical history , 
muscle cramping, as well as , stretching and warm up questionnaires and understand that all the 
information that is collected during the study w ill be treated with the stri ctest confidentiali ty and will 
only be used for scientific research purposes. I also understand that my name and personal 
particulars w ill not be released under any ci rcumstances and that all data will be analysed 
anonymously. 
I am also prepared to visit the Sports Science Institute of South Africa (SS ISA) in Boundary Road , 
Newlands for a cl inical examination in order to confirm my diagnosis (at no cost to myself). If 
requested , I am prepared to visit the Sports Science Institute of South Africa (SS ISA) in Boundary 
Road , Newlands to undergo an ul trasound or MRI in order to confirm my diagnosis (at no cost to 
myself). If requested , I am also prepared to visit the Sports Science Institute of South A frica (SS ISA) in 
Boundary Road , Newlands for measurements to determine musculo-tendinous stiffness. I give 
permission that the study investigators may access my medical records (doctor/physiotherapist) in 
order to confirm my diagnosis. 
I agree to participate in the study and I have been informed that I will be free to w ithdraw from the 
study at any time if I so wish. I understand that my DNA sample w ill be destroyed on completion of 
the study to identify genetic risk factors associated w ith Achilles tendon pathology. I also understand 




The University of Cape Town is committed to polic ies of equal opportunity and affirmatl~ e ac tion 
which are essential to ~s mission of promoting critical inquiry and scholarship 


















The poten tial risks associated w ith blood collection techn ique from the an te-cubital veins are: infection, 
delayed healing, haem atom a, physical pain, men tal discomfort and injury to a nerve or a vessel. 
These risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techn iques and the use of disposable, single use materials. 
I understand that the DNA will be genotyped (analysed) for variations (polymorphisms) w ithin the type 
V collagen gene (COL5A 1), the Tenacin-C gene (TNC) , the matrix metalloproteinase-3 gene (MMP3) , 
the grow th and differen tiation factor-S gene (GDF5) , as well as add itional genes, which may become 
relevan t during the course of the investigation. 
I understand that whil st there is no direct benefit to myself , if a genetic pred isposition for Achilles 
tendon injuries can be establi shed , then future generations w ill be able to establi sh their risk for this 
cond ition. This may allow better preven tion and treatmen t options in the future . I understand that I w ill 
receive the overall resul ts of the study. I have read (or where appropriate, have had read to me) and 
understand the information about this study, and any questions I have asked have been answered to 
my satisfaction. I agree to participate in the study, reali sing that I have the right to request that my 
DNA sample be destroyed at any time. I agree that research data provided by me or w ith my 
permission during the project may be included in a thesis, presen ted at conferences and publi shed in 
journals on the cond ition that neither my name nor any other iden tifying information is used . 
Any questions regard ing this project may be directed to Dr Alison September on telephone number 
021 650 4559 or e-mail alison.september@uct.ac.za or to Prof Malcolm Collins on telephone 
number 021 6504574 or e-mail malcolm.collins@uct.ac.za. 
If you have any complaints or queries that the investigator has not been able to answer to your 
satisfaction, you may con tact the Facul ty of Health Sciences Human Research Ethics Committee at 
the University of Cape Town Prof Marc Blockman on telephone number 021 4066452. 
Name of Participant: ______________ _ 
Signature: _________________ ___ Date: ______ _ 
Name of Researcher: _______________ _ 












Appendix B: Achilles tendinopathy Questionnaire 
 
'-'-~.~. ~ . ~.j~ .. :, . 
Department of Human Biology 
UC TIMRC RESEARCH Urn FOR EXERCISE S CIENCE & SPORTS MEDICINE 
Faculty of Health Sciences, University of Cape Town 
Private Bag, Rondebosch 7700, South Afr ica 
Tel: + 27·2 1-650-456 1 Fax: + 27-2 1-686-7530 
The identification of genetic susceptibility loci underlying Achilles 
tendon pathology: A Repeat Study. 
Instructions 
Please answer each question by fi lling in the details in the allocated space or 

















Please complete all twelve sections A to L 
Personal Detail s Page 2 
Sporting Detail s Page 3 
Flexibili ty Training History Page 4 
Lifestyle and habits history Page 4 
General Personal Medical History Page 5 
Famil y Medical History Page 6 
History of Medication Use Page 7 
Muscle Cramping Page 8 
Past History of Skeletal Muscle Injury Page 9-10 
History of Tendon, Ligament or Joint Capsule Injury Pages 11 
Medical Deta ils of Tendon Injuries Pages 12-13 
History if Any Other Chron ic Current Injury Pages 14 
Subject Numb er: ___ _ 
The Uni""rsil y 01 Cape Town i. oommlled 10 pcH id". 01 equal opponunily and alli rm'l i"" acl ioo 


















Subj ect No: ___ _ 




I Postal! Zip Code 
E-mail address 
Alternate E -mail address Phone (day time) 
Date of birth , - , -, Cell (Mobile) 
Height om So< Ma le 0 Fema le 0 
Weight kg Ag' Y" 
Ethnic group Black/African 0 White 0 Indian 0 
(Only Required and Used for 
0 0 0 Research Purposes) Mixed An cestry (Coloured ) Asian Other 
Ancestry: Tribal or Father: Unknown 0 
national background 
(eg Xhosa, Dutch, Zulu, 
0 German, Italian) Mother: Unknown 
Country o f Birth 
Dominant Hand Left 0 Right 0 Both 0 I Dominant Leg I Left 0 Right 0 Both 0 
Current Occupation 
Sitting: -- % 
What perc enta ae of your Standing : % 
working day is spent in --
the following activities? Walking (Lower body activity) -- % 
Manual Labour (upp er and body activi ty) -- % 
Occupation prior to muscle injury? I 
Prior to injury, did your occupation involve lower or upper limb activity? I Yes 0 No 0 
If yes please indicate Right arm 0 Left arm D Both arms 0 














S b"ect No U J 
Section B. Sporting Details 
Please record your sporting activities in order of importance 
Use an additional form if you participate(d ) in more than 6 sports 
Type of sport(s) you have particip ated Main sport 1 Other sport 2 Other sport 3 
in (please name) 
Current or past participation Current D Past D Current D Past D Current D Past D 
Year started participation 
Number of years involved in the sport 
Years in competitive sport 
Professional or amateur 
Hours of training per week 
(last 3 months) 
Hours of training per week 
(3-12 months) 
Hours of training per week 
(1 2-24 months) 
Type of sport(s) you have participated Other sport 4 Other sport 5 Oth er sport 6 
in (please name) 
Current or past participation Current D Past D Current D Past 0 Current 0 Past 0 
Year started participation 
Years involved in the sport 
Years in competitive sport 
Professional or amateur 
Hours of training per week 
(last 3 months) 
Hours of training per week 
(3-12 months) 
Hours of training per week 














Subj ect No : ___ _ 
Section E. General Personal Medical History 
Do you currently suffer from any of these medical conditions : 
o High Blood Pressure o Angin a/Heart Attack o Asthma o Emphysema o Rheumatoid arthritis o Osteoarthritis (wear & tear) 
o Malignant disease (cancer) o Elevated Blood Cholesterol D Adrenal disord ers 
If Yes, what type? o Diabetes mellitu s o Thyroid disord ers o Renal disease D Amyloidosis 
Do you currently su ffer from any other 
Connective Tissue, Rheumatological Yes 0 No D If Yes , please se lect from the list below 
Or Muscle Diseases & Disorders? 
List of some Connective Tissue and/or Rheumatic Diseases and Disorders 
o Ankylosing Spondylitis o Lipid Storage Diseases o Pseudogout 
o Aspar tylglycosaminuria (AGU) o MarIan Syndrome o React ive Arthr itis 
o Behcet's Syndrome o Menkes Kinky Hair Syndrome o Reiter's Syndrome 
o Crohn's Disease o Mucopolysaccharidoses o Relapsing Polychrondritis 
o Discoid Lupus Erythematosus o Myopathies and Dystrophies o Scleroderma 
o Ehlers-Danlos syndrome (EDS) o Ochronosis (Homocystinuria) o Sjogren's Syndrome 
o Eosinophilic Fascit is o Osteogenesis imperfecta (01) o Systemk: lupus Erythem atosus (SlE) 
o Giant Cell (Temporal) Ar thrit is o Polyarteritis Nodosa o Systemic Sclerosis 
o Gout o Polymyalgia Rheumatica o Wegener's Granulomatosis 
o Hypersentive Vasulatis o Polymyositis & Dermatomyositis o Rhabdomyolysis 
o Muscular dystrophy o Myopathy D Other 
Operation Date 
What surgica l operations have you 
had? (please list and give dates) 
If femal e: 
At what age did you start menstruating? (years) 
Are you currently using any type of contraception? 0 y" 0 No 
If Yes, what type of contraception are you using? 0 Pill 0 Injection o IUD 
o Pre-menopausa l (112 cycles per yea r at in tervals of 23- 33 da ys & 
bleeding lasts 3-7 days) 
Are you currently? D Menopausal (cycles are irregul ar and less frequ ent) 














S b"ect No U J 
Section C. Flexibility training history 
Do you perform flexibility training (regular stretching exercises)? Yes 0 No D 
If YES. please complete the rest of the f lexibility training history section below:-
If NO, continue completing the questionnaire from section D. 
On average, how many days a week do you perform a stretch ing 
days/week 
session? 
On average , how times a day do you perform a stretching session? tim es/day 
o Hamstrin gs 
D Quadriceps 
Please tick which muscle groups do you include in your 
o Ca lf (ga strocnemius) o Ca lf (soleus) stretching session? o Groin (inner thigh) o Upper body limbs o Other: 
o Before Exercise 
Please tick when you stretch? (before. during and/or after exercising . D During Exercise You can tick more than one box) 
D After Exercise 
When you stretch an individual muscle group, on average, how long do 
second s 
lioU hold the stretch for? 
Dance 
D Twice 
Wh en you stretch an individual muscle group, on average, how D 3 times 
manli times do lioU stretch the muscle for? D 4 times 
D 5 times 
D 6 or more tim es 
Section D, Lifestyle and habits history 
Please indicate your smoking status I Current smoker 0 Ex smoker D I Never smoked 0 
If you answered yes, Number of years of smokin g: If stopped, how many years ago: 
(past or current 
smoker) please 
complete the section on What is (was) the average number of cigarettes per day: 
the right 
--- glasses beer/cider per week 
On average, how much alcohol do you drink per week (tots, 
glasses wine per week 
glasses) of spirits, wine or beer? - - -














Subj ect No : ___ _ 
Section E. General Personal Medical History 
Do you currently suffer from any of these medical conditions : 
o High Blood Pressure o Angin a/Heart Attack D Asthma o Emphysema o Rheumatoid arthritis D Osteoarthritis (wear & tear) 
o Malignant disease (ca ncer) o Elevated Blood Cholesterol D Adrenal disord ers 
If Yes, what type? o Diabetes mellitus D Thyroid disord ers o Renal disease D Amyloidosis 
Do you currently suffer from any other 
Connective Tissue, Rheumatological Yes 0 No D If Yes, please se lect from the list below 
Or Muscle Diseases & Disorders? 
List of some Connective Tissue and/or Rheumatic Diseases and Disorders 
D Ankylosing Spondyli tis D Lipid Storage Diseases D Pseudogout 
D Aspartylglycosaminuria (AGU) D Marfan Syndrome D React ive Arthr itis 
D Behcet's Syndrome D Menkes Kinky Hair Syndrome D Reiter's Syndrome 
D Crohn's Disease D Mucopolysaccharidoses D Relapsing Pol ychrond r~ i s 
D Discoid Lupus Erythematosus D Myopathies and Dystrophies D Scleroderma 
D Ehlers-Danlos syndrome (EDS) D Ochronosis (Homocystinuria) D Sjogren's Syndrome 
D Eosinophilic Fascit is D Osteogenesis imperfecta (0 1) D Systemk: l upus Erythematosus (SlE) 
D Giant Cell (Temporal) Arthrit is D Polyarteritis Nodosa D Systemic Sclerosis 
D Gout D Polymyalgia Rheumatica D Wegener's Granulomatosis 
D Hypersentive Vasulatis D Polymyositis & Dermatomyositis D Rhabd omyolysis 
D Muscular dystrophy D Myopathy D Other 
Operation Date 
What surgica l operations have you 
had? (please list and give dates) 
If f emal e: 
At what age did you start menstruating? (years) 
Are you currently using any type of contraception? 0 Yp.~ 0 No 
If Yes, what type of contraception are you using? 0 Pill 0 Injection o IUD 
o Pre-menopausa l (112 cycles per yea r at in tervals of 23- 33 days & 
bleedin g lasts 3-7 days) 
Are you currently? D Menopausal (cycles are irregul ar and less frequ ent) 














S b"ect No U J 
Section F. Family Medical History 
Have any of your blood (biological) relati ves ever had the following? 
Please tick yes or no. If yes, please tick the relat ionship of that person to yo u (You may t ick 
more than one of the relationship b locks). 
Description If Yes, p lease indicate the relat ionship 
D Father o Mother o Brother 
Chronic A chilles tendon 
Yes D No D D Sister o Child injury 
D Grandfather D Grandmother 
D Father o Mother D Brother 
Achilles tendon rupture Yes D No D D Sister o Child 
D Grandfather D Grandmother 
o Father o Mother o Brother 
Any other (not Achilles) 
Yes DNo D D Sister o Child tendon injury/rupture 
D Grandfather D Grandmother 
D Father o Mother o Brother 
Any ligament injury Yes D No D D Sister o Child 
o Grandfather 0 Grandmother 
D Father D Mother D Brother 
Exercise associated muscle 
Yes D No D D Sister D Child cramps 
D Grandfather D Grandmother 
D Father D Mother D Brother 
Night muscle cramps Yes D No D D Sister D Child 
D Grandfather D Grandmother 
Do any other members of D Fa ther D Mother D Brother 
your family suffer from Yes DNo D D Sister D Child 
elevated blood cholesterol? D Grandfather D Grandmother 
Is there any history of 
D Father D Mother D Brother 
Yes D No D D Sister D Child arthritis in your family? 
D Grandfather D Grandmother 
D Father D Mother D Brother 
Heart Disease Yes DNo D D Sister D Child 
D Grandfather D Grandmother 
D Fa ther D Mother D Brother 
Diabetes Yes D No D D Sister D Child 














S b"ect No U J 
Section G. History of Medication Use 
Name of med ication Years taken 
What med ication , if any, are you 
currently using? (please li st) 
Have you ever used oral o 3 months D 6 months 
corticosteroids (cortisone Yes D No D D 12 months D 24 or more months tablets)? (I f yes , how long ago?) 
Have you ever been given an 
Yes D No D 
o 3 months D 6 months 
injection w ith corticosteroids? (I f o 12 months D 24 or more months yes , how long ago?) 
Have you ever used D 3 months D 6 months 
f1uoroquinoline antibiotics? (refe r Yes D No D D 12 months D 24 or more months to the following list) 
list of some fluoroquinoline antibiotics (may be used in treatm ent of chlamydia, pn eumonia, 
acute bronchitis, urinary tract infections, skin and soft tissue infection): 
ADCO·CIPRIN CIPROBAY SANDOZ CIPROFLOXACIN 
AVELON CIPROGEN TAF LOC 
BACTIDRON CPL ALLIANCE CIPROFLOXACIN TARIVID 
CIFLOC DYNAFLOC TAVANIC 
CIFRAN FACTIVE TEQUIN 
CIPLA·CIPROFLOXACIN FLOXIN UNIQUIN 
CIPLOXX IVtAXAQUIN UTIN-400 















S b"ect No U J 
Section H. Muscle Cramping 
Have you ever in your athletic career su ffered from muscle cramping (painful. 
spontaneous, susta ined spasm of a muscle) during or immed iately (within 6 hours) Yes D No D 
after exercise (in training or competition) 
If YES, please complete the rest of the muscle cramping section below:-
If NO, continue completing the questionnaire from section I. 
For how many years have you suffered from cramping? (years) 
Did you suffer from cramping during or after exercise in the last 12 months? Yes 0 No D 
With what type of exercise is your cramping associated 
D Swimming D Cycling D Runn ing (You can tick more than one form of exercise)? 
In the last 10 races or 
training sessions how many Races : __ 110 
tim es have you experienced Training sessions : __ 110 
cramping? 
o Stretchin g o Resting 
Wh at treatmenUs have you had that o Drinking flu id o Ice application 
successfuillt relieved an acute cramp? o Massage 0 Magnesium 
(can tick more than one) o Salt (tablets or solut ion) o Other (Specify : ) 
At what p:oint in the race or training run 
I g First quarter g Second quarter o Third quarter o Fourth quarter 
do you usually first experience cramping? 
I Fi After the race Fi No pattern 
In which muscles do you usually cramp o Calves o Hamstrings 
(please list the muscle by the one which o Quadriceps (thigh) o Foot muscles cramps most frequently (as 1) and the 
others after that (2-4)? o Other (Specify : ) 
Have you ever suffered from cramping in your who le bodlt (arms and legs)? Yes 0 No O 
Have you ever been admitted to hosp:ital following cramping? Yes 0 No O 
Have you ever been confused or in a coma during or after a cramping episode? Yes 0 No O 
Have you ever had " dark urine" in the 3 days following a cramping episode? Yes 0 NoO 
If you cramp. how long does the cramp usually last for (min)? I (minutes) 
If you cramp. how severe is 0 Mild : < 5 minutes and you are able to continu e exe rcising 
the cramp usually? (please 0 Moderate : 5-15 minutes and you are able to continue exercisin g 














S b' ect No U J 
SECTION I. Past History of Ske letal Muscle Injury (Muscle StrainlTear) 
Please complete this section for each muscle injured. If you have had more than one muscle injury 
additional forms w ill be available. 
Have you ever injured a muscle in the past? I Yes D No 0 
If YES, please complete the rest of Skeletal Muscle Injury section below:-
If NO, continu e completinq the questionnaire from section J . 
Muscle Partial Complete 
Muscle Group Tear Tear 
(L -Ieft, R-riQht\ L R L R 
Vastus Lateralis DO 0 0 
If yes, please specify which Quadriceps Vastus Medialis DO 0 0 
mu scle? Vastus Intermedius U U U U 
(You may tick more than one Rectus Femoris I 
block, please select eith er L 
Semite ndinosus DO 0 0 (left) or R (right» 
Semimembranosus DO 0 0 
Also indicate if you partially or Hamstring Biceps femoris long DO 0 0 completely tore the muscle. 
DO 0 0 Biceps femoris short 
Partial tear re fers to tearing of a Adductor longus D O 0 0 
few muscle fibres with minor 
Hip adductor (groin) Adductor magnu D O 0 0 sw elling, possible loss of 
strength and restriction of Adductor brevi D O 0 0 
movement. Gastrocnem ius D O 0 0 
Complete tear re fers to a tear Ca lf Plantar is D O 0 0 
extending across the whole Soleus D O 0 0 
muscle resulting in complete 
Anterior Left D Right D loss of muscle fuction (lo ss of Chronic 
Left D Right D strength. movement and ability compartment Lateral 
to contract the muscle). syndrome of the Superficial posterior Left D Right D 
lower leg 
Deep posterior Left D Right D 
Other: (Please Specify) . 
D Contact with another player 
D Contact with another object (e.g. equipment) 
D No contact (sprinting) 
How was the muscle injured? D No contact (l anding) 
(pl ease also explain exactly D No contact (kicking) 
ho w the injury occurred) D No contact (falling) 
D No contact Uu mpin g) 
D No contact (Other) 
D Other: (Please Specify) . 
After sustaining the muscle 
injury approximate ly how many 
days were you off from training Approximate number of days : . . . . . . . . . . . . 
or competition? 














Subj ect No: 
Investigation done to confi rm D Ultrasound O MR I D CT scan D None the diag nosis 
If Yes, please specify the family memb er 
0 Mo ther 
To your knowledge , have any 0 Father 
other membe rs of your family 
Yes O No 0 0 Sibling suffered from any muscle 0 Son I daughter 
pathology? 0 Other family memb er: 
Condition: Pleas e choose musc le in jury f rom the lis t 
above 
!=! Rest o Ice application 
Wh at was the initial treatment D Compression 
(fi rst 5 days)? D Elevation 
(You may tick more than one D 1m mobilisation block.) o Medication (analgesics - pain killers) o Medication (anti-inflamm atory drugs) 
D Other: (Please Specify) . 
!=! Re habili tation (stretchin g) 
Wh at was the final treatment? o Re habili tation (strengthening) 
(You may tick more than one o Re habilitation (other) 
block.) D Strapping/taping o Surgery o Other: (Please Specify) . 
Followin g this injury please 
W. No return to any sport 
Return to sport but ... 
indicate whether you were able o Limited to non-sprintin g exe rcise 
to return to sports (indicate o Limite d to non-jumpin g exe rcise category). o Limited, not to same level as pre-injury o Return to full participation in sport 
o Wet and soft ground 
If you are abl e to recall, what o Dry, but soft ground 
were the weather and pi tch o Dry and firm ground conditions like at the tim e of 
injury? o Wet, but firm ground o Other: (Please Specify) . 
o Other muscle injury 
Associated injuries (Injuries o Tendon injury 
sustained at the sa me time as D Ligament Injury 
the muscle injury)? o Bone bruisin g 














S b"ect No U J 
Section J . Past History of Tendon, Ligament or Joint Capsule Injury 
Please complete this section for each injury. If you have had more than one past injury additional forms 
will be available. 
Have you ever in your su ffered from a tendon or ligament in jury (pain. swelling, 
stiffness) in any tendon (including Achilles tendon, knee tendons, and shoulder Yes D No D 
tendons) or ligaments (partial or complete tear)? 
If YES, please complete the rest of the section below:-
If NO, continue completin g the questionnaire from section L. 




Left Right l eft Righ t 
Foot and ankle: 
o Achilles tendon DD DD 
Please tick which D Tibialis posterior DD DD 
tendon/s you have o Plantar fascia DD DD injured? (next column 
on the tright) 
Knee : D Patellar tendon 
Also indicate (tick) if 
DD DD 
your injured tendon 
was longsatnd ing pain 
Elbow and wrist : D Wrist extensor tendon DD DD (tendinopathy) or an 
acute tear/rupture 
Shou lder: D Rotator cuff DD DD 




l eft Right 
Tear 
l eft Right 
D Shoulder ligaments DD DD 
Please tick which D Elbow ligaments DD DD 
l igamenUs you have D Wrist ligaments DD DD 
injured? (next column D Finger ligaments DD DD 
on the tright) D Knee (ACl) DD DD 
D Knee (MCl) DD DD 
Also indicate if your D Knee (PCl) DD DD spra ined or completely D Knee (lCl) DD DD tore the ligamant. 
D Ankle lateral ligaments DD DD 
D Ankle medial ligaments DD DD 
D Spinal ligaments DD DD 
D Other: DD DD 
D Acute shoulder dislocation 
Have you ever suffered f rom any of the D Chronic should er instability 















Subject No: ___ _ 
SECTION K. MEDICAL DETAILS OF TENDON INJURIES 
Symptoms 
How many times have Tendon Injured 
Date of Acute or Sudden DC 
In·urv Chronic In·urv Gradual2 Onset 
you had tendon injuries? 
1 
lSudden onset is within a 2 
few seconds or minutes 
3 
2Gradual onset is over 4 
days or weeks 
5 
Please complete a separate form , Part K only, for each Tendon Injury you have had 
Injury Number (1,2,3,4,or 5) o 1 0 2 o 3 0 4 0 5 0 ---
Rotator cuff tendon 0 Patellar tendon 0 
· Supraspinatus 0 Wrist extensor tendons 0 Which tendon did you injure? · Infraspin atus 0 Achilles tendon 0 · teres min or 0 
Which side was injured? D Left D Right D Both 
D Upper 113 D Middle 1/3 D Lower 1/3 
Which region of your tendon was 
injured? Please indicate on a 
diagram. (Only if applicab le) 
To what extent was your Tendon 
D Complete D Part ial D None 
ruptured? 
How were you injured? 
(e.g . sport, walking) 
D pain only afte r exercise 
D pain during exercise , but did not cause you to alter training 
D pain during exercise , which causes you to alter training 
D pain whi ch causes you to stop training 
Grade of injury at the time of D no pain 
injury D not sure 
D Other (Specify ) 
D pain only afte r exercise 
D pain during exercise , but did not cause you to alter training. 
D pain during exercise , which causes you to alter training 
D pain whi ch causes you to stop training 
Grade of injury currently D no pain 
D not sure 















D Pain (less than 1 week) D Stiffness 
Which of the following sym ptoms 
were prese nt before the injury D Pain (1-4 wee ks) D Swelling 
D Pain (> 4 weeks) D None 
D Pain (less than 1 week) D Stiffness 
Which of the following sym ptoms 
were prese nt after the injury D Pain (1-4 weeks) D Swelling 
D Pain (> 4 weeks) D None 
If you have or had chronic 
tendon pa in, wh at seems to 
alleviate the pa in? 
Diagnosis 
Which type of Tendon Disease were you I 
diagnosed with e.g . Rupture , Tendinitis, etc. 
Diagnosed by D Doctor 
D Physiotherapist 
(Please in dicate the name and D Biokineticist 
contact number of the clini cian D Pod iatrist 
who diagnosed you) D Other 
If you had a tendon rupture . 
D Surgically DNon-surgically How was it treated? 
If applicable, wh o was the 
Surg eon Phone surgeon? 
If applicable, wh at diagnostic D Ultrasound D MRI D CT Other imaq inq was performed? 
If applicable, wh o did the 














S b"ect No U J 
Section l. Details of Any Other Chronic (Longstanding) Current Injury 
Please complete this section for each injury . If you have had more than one past injury add itional forms 
will be ava ilable . 
What was the approximate date when you first became aware o f the M, (e, 
injury? 
Please indicate which side of your body is injured (if applicable) D Right DLeft 
o Head o Elbow D Hamstring 
D Neck D Forea rm D Quadriceps o Face o Wrist D Knee 
Please indicate which anatomica l area is D Front chest D Finger D Shin 
curre ntly injured D Back chest D Lower back D Achilles 
D Shoulder D Hip D Ankle 
D Upper arm D Thigh o Foot 
Other (Speci fy: ) 
D Muscle D Ligam ent 
Please indicate the type of structure th at was o Tendon o Joint 
injured D Bone 
Other (Speci fy): ) 
Please indicate in whi ch sport (discipline) the 
D Running 0 Soccer D Rugby D Cricket 
D Hockey injury occurred 
Other (Speci fy: \ 
D I only experience symptoms after exercise - Grade 1 
Please indicate the D I experience symptoms during exercise , but it does not interfere with exercise 
severi ty of the injury - Grade 2 
(tick one box D I experience symptoms during exercise that may interfere with my training! 
please) competition - Grade 3 
D I am so painful that I may not be abl e to train or compete - Grade 4 
D Rest D Tablets 
D Stretches D Cortisone injection 
Please indicate how your injury was treated 
D Physiotherapy D Other injection 
D Surgery D Orthotics to date (you can tick more than one)? 
D Strengthening exerci ses 
D Equipment change 
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Department of Human Biology 
UCT/M RC RESEARCH UNIT FOR EXERCISE SCIENCE & SPORTS MEDICINE 
Facu lty of Health Sciences , University of Cape Town 
Private Bag , Rondebosch 7700 , Sou th Africa 
Tel: + 27-21-650-4561 Fax: + 27-21-686-7530 
CLINICAL DIAGNOSIS OF ACHILLES TENDINOPATHY 
SUBJECT NAME/NUMBER/CODE: ______________ _ 
Clinical criteria 1;2 Present 
Gradual progressive pain over the posterior lower leg - Achilles 
tendon area (> 6 weeks) 
Earl y morning pa in 
Early morning stiffness 
History of swelling over the Achilles tendon area 
Tenderness to palpation over the Achilles tendon 
Palpable nodular thickening over the affected Achilles 
Positive "shift" test (movement of the nodular area with plantar-
Idorsi-flexion) 
Other criteria Present 
Confi rmation of the diagnosis by ultrasound' 
Confi rmation of the diagnosis by MRI • 
Confi rmation of the diagnosis by CT scan' 
' : One of these cri teria must be present to confi rm the diagnosis 
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Appendix G: Nested PCR primer sets 
 
 
Primer set 1 : 
FWD: 5’-GCTTGCTTCATGGGCTAGCAGCCGC-3’ 
REV: 5’-GAGTCACTCGGATCCGTTTACGGTGG-3’ 
N.B. – the forward primer in set 1 contains a NheI restriction site (bold, underlined), the reverse 
primer in set 1 contains a BamHI restriction site. These two site were used to clone the COL5A1 3’-
UTR into the pGL3-Promoter vector 
Primer set 2 : 
FWD: 5’-GATCAGCTTCAATCCTGTGTGTGC-3’ 
























































































Appendix J: The primers used to sequence the 2.5 kb COL5A1 3’-UTR cloned into pGL3-
Promoter vector.  
Primer 
Name 
5’- Position within 
exon 66  
5’-3’Primer Sequence  
FWD1 1850b AAG GTC TTA CCG GAA AAC TCG ACG 
REV1 488 CCT GAG ACC TAT TCA CGA AC 
FWD2 667 GTC ATT CTG CAG GTG CCT TC 
REV2 774 GAA AGC CAG GCA CAC TTA AC 
FWD3 1058 AGA CTA AAA ACA CAG GTT TGG 
REV3 1230 CAC CAC AAG AGA GCC ACA AG 
REV4 1468 AAG TAG GCA CAA CCC AGT CC 
FWD4 1546 TTC CTG AAT TGT GGT GC 
REV5 1912 AGC CTG CAT TTC CCA TGG 
FWD5 2087 TCT GGC TTG GAG AGT CTC TGG 
REV6 2278 CAG AGG AAG AAA ATG ACA GG 
FWD6 2483 GAT AAA GTT TCG AGG ACA TC 
REV7 2284b CAT AAG TGC GGC GAC GAT AGT CAT GC 
 















Appendix K: Attractene Reagent Transfection Protocol (Hsa-miR-608 HT1080) 
 
1 .  T wen t y  f ou r  h our s  p r io r  t o  t r an s f ec t i on ,  7 . 5  x  10 4  c e l l s  were  se ede d  
p e r  we l l  i n  a  1 2 - we l l  p la t e .  Ce l l s  were  s ee de d  i n  1  m l  o f  Du lbe cco ’s  
Mo d i f i e d  Eag le  Me d ium (DMEM)  (H ig h ve ld  B io l og ica l ,  Sou t h  
A f r i ca )  co n ta in i ng  10% GI BCO Fe t a l  Bov in e  Ser um (FBS)  (H ig h ve ld  
B io log ic a l ,  Sou t h  A f r i c a )  an d  1% Pe n ic i l l i n / S t re p tom yc in  an t i b io t i c  
s o lu t i on .  
2 .  Ce l l s  wer e  i nc ub a te d  u nd er  no rm a l  g ro wt h  co nd i t i o ns  a t  3 7  ºC ,  5% 
CO 2  an d  6 5% h umid i t y .  
3 .  The  n e x t  d a y ,  wh en  ce l l s  r e ach ed  con f l ue nc y  o f  60 - 80%,  150 0  ng  
o f  co ns t r uc t  DNA a lo ng  w i t h  1 50  ng  o f  r en i l l a  l uc i f e ras e  c on s t ruc t  
DNA d is so l ved  in  s te r i l e  H 2 O was  a dde d  to  a  t u be  an d  ma de  up  t o  
a  vo lume o f  24 0  µ l  w i t h  DMEM wi th ou t  s e rum o r  a n t i b io t i c s .  
4 .  The  r ea c t io n  m ix t u r e  was  b r i e f l y  vo r te xe d  a nd  c en t r i f uge d  t o  m i x  
s amp le  DNA.  
5 .  A  c o r re sp on d ing  vo lum e o f  Hs a-m iR -6 08  m ic ro RNA m im ic  o r  
s c ram b led  s iRNA co n t ro l  wa s  a dd ed  to  t he i r  r es pec t i ve  t u be s  t o  
a bs o lu t e  va lue s  o f  0 ;  3 ;  3 0 ;  1 50 ;  30 0  pm o l .  
6 .  Re ac t io n  m ix t u res  we r e  b r i e f l y  vo r te xe d  an d  c en t r i f ug ed  t o  m ix  
s amp le  DNA an d  RNA 
7 .  9  µ l  o f  A t t r ac t en e  t r a ns f ec t io n  r eag en t  (Q IAG EN®)  was  ad de d  to  
e ac h  e pp en dor f .  
8 .  Re ac t io n  m ix tu r es  we r e  b r ie f l y  vo r t e xe d  a nd  c en t r i f ug ed  a t  h ig h  
s pe ed .  
9 .  Samp les  wer e  a l l owe d  to  i ncu ba t e  a t  r oom tem per a tu re  f o r  15  
m in u tes  t o  a l l o w f o r  c omp le x  f o rmat ion .  
1 0 .W h i l e  com p le x  f o rmat io n  was  t ak ing  p la ce ,  me d ium wa s  g en t l y    
    a sp i r a te d  f r om ce l l s  a nd  1 00 0  µ l  o f  f r esh  DMEM co n ta in i ng   
    s e rum an d  an t i b i o t i cs  was  ad de d  to  e ac h  we l l .  
1 1 . Se ven t y  se ve n  (7 7 )  µ l  o f  t he  t r an s fe c t io n  com p le xes  we r e  
    a dd ed  d ro p - w i se  o n to  t he  ce l l s  an d  g en t l y  s w i r l ed .  
1 2 . Ce l l s  wer e  in cub a te d  a t  37  º C  a nd  5% CO 2  f o r  45  ho urs  be f o re  















Appendix L: Attractene Reagent Transfection Protocol (Altered)  
 
1 .  T wen t y  f ou r  h our s  p r io r  t o  t r an s f ec t i on ,  7 . 5  x  10 4  c e l l s  were  se ede d  
p e r  we l l  i n  a  1 2 - we l l  p la t e .  Ce l l s  were  s ee de d  i n  1  m l  o f  Du lbe cco ’s  
Mo d i f i e d  Eag le  Me d ium (DMEM)  (H ig h ve ld  B io l og ica l ,  Sou t h  
A f r i ca )  co n ta in i ng  10% GI BCO Fe t a l  Bov in e  Ser um (FBS)  (H ig h ve ld  
B io log ic a l ,  Sou t h  A f r i c a )  an d  1% Pe n ic i l l i n / S t re p tom yc in  an t i b io t i c  
s o lu t i on .  
2 .  Ce l l s  wer e  i nc ub a te d  u nd er  no rm a l  g ro wt h  co nd i t i o ns  a t  3 7  ºC ,  5% 
CO 2  an d  6 5% h umid i t y .  
3 .  The  n e x t  d a y ,  wh en  ce l l s  r e ach ed  con f l ue nc y  o f  60 - 80%,  150 0  ng  
o f  co ns t r uc t  DNA a lo ng  w i t h  1 50  ng  o f  r en i l l a  l uc i f e ras e  c on s t ruc t  
DNA d is so l ved  in  s te r i l e  H 2 O was  a dde d  to  a  t u be  an d  ma de  up  t o  
a  vo lume o f  24 0  µ l  w i t h  DMEM wi th ou t  s e rum o r  a n t i b io t i c s .  
4 .  The  r ea c t io n  m ix t u r e  was  b r i e f l y  vo r te xe d  a nd  c en t r i f uge d  t o  m i x  
s amp le  DNA.  
5 .  A  c o r res po nd ing  vo lume o f  m ic ro RNA m im ic  was  ad ded  to  t he  
r esp ec t i ve  t u bes  t o  a bs o lu t e  va lue s  o f  0 ;  3 ;  3 0  o r  6 0  pm o l  o f  m iRNA 
m im ic .  W here  ne ede d ,  s iRNA n eg a t i ve  co n t ro l  wa s  t he n  a dd ed  to  
t h e  s o lu t io n  t o  b r ing  t he  t o ta l  amou n t  o f  RNA up  t o  6 0  pmo l .  
6 .  Re ac t io n  m ix t u res  we r e  b r i e f l y  vo r te xe d  an d  c en t r i f ug ed  t o  m ix  
s amp le  DNA an d  RNA 
7 .  9  µ l  o f  A t t r ac t en e  t r a ns f ec t io n  r eag en t  (Q IAG EN®)  was  ad de d  to  
e ac h  e pp en dor f .  
8 .  Re ac t io n  m ix tu r es  we r e  b r ie f l y  vo r t e xe d  a nd  c en t r i f ug ed  a t  h ig h  
s pe ed .  
9 .  Samp les  wer e  a l l owe d  to  i ncu ba t e  a t  r oom tem per a tu re  f o r  15  
m in u tes  t o  a l l o w f o r  c omp le x  f o rmat ion .  
1 0 .W h i l e  com p le x  f o rmat io n  was  t ak ing  p la ce ,  me d ium wa s  g en t l y   
    a sp i r a te d  f r om ce l l s  a nd  1 00 0  µ l  o f  f r esh  DMEM co n ta in i ng   
    s e rum an d  an t i b i o t i cs  was  ad de d  to  e ac h  we l l .  
1 1 . Se ven t y  se ve n  (7 7 )  µ l  o f  t he  t r an s fe c t io n  com p le xes  we r e  
    a dd ed  d ro p - w i se  o n to  t he  ce l l s  an d  g en t l y  s w i r l ed .  
1 2 . Ce l l s  wer e  in cub a te d  a t  37  º C  a nd  5% CO 2  f o r  45  ho urs  be f o re  
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Appendix N: Confirmation of polymorphic miRNA binding sites Hsa-miR-886-5p 




















miR-886-5p [MIMAT0004905] vs_ COL5A 1 [ENSG00000130635] 
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miR-608 [MIMAT0003276] vs . COL5A1 [ENSG00000130635] 
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F ig u r e  L eg en d  
 
Code Organism System 
ADP Mus musculus adipose tissue 
CNS Homo sapiens central nervous system 
CNS Mus musculus central nervous system 
EMB Mus musculus embryo 
HRT Homo sapiens heart 
HPS Homo sapiens hematopoietic system 
HPS Mus musculus hematopoietic system 
IMS Homo sapiens immune system 
INT Mus musculus intestine 
KID Homo sapiens kidney 
KID Mus musculus kidney 
NS Homo sapiens nervous system 
NS Mus musculus nervous system 
PAN Homo sapiens pancreas 
PAN Mus musculus pancreas 
TES Homo sapiens testis 
TES Mus musculus testis 
UTS Homo sapiens uterus 


























Appendix O: 33 putative miRNA targets predicted by MicroCOSM algorithm 
 
Rfam ID Score Energy Base P Poisson P Org P Start End 

























































































































































































































































N.B – The start and end positions of the miRNA binding sites indicated in the table represent the wild- 















Appendix P: Sequence Conservation of the COL5A1 gene  
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B) Conservation of the COL5A1 3’-UTR across species  
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Appendix Q: Annotated sequence of the COL5A1 3’-UTR 
 
                       Hsa-miR-377* 
COL5A1 3'-UTR  GCTTGCTTCA TGGGCTAGGA GCCGCCGAGC CCGGGCTCCC GAGAGCAACC TCGTGACCTC  60  
                              “NheI”   
SNPs            ---------- ---------- ---------- -Y-------- ---------- ---------- 
                                                 rs12553247 
 
COL5A1 3'-UTR  AGCATGCCAT TCGTTCGTGA GTGTCCCGTG CACGTCCTGA CCCTGGACAG TGAAGGCTTC  120  
                                                        DpnII  
SNPs            ---------- -----Y---- ---------- ---------- Y--------- ----------   
                               rs56259444                  rs13946 
           
COL5A1 3'-UTR   TCCCTCCCCT CCCACCTGAC TTCATCTACG CCTCGGCACC ACGGGGTGTG GGACCCCAGC 180   
 
SNPs            ---------- ---------- ---------- ---------- ---------- --------S-   
                                                                                                                                  rs55951876 
       Hsa-miR-330-5p 
COL5A1 3'-UTR  CCGGAGAGAA CAGAGGGAAG GAGCCGCGCC CCCACCTGGA GCTGAATCAC ATGACCTAGC  240  
 
SNPs            ---------- ---------- -------R-- ---------- ---------- ---------- 
                                            rs55748801 
 
COL5A1 3'-UTR  TGCACCCCAG CGCCTGGGCC CGCCCCACGC TCTGTCCACA CCCACGCGCC CCGGGAGCGG  300  
                                                             BstUI       
SNPs            ---------- ---------- ---------- ---------- ----Y----- ---------- 
                                                         rs12722     rs35115861 (3G/4G) 
  
       Hsa-miR886-5p     miR331-3p/miR125a-5p/miR125b 
COL5A1 3'-UTR  GGCCATGCCT CCAGCCCCCC AGCTCGCCCG ACCCATCCTG TTCTCTGTGAATA GGTCTCAGGG  360  
 
SNPs            ---------- ---------- --------Y- ---------- ---------- ---------- 
  
                                            rs1134114 
        Hsa-miR-150 
COL5A1 3'-UTR  GTTGGGGGAG GGACTGCCAG ATTTGGACAC TATATTTTTT TCTAAATTCA ACTTGAAGAT  420  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  GTGTATTTCC CCTGACCTTC AAAAAATGTT CCAAGGTAAG CCTCGTAAAG GTCATCCCAC  480   
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
         Hsa-miR-768-5p 
COL5A1 3'-UTR  CATCACCAAA GCCTCCGTTT TTAACAACCT CCAACACGAT CCATTTAGAG GCCAAATGTC  540   
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
   Hsa-miR-124           Hsa-miR-570  Hsa-miR-499-5p 
COL5A1 3'-UTR  ATTCTGCAGG TGCCTTCCCG ATGGATTAAA GGTGCTTATG TTTTTGTGAG TTTTAAGTAA  600   
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  ATATTTGTAT TGTATTGTTA TAAATGTTAA GTGTGCCTGG CTTTCAATCA TGCACGGAAA  660   
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  CCCAGTCTCA GTCCCACGGA CAGAATGGGC GAGGCATGGA TTCTGGGTTG CAGTACCGTT  720   
 
SNPs            ---------- -------R-- ---------- ---------- ---------- ---------- 
                                 rs73664168 
 
                                       Hsa-miR-608      
COL5A1 3'-UTR  CTGATTAGAA ATAGGAAGTC TCCCCACCCC CGCCCTGGCC AAGAACGTGC AATAAATTGG  780  
            AciI  
SNPs            ---------- ---------- ---------- M--------- ---------- ---------- 
















COL5A1 3'-UTR  AAGTTTGCCC CGGGGCAGCA AGAATTTATG CTGCCATTGA AAAGCAGGTA CCAGTGCCCC  840   
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
                                                        
COL5A1 3'-UTR  TTTTCAGACA GTTTTTGATT CGCTCTAGAC TTTTTTTTTT TTTAATAGGG AAAAAATTTG  900   
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
                                                (11, 12, 13 T)   rs71746744(-/AGGG) 
 
    Unknown miRNA 
COL5A1 3'-UTR  ATAATTTTCT TTTTTCTACA TGCACTTAAG ACTAAAACAC AGGTTTGGAT TAATTTTATT  960 
     MboII (rs11103544)  
SNPs            ---------- -Y-------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  TGCTTCCTTT TTCCGCTTTT CTTCCCGCAG AGCCTGATGG GAGAATGTCC AGGGCAGGGA  1020  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  AACCACATTT TTTGTAGGTG ATAACTCAAT GAAAATTGGT GCTTATTTTT TACACTTCTC  1080  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  TCTTGTGGCT CTCTTGTGGT GCTATCTATC TGTTTTAAGG TCTCCTTGAA GGCGCACTGG  1140  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
                                    rs16399 (ATCT/-) 
 
COL5A1 3'-UTR  GGACCCTGGC CATGCCTCGT TCTCCCTGCT TTCTTTATCC TGTTATTGCC TCCACAGTCT  1200  
 
SNPs             --W------- ---------- ---------- ---------- ---------- ---------- 
                 rs1134170 
 
COL5A1 3'-UTR  GTTGCCAAGG ACTCTAAGAT CAATGCACGT CACTTTCCTT TCCACTGGGC AGGATAGCCA  1260  
 
SNPs             ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  AGCACACTCC CTCCTGCGCT CTCCCGCCCC GGTGCGTCCA CTCCCGAGGG CTGTTATGAG  1320  
 
SNPs             ---------- ---------- ---------- ---------- ---------- ---------- 
                                         (2G/3G)rs34156194 
                                                  
COL5A1 3'-UTR  GACTGGGTTG TGCCTACTTG ATTTGAAAAC ACACACAAGC AATAAAAAGC CTCTTCCTGC  1380  
 
SNPs             ---------- ---------- ---------- ---------- ---------- ---------- 
 
COL5A1 3'-UTR  ATTGTCTGTG GTGTGACCAT AGCAGATTAT ATTTGGTTCC TGAATGTTTG TGGTGCTAAT  1440  
 
SNPs             ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  TTCTGTGTTT GTTCCAAGCC GTTCAGTCAT GCCATGCGCT GCCTCGGTAG ATGGAGTAAT  1500  
 
SNPs             ---------- ---------- R--------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  GTACAATGAA CTCCATGAGT CTCTCCAGGG CTGCCTGCAG CACGTCTTTT CCAAGTAGCC  1560  
 
SNPs             ---------- ---------- ---------- ---------- ---------- Y--------- 
 
 
COL5A1 3'-UTR  TATTTGGATT CCCATCTCAA ATGTCCTGGA TGCGAGCGTC AGCGGCTCCA GAGCTCGGGG  1620  
 
SNPs             ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  CGGGTGAGGT CCCCTTTGGG GAACCCTTTC CTGGCCATCG AGGTCGGGGG GCTGCCGTCT  1680  
 
















COL5A1 3'-UTR  GTGGGCAGGA GGACCCGAGG GGCAGCCAGG AAAGGCGATC TCTTCACTGT GAAAAGTTGC  1740  
 
SNPs             ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  CCGGGTGCAG CGCCTTTTCC TTCTACCATG GGAAATGCAG GCTGGGCCCT TGGGGTGAGC  1800  
 




COL5A1 3'-UTR  CTGCGGGGCT CTGGTGCTGT CCCCGACCCC CACCACCACC AGAATGCAGT TCCAGCTTAG  1860  
 
SNPs            ---------- ---------- ---Y------ ---------- ---------- ---------- 
 
 
                          
COL5A1 3'-UTR  GAAGCCACAA ACAAGCCACC CAGGAGGAAC AAAACACCGC CAGCGTGGAT TTTCCAAATT  1920  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
                                      
COL5A1 3'-UTR  TCCCTGGAAA GTAAGTCTCG CTCTTGCCAA AGAAAAGTCT GGCTTGGAGA GTCTCTGGAG  1980  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
                                         
COL5A1 3'-UTR  CCCAGGATGC CAGCATGTGC CAATGACTGT CACCTTCATC TCTTCAAAAG AAAAGCCATA  2040  
 




COL5A1 3'-UTR  GCCGAGGACT GTCCCGCGAC CCCCGTGGAC TGCGTCTAGG TCATGTGATT CTGTTTTCAT  2100  
                                              TthIII 




COL5A1 3'-UTR  TTCTCATCCC ATCCAATTTG TCCTTTTCTC CTGTCATTTT CTTCCTCTGT GGTCCCTTCA  2160  
 




COL5A1 3'-UTR  AAGTTGTTAT AATTTGTACT GAACTTCAAA ATGTGTCCCG TTCTCCCCAG ACCACTCTAG  2220  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
                              Poly(A) 
COL5A1 3'-UTR  CCACAGTATA TTGCAATAAA ATTACTTCTT ATATTTGCAG AAATTCTTTT GGTGTAATTT  2280  
 




COL5A1 3'-UTR  TATTTTTTCC TCTCAATATA TATAATTGGA CAAACGCTGG CAAAAAGAAA AAAATGGTAA  2340  
 
SNPs            ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
COL5A1 3'-UTR  GCAAAAAACC CAAGATAAAG TTTCGAGGAC ATCAGGCCTT TTGAAATACA ATGTCAAATG  2400  
 




COL5A1 3'-UTR  ACACATTGTA CGGTTTCAAA AAATCCGCTA GACATGTCAT AAGTTTTAAC TGTAATGCCC  2460  
 
SNPs            ---------- --K------- ---------- ---------- ------Y--- ---------- 
















COL5A1 3'-UTR  AGGAAAGGAT ATCTTAAAAT ATTCTAAACT TGTGTAACAA AGGAATAATT AACTGTAATA  2520  
 
SNPs            ---------- ---------- ---------- ---------- ---------- --------Y- 
                                                                            rs3128575 
                      Poly(A) 
COL5A1 3'-UTR  GTTTTTCAAT AAATCGAGTT GGGTGTTTCC ACCGTaaacG gatCCgagtg actc        2574 
                                                          BamHI  



























Start End Matching sequence 
8.6471013 100% a2bp1 191 195 GCAUG 
8.6471013 100% a2bp1 823 827 GCAUG 
8.6471013 100% a2bp1 2122 2126 GCAUG 
6.93292615 94% ACO1 237 242 CAGUGA 
7.35090902 100% ACO1 961 966 CAGUGC 
5.256645851 81% EIF4B 69 72 GGAC 
5.256645851 81% EIF4B 234 237 GGAC 
7.96844717 87% EIF4B 297 303 GUGGGAC 
5.256645851 81% EIF4B 300 303 GGAC 
6.4668404 100% EIF4B 325 328 GGAA 
5.256645851 81% EIF4B 500 503 GGAC 
5.256645851 81% EIF4B 514 517 GGAC 
6.4668404 100% EIF4B 785 788 GGAA 
5.256645851 81% EIF4B 807 810 GGAC 
6.4668404 100% EIF4B 863 866 GGAA 
6.4668404 100% EIF4B 908 911 GGAA 
6.4668404 100% EIF4B 1018 1021 GGAA 
6.4668404 100% EIF4B 1147 1150 GGAA 
5.256645851 81% EIF4B 1270 1273 GGAC 
5.256645851 81% EIF4B 1338 1341 GGAC 
5.256645851 81% EIF4B 1449 1452 GGAC 
6.4668404 100% EIF4B 1769 1772 GGAA 
5.256645851 81% EIF4B 1820 1823 GGAC 
6.4668404 100% EIF4B 1838 1841 GGAA 
6.4668404 100% EIF4B 1900 1903 GGAA 
7.590657808 80% EIF4B 1986 1992 UUAGGAA 
6.4668404 100% EIF4B 1989 1992 GGAA 
6.4668404 100% EIF4B 2015 2018 GGAA 
6.4668404 100% EIF4B 2055 2058 GGAA 
5.256645851 81% EIF4B 2175 2178 GGAC 
5.256645851 81% EIF4B 2196 2199 GGAC 
5.256645851 81% EIF4B 2437 2440 GGAC 
5.256645851 81% EIF4B 2496 2499 GGAC 
6.4668404 100% EIF4B 2591 2594 GGAA 
6.4668404 100% EIF4B 2631 2634 GGAA 
3.82636396 86% ELAVL1 108 111 AUUU 
3.82636396 86% ELAVL1 114 117 AUUU 
3.82636396 86% ELAVL1 510 513 AUUU 
3.82636396 86% ELAVL1 523 526 AUUU 
3.82636396 86% ELAVL1 554 557 AUUU 
4.40359056 100% ELAVL1 626 629 GUUU 













4.40359056 100% ELAVL1 709 712 GUUU 
4.40359056 100% ELAVL1 719 722 GUUU 
3.82636396 86% ELAVL1 732 735 AUUU 
4.40359056 100% ELAVL1 912 915 GUUU 
3.82636396 86% ELAVL1 933 936 AUUU 
4.40359056 100% ELAVL1 980 983 GUUU 
3.82636396 86% ELAVL1 1025 1028 AUUU 
3.82636396 86% ELAVL1 1033 1036 AUUU 
4.40359056 100% ELAVL1 1072 1075 GUUU 
3.82636396 86% ELAVL1 1082 1085 AUUU 
3.82636396 86% ELAVL1 1087 1090 AUUU 
3.82636396 86% ELAVL1 1156 1159 AUUU 
3.82636396 86% ELAVL1 1194 1197 AUUU 
4.40359056 100% ELAVL1 1241 1244 GUUU 
3.82636396 86% ELAVL1 1470 1473 AUUU 
3.82636396 86% ELAVL1 1540 1543 AUUU 
4.40359056 100% ELAVL1 1555 1558 GUUU 
3.82636396 86% ELAVL1 1568 1571 AUUU 
4.40359056 100% ELAVL1 1576 1579 GUUU 
3.82636396 86% ELAVL1 1691 1694 AUUU 
3.82636396 86% ELAVL1 2038 2041 AUUU 
3.82636396 86% ELAVL1 2047 2050 AUUU 
4.40359056 100% ELAVL1 2222 2225 GUUU 
3.82636396 86% ELAVL1 2228 2231 AUUU 
3.82636396 86% ELAVL1 2245 2248 AUUU 
3.82636396 86% ELAVL1 2265 2268 AUUU 
3.82636396 86% ELAVL1 2301 2304 AUUU 
3.82636396 86% ELAVL1 2382 2385 AUUU 
3.82636396 86% ELAVL1 2406 2409 AUUU 
3.82636396 86% ELAVL1 2411 2414 AUUU 
4.40359056 100% ELAVL1 2489 2492 GUUU 
4.40359056 100% ELAVL1 2542 2545 GUUU 
4.40359056 100% ELAVL1 2572 2575 GUUU 
4.40359056 100% ELAVL1 2650 2653 GUUU 
4.40359056 100% ELAVL1 2674 2677 GUUU 
11.4274791 81% ELAVL2 1083 1091 UUUUAUUUG 
14.058233 100% ELAVL2 2407 2415 UUUUAUUUU 
12.7846426 100% ELAVL2 2407 2415 UUUUAUUUU 
7.3693752 100% FUS 57 60 GGUG 
7.3693752 100% FUS 91 94 GGUG 
7.3693752 100% FUS 294 297 GGUG 
7.3693752 100% FUS 678 681 GGUG 
7.3693752 100% FUS 700 703 GGUG 













7.3693752 100% FUS 1187 1190 GGUG 
7.3693752 100% FUS 1227 1230 GGUG 
7.3693752 100% FUS 1420 1423 GGUG 
7.3693752 100% FUS 1519 1522 GGUG 
7.3693752 100% FUS 1561 1564 GGUG 
7.3693752 100% FUS 1752 1755 GGUG 
7.3693752 100% FUS 1873 1876 GGUG 
7.3693752 100% FUS 1923 1926 GGUG 
7.3693752 100% FUS 1942 1945 GGUG 
7.3693752 100% FUS 2400 2403 GGUG 
7.3693752 100% FUS 2671 2674 GGUG 
9.8958058 100% HNRNPA1  1015 1020 UAGGGA 
4.09404991 88% KHDRBS3  530 535 UCUAAA 
3.826116535 82% KHDRBS3  593 598 CGUAAA 
3.739441123 80% KHDRBS3  629 634 UUUAAC 
4.092388301 87% KHDRBS3  694 699 AUUAAA 
3.874209753 83% KHDRBS3  725 730 AGUAAA 
4.277494655 91% KHDRBS3  748 753 UAUAAA 
4.325587873 92% KHDRBS3  900 905 AAUAAA 
4.370796073 93% KHDRBS3  1010 1015 UUUAAU 
4.44927358 95% KHDRBS3  1029 1034 GAUAAU 
4.142143128 89% KHDRBS3  1060 1065 ACUAAA 
4.418889291 94% KHDRBS3  1078 1083 AUUAAU 
3.81791863 82% KHDRBS3  1169 1174 GAUAAC 
4.325587873 92% KHDRBS3  1490 1495 AAUAAA 
4.265828835 91% KHDRBS3  1564 1569 GCUAAU 
4.200710743 90% KHDRBS3  1624 1629 AGUAAU 
4.603995645 98% KHDRBS3  2297 2302 UAUAAU 
4.325587873 92% KHDRBS3  2364 2369 AAUAAA 
4.152617525 89% KHDRBS3  2402 2407 UGUAAU 
4.603995645 98% KHDRBS3  2430 2435 UAUAAU 
4.12277259 88% KHDRBS3  2483 2488 GAUAAA 
3.739441123 80% KHDRBS3  2574 2579 UUUAAC 
4.152617525 89% KHDRBS3  2580 2585 UGUAAU 
4.044295083 86% KHDRBS3  2602 2607 CUUAAA 
4.09404991 88% KHDRBS3  2612 2617 UCUAAA 
4.652088863 100% KHDRBS3  2633 2638 AAUAAU 
3.787534341 81% KHDRBS3  2637 2642 AUUAAC 
4.152617525 89% KHDRBS3  2643 2648 UGUAAU 
4.325587873 92% KHDRBS3  2657 2662 AAUAAA 
3.826116535 82% KHDRBS3  2682 2687 CGUAAA 
6.33985 100% KHSRP  212 215 GUCC 
6.33985 100% KHSRP  223 226 GUCC 













6.33985 100% KHSRP  800 803 GUCC 
6.33985 100% KHSRP  1136 1139 GUCC 
6.33985 100% KHSRP  1425 1428 GUCC 
6.33985 100% KHSRP  1712 1715 GUCC 
6.33985 100% KHSRP  1758 1761 GUCC 
6.33985 100% KHSRP  1948 1951 GUCC 
6.33985 100% KHSRP  2180 2183 GUCC 
6.33985 100% KHSRP  2249 2252 GUCC 
6.33985 100% KHSRP  2281 2284 GUCC 
6.33985 100% KHSRP  2324 2327 GUCC 
6.6279899 100% MBNL1  133 136 UGCU 
6.17832025 93% MBNL1  397 400 CGCU 
6.6279899 100% MBNL1  702 705 UGCU 
6.6279899 100% MBNL1  938 941 UGCU 
6.17832025 93% MBNL1  990 993 CGCU 
6.6279899 100% MBNL1  1090 1093 UGCU 
6.17832025 93% MBNL1  1103 1106 CGCU 
6.6279899 100% MBNL1  1189 1192 UGCU 
6.6279899 100% MBNL1  1229 1232 UGCU 
6.6279899 100% MBNL1  1296 1299 UGCU 
6.17832025 93% MBNL1  1406 1409 CGCU 
6.6279899 100% MBNL1  1563 1566 UGCU 
6.17832025 93% MBNL1  1606 1609 CGCU 
6.6279899 100% MBNL1  1944 1947 UGCU 
6.17832025 93% MBNL1  2068 2071 CGCU 
6.17832025 93% MBNL1  2444 2447 CGCU 
6.17832025 93% MBNL1  2555 2558 CGCU 
8.9484945 100% NONO 323 327 AGGGA 
8.9484945 100% NONO 498 502 AGGGA 
8.9484945 100% NONO 1016 1020 AGGGA 
8.9484945 100% NONO 1145 1149 AGGGA 
8.7178165 100% PABPC1  570 574 AAAAA 
8.7178165 100% PABPC1  571 575 AAAAA 
8.7178165 100% PABPC1  1020 1024 AAAAA 
8.7178165 100% PABPC1  1021 1025 AAAAA 
8.7178165 100% PABPC1  1493 1497 AAAAA 
7.15446438 84% PABPC1  1996 2002 ACAAACA 
8.7178165 100% PABPC1  2451 2455 AAAAA 
8.7178165 100% PABPC1  2457 2461 AAAAA 
8.7178165 100% PABPC1  2458 2462 AAAAA 
8.7178165 100% PABPC1  2459 2463 AAAAA 
8.7178165 100% PABPC1  2472 2476 AAAAA 
8.7178165 100% PABPC1  2473 2477 AAAAA 













8.7178165 100% PABPC1  2548 2552 AAAAA 
8.244610744 96% PTBP1 996 1010 AGACUUUUUUUUUUU 
7.2294196 100% Pum2 551 554 UGUA 
7.2294196 100% Pum2 735 738 UGUA 
7.2294196 100% Pum2 740 743 UGUA 
7.2294196 100% Pum2 1162 1165 UGUA 
7.2294196 100% Pum2 1629 1632 UGUA 
7.2294196 100% Pum2 2304 2307 UGUA 
7.2294196 100% Pum2 2402 2405 UGUA 
7.2294196 100% Pum2 2536 2539 UGUA 
7.2294196 100% Pum2 2580 2583 UGUA 
7.2294196 100% Pum2 2622 2625 UGUA 
7.2294196 100% Pum2 2643 2646 UGUA 
4.84132568 100% RBM4  334 337 CGCG 
4.84132568 100% RBM4  414 417 CGCG 
4.84132568 100% RBM4  2184 2187 CGCG 
5.2682554 100% RBMX 15 18 CCAG 
4.99861593 94% RBMX  62 65 CCAU 
4.40271173 83% RBMX  159 162 CCCG 
4.40271173 83% RBMX  167 170 CCCG 
4.99861593 94% RBMX  196 199 CCAU 
4.40271173 83% RBMX  214 217 CCCG 
4.6667232 88% RBMX  261 264 CCAC 
4.6667232 88% RBMX  288 291 CCAC 
5.2682554 100% RBMX 305 308 CCAG 
4.40271173 83% RBMX  309 312 CCCG 
4.6667232 88% RBMX  341 344 CCAC 
5.2682554 100% RBMX 376 379 CCAG 
4.40271173 83% RBMX  388 391 CCCG 
4.6667232 88% RBMX  394 397 CCAC 
4.6667232 88% RBMX  405 408 CCAC 
4.6667232 88% RBMX  411 414 CCAC 
4.40271173 83% RBMX  419 422 CCCG 
4.99861593 94% RBMX  432 435 CCAU 
5.2682554 100% RBMX 440 443 CCAG 
5.2682554 100% RBMX 448 451 CCAG 
4.40271173 83% RBMX  456 459 CCCG 
4.99861593 94% RBMX  462 465 CCAU 
5.2682554 100% RBMX 506 509 CCAG 
4.6667232 88% RBMX  606 609 CCAC 
4.99861593 94% RBMX  609 612 CCAU 
4.99861593 94% RBMX  650 653 CCAU 
4.40271173 83% RBMX  686 689 CCCG 













4.6667232 88% RBMX  803 806 CCAC 
4.6667232 88% RBMX  873 876 CCAC 
4.40271173 83% RBMX  878 881 CCCG 
4.40271173 83% RBMX  918 921 CCCG 
4.99861593 94% RBMX  943 946 CCAU 
5.2682554 100% RBMX 960 963 CCAG 
4.40271173 83% RBMX  1113 1116 CCCG 
5.2682554 100% RBMX 1138 1141 CCAG 
4.6667232 88% RBMX  1152 1155 CCAC 
4.99861593 94% RBMX  1279 1282 CCAU 
4.6667232 88% RBMX  1321 1324 CCAC 
4.6667232 88% RBMX  1371 1374 CCAC 
4.40271173 83% RBMX  1412 1415 CCCG 
4.40271173 83% RBMX  1417 1420 CCCG 
4.6667232 88% RBMX  1427 1430 CCAC 
4.40271173 83% RBMX  1432 1435 CCCG 
4.99861593 94% RBMX  1526 1529 CCAU 
4.99861593 94% RBMX  1601 1604 CCAU 
4.99861593 94% RBMX  1642 1645 CCAU 
5.2682554 100% RBMX 1654 1657 CCAG 
4.99861593 94% RBMX  1701 1704 CCAU 
5.2682554 100% RBMX 1737 1740 CCAG 
4.99861593 94% RBMX  1784 1787 CCAU 
4.40271173 83% RBMX  1823 1826 CCCG 
5.2682554 100% RBMX 1835 1838 CCAG 
4.40271173 83% RBMX  1869 1872 CCCG 
4.99861593 94% RBMX  1895 1898 CCAU 
4.40271173 83% RBMX  1951 1954 CCCG 
4.6667232 88% RBMX  1959 1962 CCAC 
4.6667232 88% RBMX  1962 1965 CCAC 
4.6667232 88% RBMX  1965 1968 CCAC 
5.2682554 100% RBMX 1968 1971 CCAG 
5.2682554 100% RBMX 1981 1984 CCAG 
4.6667232 88% RBMX  1994 1997 CCAC 
4.6667232 88% RBMX  2005 2008 CCAC 
5.2682554 100% RBMX 2009 2012 CCAG 
5.2682554 100% RBMX 2029 2032 CCAG 
5.2682554 100% RBMX 2111 2114 CCAG 
5.2682554 100% RBMX 2119 2122 CCAG 
4.99861593 94% RBMX  2165 2168 CCAU 
4.40271173 83% RBMX  2182 2185 CCCG 
4.40271173 83% RBMX  2191 2194 CCCG 
4.99861593 94% RBMX  2238 2241 CCAU 













5.2682554 100% RBMX 2336 2339 CCAG 
4.6667232 88% RBMX  2341 2344 CCAC 
4.6667232 88% RBMX  2350 2353 CCAC 
5.2682554 100% RBMX 2588 2591 CCAG 
4.6667232 88% RBMX  2678 2681 CCAC 
8.6696024 100% RBMY1A1  1174 1178 CUCAA 
8.6272192 100% RBMY1A1  1174 1178 CUCAA 
7.65633614 88% RBMY1A1  1483 1487 CACAA 
8.6696024 100% RBMY1A1  1705 1709 CUCAA 
8.6272192 100% RBMY1A1  1705 1709 CUCAA 
7.65633614 88% RBMY1A1  1995 1999 CACAA 
8.6696024 100% RBMY1A1  2421 2425 CUCAA 
8.6272192 100% RBMY1A1  2421 2425 CUCAA 
7.5622424 86% sap-49 713 718 UUGUGA 
8.7846348 100% sap-49 1520 1525 GUGUGA 
4.1881759 90% SFRS1 29 32 UGGA 
4.1881759 90% SFRS1 50 53 UGGA 
4.1881759 90% SFRS1 68 71 UGGA 
4.1881759 90% SFRS1 111 114 UGGA 
4.62028767 100% SFRS1 146 149 AGGA 
4.1881759 90% SFRS1 233 236 UGGA 
4.62028767 100% SFRS1 328 331 AGGA 
4.1881759 90% SFRS1 346 349 UGGA 
4.1881759 90% SFRS1 513 516 UGGA 
4.1881759 90% SFRS1 691 694 UGGA 
4.1881759 90% SFRS1 826 829 UGGA 
4.62028767 100% SFRS1 862 865 AGGA 
4.1881759 90% SFRS1 907 910 UGGA 
4.1881759 90% SFRS1 1075 1078 UGGA 
4.62028767 100% SFRS1 1337 1340 AGGA 
4.62028767 100% SFRS1 1380 1383 AGGA 
4.62028767 100% SFRS1 1448 1451 AGGA 
4.1881759 90% SFRS1 1621 1624 UGGA 
4.1881759 90% SFRS1 1694 1697 UGGA 
4.1881759 90% SFRS1 1716 1719 UGGA 
4.62028767 100% SFRS1 1816 1819 AGGA 
4.62028767 100% SFRS1 1819 1822 AGGA 
4.62028767 100% SFRS1 1837 1840 AGGA 
4.62028767 100% SFRS1 1988 1991 AGGA 
4.62028767 100% SFRS1 2011 2014 AGGA 
4.62028767 100% SFRS1 2014 2017 AGGA 
4.1881759 90% SFRS1 2035 2038 UGGA 
4.1881759 90% SFRS1 2054 2057 UGGA 













4.1881759 90% SFRS1 2105 2108 UGGA 
4.62028767 100% SFRS1 2113 2116 AGGA 
4.62028767 100% SFRS1 2174 2177 AGGA 
4.1881759 90% SFRS1 2195 2198 UGGA 
4.1881759 90% SFRS1 2436 2439 UGGA 
4.62028767 100% SFRS1 2495 2498 AGGA 
4.62028767 100% SFRS1 2590 2593 AGGA 
4.62028767 100% SFRS1 2595 2598 AGGA 
4.62028767 100% SFRS1 2630 2633 AGGA 
4.567833375 89% SFRS13A  7 13 AAAGGCU 
4.53689248 88% SFRS13A  314 320 AGAGAAC 
4.6654368 91% SFRS13A  596 602 AAAGGUC 
4.365802746 85% SFRS13A  656 662 AGAGGCC 
4.357615916 85% SFRS13A  697 703 AAAGGUG 
4.236719035 82% SFRS13A  889 895 CAAGAAC 
4.213726735 82% SFRS13A  1335 1341 CAAGGAC 
4.631611151 90% SFRS13A  1840 1846 AAAGGCG 
4.52870565 88% SFRS13A  2078 2084 AAAGAAA 
4.52870565 88% SFRS13A  2156 2162 AAAGAAA 
4.52870565 88% SFRS13A  2453 2459 AAAGAAA 
4.715930809 92% SFRS13A  2593 2599 AAAGGAU 
4.50571335 88% SFRS13A  2628 2634 AAAGGAA 
6.63255189 93% SFRS9 146 150 AGGAG 
6.63255189 93% SFRS9 328 332 AGGAG 
7.08652094 100% SFRS9 1337 1341 AGGAC 
5.830231484 82% SFRS9 1390 1394 AGCAC 
7.08652094 100% SFRS9 1448 1452 AGGAC 
5.830231484 82% SFRS9 1668 1672 AGCAC 
6.63255189 93% SFRS9 1816 1820 AGGAG 
7.08652094 100% SFRS9 1819 1823 AGGAC 
6.63255189 93% SFRS9 2011 2015 AGGAG 
7.08652094 100% SFRS9 2174 2178 AGGAC 
7.08652094 100% SFRS9 2495 2499 AGGAC 
8.883996 87% SNRPA  29 35 UGGAGAU 
5.205931269 81% Vts1 54 60 GCAGGUG 
5.53207395 86% Vts1 426 432 GCGGGGC 
5.205931269 81% Vts1 675 681 GCAGGUG 
5.508778455 85% Vts1 1749 1755 GCGGGUG 
5.603586804 87% Vts1 1906 1912 GCAGGCU 
5.42581595 84% Vts1 1910 1916 GCUGGGC 
5.53207395 86% Vts1 1932 1938 GCGGGGC 
5.73001591 89% Vts1 2445 2451 GCUGGCA 
6.33890598 100% YBX1 1402 1407 CCUGCG 













5.09233667 80% YBX1 2198 2203 ACUGCG 
7.945691304 84% ybx2-a 1345 1350 AAGAUC 
7.89298258 84% ybx2-a 2022 2027 AACACC 
5.8842352 94% YTHDC1 191 196 GCAUGC 
5.27877629 84% YTHDC1 501 506 GACUGC 
5.62897815 90% YTHDC1 777 782 UCAUGC 
5.62897815 90% YTHDC1 1596 1601 UCAUGC 
6.23570757 100% YTHDC1 1971 1976 GAAUGC 
5.27877629 84% YTHDC1 2197 2202 GACUGC 
5.98045052 95% YTHDC1 2582 2587 UAAUGC 



































Start End Matching sequence 
8.6471013 100% a2bp1 191 195 GCAUG 
8.6471013 100% a2bp1 823 827 GCAUG 
8.6471013 100% a2bp1 2122 2126 GCAUG 
6.93292615 94% ACO1 237 242 CAGUGA 
7.35090902 100% ACO1 961 966 CAGUGC 
5.25664585 81% EIF4B 69 72 GGAC 
5.25664585 81% EIF4B 234 237 GGAC 
7.96844717 87% EIF4B 297 303 GUGGGAC 
5.25664585 81% EIF4B 300 303 GGAC 
6.4668404 100% EIF4B 325 328 GGAA 
5.25664585 81% EIF4B 500 503 GGAC 
5.25664585 81% EIF4B 514 517 GGAC 
6.4668404 100% EIF4B 785 788 GGAA 
5.25664585 81% EIF4B 807 810 GGAC 
6.4668404 100% EIF4B 863 866 GGAA 
6.4668404 100% EIF4B 908 911 GGAA 
6.4668404 100% EIF4B 1022 1025 GGAA 
6.4668404 100% EIF4B 1151 1154 GGAA 
5.25664585 81% EIF4B 1338 1341 GGAC 
5.25664585 81% EIF4B 1449 1452 GGAC 
6.4668404 100% EIF4B 1769 1772 GGAA 
5.25664585 81% EIF4B 1820 1823 GGAC 
6.4668404 100% EIF4B 1838 1841 GGAA 
6.4668404 100% EIF4B 1900 1903 GGAA 
7.59065781 80% EIF4B 1986 1992 UUAGGAA 
6.4668404 100% EIF4B 1989 1992 GGAA 
6.4668404 100% EIF4B 2015 2018 GGAA 
6.4668404 100% EIF4B 2055 2058 GGAA 
5.25664585 81% EIF4B 2175 2178 GGAC 
5.25664585 81% EIF4B 2196 2199 GGAC 
5.25664585 81% EIF4B 2437 2440 GGAC 
5.25664585 81% EIF4B 2496 2499 GGAC 
6.4668404 100% EIF4B 2591 2594 GGAA 
6.4668404 100% EIF4B 2631 2634 GGAA 
3.82636396 86% ELAVL1 108 111 AUUU 
3.82636396 86% ELAVL1 114 117 AUUU 
3.82636396 86% ELAVL1 510 513 AUUU 
3.82636396 86% ELAVL1 523 526 AUUU 
3.82636396 86% ELAVL1 554 557 AUUU 
4.40359056 100% ELAVL1 626 629 GUUU 
3.82636396 86% ELAVL1 652 655 AUUU 













4.40359056 100% ELAVL1 719 722 GUUU 
3.82636396 86% ELAVL1 732 735 AUUU 
4.40359056 100% ELAVL1 912 915 GUUU 
3.82636396 86% ELAVL1 933 936 AUUU 
4.40359056 100% ELAVL1 980 983 GUUU 
3.82636396 86% ELAVL1 1029 1032 AUUU 
3.82636396 86% ELAVL1 1037 1040 AUUU 
4.40359056 100% ELAVL1 1076 1079 GUUU 
3.82636396 86% ELAVL1 1086 1089 AUUU 
3.82636396 86% ELAVL1 1091 1094 AUUU 
3.82636396 86% ELAVL1 1160 1163 AUUU 
3.82636396 86% ELAVL1 1198 1201 AUUU 
4.40359056 100% ELAVL1 1241 1244 GUUU 
3.82636396 86% ELAVL1 1470 1473 AUUU 
3.82636396 86% ELAVL1 1540 1543 AUUU 
4.40359056 100% ELAVL1 1555 1558 GUUU 
3.82636396 86% ELAVL1 1568 1571 AUUU 
4.40359056 100% ELAVL1 1576 1579 GUUU 
3.82636396 86% ELAVL1 1691 1694 AUUU 
3.82636396 86% ELAVL1 2038 2041 AUUU 
3.82636396 86% ELAVL1 2047 2050 AUUU 
4.40359056 100% ELAVL1 2222 2225 GUUU 
3.82636396 86% ELAVL1 2228 2231 AUUU 
3.82636396 86% ELAVL1 2245 2248 AUUU 
3.82636396 86% ELAVL1 2265 2268 AUUU 
3.82636396 86% ELAVL1 2301 2304 AUUU 
3.82636396 86% ELAVL1 2382 2385 AUUU 
3.82636396 86% ELAVL1 2406 2409 AUUU 
3.82636396 86% ELAVL1 2411 2414 AUUU 
4.40359056 100% ELAVL1 2489 2492 GUUU 
4.40359056 100% ELAVL1 2542 2545 GUUU 
4.40359056 100% ELAVL1 2572 2575 GUUU 
4.40359056 100% ELAVL1 2650 2653 GUUU 
4.40359056 100% ELAVL1 2674 2677 GUUU 
11.4274791 81% ELAVL2 1087 1095 UUUUAUUUG 
14.058233 100% ELAVL2 2407 2415 UUUUAUUUU 
12.7846426 100% ELAVL2 2407 2415 UUUUAUUUU 
7.3693752 100% FUS 57 60 GGUG 
7.3693752 100% FUS 91 94 GGUG 
7.3693752 100% FUS 294 297 GGUG 
7.3693752 100% FUS 678 681 GGUG 
7.3693752 100% FUS 700 703 GGUG 
7.3693752 100% FUS 1170 1173 GGUG 













7.3693752 100% FUS 1231 1234 GGUG 
7.3693752 100% FUS 1420 1423 GGUG 
7.3693752 100% FUS 1519 1522 GGUG 
7.3693752 100% FUS 1561 1564 GGUG 
7.3693752 100% FUS 1752 1755 GGUG 
7.3693752 100% FUS 1873 1876 GGUG 
7.3693752 100% FUS 1923 1926 GGUG 
7.3693752 100% FUS 1942 1945 GGUG 
7.3693752 100% FUS 2400 2403 GGUG 
7.3693752 100% FUS 2671 2674 GGUG 
9.8958058 100% HNRNPA1  1015 1020 UAGGGA 
4.09404991 88% KHDRBS3  530 535 UCUAAA 
3.82611654 82% KHDRBS3  593 598 CGUAAA 
3.73944112 80% KHDRBS3  629 634 UUUAAC 
4.0923883 87% KHDRBS3  694 699 AUUAAA 
3.87420975 83% KHDRBS3  725 730 AGUAAA 
4.27749466 91% KHDRBS3  748 753 UAUAAA 
4.32558787 92% KHDRBS3  900 905 AAUAAA 
4.37079607 93% KHDRBS3  1010 1015 UUUAAU 
4.44927358 95% KHDRBS3  1033 1038 GAUAAU 
4.14214313 89% KHDRBS3  1064 1069 ACUAAA 
4.41888929 94% KHDRBS3  1082 1087 AUUAAU 
3.81791863 82% KHDRBS3  1173 1178 GAUAAC 
4.32558787 92% KHDRBS3  1490 1495 AAUAAA 
4.26582884 91% KHDRBS3  1564 1569 GCUAAU 
4.20071074 90% KHDRBS3  1624 1629 AGUAAU 
4.60399565 98% KHDRBS3  2297 2302 UAUAAU 
4.32558787 92% KHDRBS3  2364 2369 AAUAAA 
4.15261753 89% KHDRBS3  2402 2407 UGUAAU 
4.60399565 98% KHDRBS3  2430 2435 UAUAAU 
4.12277259 88% KHDRBS3  2483 2488 GAUAAA 
3.73944112 80% KHDRBS3  2574 2579 UUUAAC 
4.15261753 89% KHDRBS3  2580 2585 UGUAAU 
4.04429508 86% KHDRBS3  2602 2607 CUUAAA 
4.09404991 88% KHDRBS3  2612 2617 UCUAAA 
4.65208886 100% KHDRBS3  2633 2638 AAUAAU 
3.78753434 81% KHDRBS3  2637 2642 AUUAAC 
4.32558787 92% KHDRBS3  2657 2662 AAUAAA 
3.82611654 82% KHDRBS3  2682 2687 CGUAAA 
6.33985 100% KHSRP  212 215 GUCC 
6.33985 100% KHSRP  223 226 GUCC 
6.33985 100% KHSRP  403 406 GUCC 
6.33985 100% KHSRP  800 803 GUCC 













6.33985 100% KHSRP  1271 1274 GUCC 
6.33985 100% KHSRP  1425 1428 GUCC 
6.33985 100% KHSRP  1712 1715 GUCC 
6.33985 100% KHSRP  1758 1761 GUCC 
6.33985 100% KHSRP  1948 1951 GUCC 
6.33985 100% KHSRP  2180 2183 GUCC 
6.33985 100% KHSRP  2249 2252 GUCC 
6.33985 100% KHSRP  2281 2284 GUCC 
6.33985 100% KHSRP  2324 2327 GUCC 
6.6279899 100% MBNL1  133 136 UGCU 
6.17832025 93% MBNL1  397 400 CGCU 
6.6279899 100% MBNL1  702 705 UGCU 
6.6279899 100% MBNL1  938 941 UGCU 
6.17832025 93% MBNL1  990 993 CGCU 
6.6279899 100% MBNL1  1094 1097 UGCU 
6.17832025 93% MBNL1  1107 1110 CGCU 
6.6279899 100% MBNL1  1193 1196 UGCU 
6.6279899 100% MBNL1  1233 1236 UGCU 
6.6279899 100% MBNL1  1296 1299 UGCU 
6.17832025 93% MBNL1  1406 1409 CGCU 
6.6279899 100% MBNL1  1563 1566 UGCU 
6.17832025 93% MBNL1  1606 1609 CGCU 
6.6279899 100% MBNL1  1944 1947 UGCU 
6.17832025 93% MBNL1  2068 2071 CGCU 
6.17832025 93% MBNL1  2444 2447 CGCU 
6.17832025 93% MBNL1  2555 2558 CGCU 
8.9484945 100% NONO 323 327 AGGGA 
8.9484945 100% NONO 498 502 AGGGA 
8.9484945 100% NONO 1016 1020 AGGGA 
8.9484945 100% NONO 1020 1024 AGGGA 
8.9484945 100% NONO 1149 1153 AGGGA 
8.7178165 100% PABPC1  570 574 AAAAA 
8.7178165 100% PABPC1  571 575 AAAAA 
8.7178165 100% PABPC1  1024 1028 AAAAA 
8.7178165 100% PABPC1  1025 1029 AAAAA 
8.7178165 100% PABPC1  1493 1497 AAAAA 
7.15446438 84% PABPC1  1996 2002 ACAAACA 
8.7178165 100% PABPC1  2451 2455 AAAAA 
8.7178165 100% PABPC1  2457 2461 AAAAA 
8.7178165 100% PABPC1  2458 2462 AAAAA 
8.7178165 100% PABPC1  2459 2463 AAAAA 
8.7178165 100% PABPC1  2472 2476 AAAAA 
8.7178165 100% PABPC1  2473 2477 AAAAA 













8.7178165 100% PABPC1  2548 2552 AAAAA 
8.24461074 96% PTBP1 996 1010 AGACUUUUUUUUUUU 
7.2294196 100% Pum2 551 554 UGUA 
7.2294196 100% Pum2 735 738 UGUA 
7.2294196 100% Pum2 740 743 UGUA 
7.2294196 100% Pum2 1166 1169 UGUA 
7.2294196 100% Pum2 1629 1632 UGUA 
7.2294196 100% Pum2 2304 2307 UGUA 
7.2294196 100% Pum2 2402 2405 UGUA 
7.2294196 100% Pum2 2536 2539 UGUA 
7.2294196 100% Pum2 2580 2583 UGUA 
7.2294196 100% Pum2 2622 2625 UGUA 
7.2294196 100% Pum2 2643 2646 UGUA 
4.84132568 100% RBM4  334 337 CGCG 
4.84132568 100% RBM4  2184 2187 CGCG 
5.2682554 100% RBMX  15 18 CCAG 
4.99861593 94% RBMX  62 65 CCAU 
4.40271173 83% RBMX  159 162 CCCG 
4.40271173 83% RBMX  167 170 CCCG 
4.99861593 94% RBMX  196 199 CCAU 
4.40271173 83% RBMX  214 217 CCCG 
4.6667232 88% RBMX  261 264 CCAC 
4.6667232 88% RBMX  288 291 CCAC 
5.2682554 100% RBMX  305 308 CCAG 
4.40271173 83% RBMX  309 312 CCCG 
4.6667232 88% RBMX  341 344 CCAC 
5.2682554 100% RBMX  376 379 CCAG 
4.40271173 83% RBMX  388 391 CCCG 
4.6667232 88% RBMX  394 397 CCAC 
4.6667232 88% RBMX  405 408 CCAC 
4.99861593 94% RBMX  411 414 CCAU 
4.40271173 83% RBMX  419 422 CCCG 
4.99861593 94% RBMX  432 435 CCAU 
5.2682554 100% RBMX  440 443 CCAG 
5.2682554 100% RBMX  448 451 CCAG 
4.40271173 83% RBMX  456 459 CCCG 
4.99861593 94% RBMX  462 465 CCAU 
5.2682554 100% RBMX  506 509 CCAG 
4.6667232 88% RBMX  606 609 CCAC 
4.99861593 94% RBMX  609 612 CCAU 
4.99861593 94% RBMX  650 653 CCAU 
4.40271173 83% RBMX  686 689 CCCG 
5.2682554 100% RBMX  791 794 CCAG 













4.6667232 88% RBMX  873 876 CCAC 
5.2682554 100% RBMX  878 881 CCAG 
4.40271173 83% RBMX  918 921 CCCG 
4.99861593 94% RBMX  943 946 CCAU 
5.2682554 100% RBMX  960 963 CCAG 
4.40271173 83% RBMX  1117 1120 CCCG 
5.2682554 100% RBMX  1142 1145 CCAG 
4.6667232 88% RBMX  1156 1159 CCAC 
4.99861593 94% RBMX  1279 1282 CCAU 
4.6667232 88% RBMX  1321 1324 CCAC 
4.6667232 88% RBMX  1371 1374 CCAC 
4.40271173 83% RBMX  1412 1415 CCCG 
4.40271173 83% RBMX  1417 1420 CCCG 
4.6667232 88% RBMX  1427 1430 CCAC 
4.40271173 83% RBMX  1432 1435 CCCG 
4.99861593 94% RBMX  1526 1529 CCAU 
4.99861593 94% RBMX  1601 1604 CCAU 
4.99861593 94% RBMX  1642 1645 CCAU 
5.2682554 100% RBMX  1654 1657 CCAG 
4.99861593 94% RBMX  1701 1704 CCAU 
5.2682554 100% RBMX  1737 1740 CCAG 
4.99861593 94% RBMX  1784 1787 CCAU 
4.40271173 83% RBMX  1823 1826 CCCG 
5.2682554 100% RBMX  1835 1838 CCAG 
4.40271173 83% RBMX  1869 1872 CCCG 
4.99861593 94% RBMX  1895 1898 CCAU 
4.40271173 83% RBMX  1951 1954 CCCG 
4.6667232 88% RBMX  1959 1962 CCAC 
4.6667232 88% RBMX  1962 1965 CCAC 
4.6667232 88% RBMX  1965 1968 CCAC 
5.2682554 100% RBMX  1968 1971 CCAG 
5.2682554 100% RBMX  1981 1984 CCAG 
4.6667232 88% RBMX  1994 1997 CCAC 
4.6667232 88% RBMX  2005 2008 CCAC 
5.2682554 100% RBMX  2009 2012 CCAG 
5.2682554 100% RBMX  2029 2032 CCAG 
5.2682554 100% RBMX  2111 2114 CCAG 
5.2682554 100% RBMX  2119 2122 CCAG 
4.99861593 94% RBMX  2165 2168 CCAU 
4.40271173 83% RBMX  2182 2185 CCCG 
4.40271173 83% RBMX  2191 2194 CCCG 
4.99861593 94% RBMX  2238 2241 CCAU 
4.40271173 83% RBMX  2326 2329 CCCG 













4.6667232 88% RBMX  2341 2344 CCAC 
4.6667232 88% RBMX  2350 2353 CCAC 
5.2682554 100% RBMX  2588 2591 CCAG 
4.6667232 88% RBMX  2678 2681 CCAC 
8.6696024 100% RBMY1A1  1178 1182 CUCAA 
8.6272192 100% RBMY1A1  1178 1182 CUCAA 
7.65633614 88% RBMY1A1  1483 1487 CACAA 
8.6696024 100% RBMY1A1  1705 1709 CUCAA 
8.6272192 100% RBMY1A1  1705 1709 CUCAA 
7.65633614 88% RBMY1A1  1995 1999 CACAA 
8.6696024 100% RBMY1A1  2421 2425 CUCAA 
8.6272192 100% RBMY1A1  2421 2425 CUCAA 
7.5622424 86% sap-49 713 718 UUGUGA 
8.7846348 100% sap-49 1520 1525 GUGUGA 
4.1881759 90% SFRS1 29 32 UGGA 
4.1881759 90% SFRS1 50 53 UGGA 
4.1881759 90% SFRS1 68 71 UGGA 
4.1881759 90% SFRS1 111 114 UGGA 
4.62028767 100% SFRS1 146 149 AGGA 
4.1881759 90% SFRS1 233 236 UGGA 
4.62028767 100% SFRS1 328 331 AGGA 
4.1881759 90% SFRS1 346 349 UGGA 
4.1881759 90% SFRS1 513 516 UGGA 
4.1881759 90% SFRS1 691 694 UGGA 
4.1881759 90% SFRS1 826 829 UGGA 
4.62028767 100% SFRS1 862 865 AGGA 
4.1881759 90% SFRS1 907 910 UGGA 
4.1881759 90% SFRS1 1079 1082 UGGA 
4.62028767 100% SFRS1 1337 1340 AGGA 
4.62028767 100% SFRS1 1380 1383 AGGA 
4.62028767 100% SFRS1 1448 1451 AGGA 
4.1881759 90% SFRS1 1621 1624 UGGA 
4.1881759 90% SFRS1 1694 1697 UGGA 
4.1881759 90% SFRS1 1716 1719 UGGA 
4.62028767 100% SFRS1 1816 1819 AGGA 
4.62028767 100% SFRS1 1819 1822 AGGA 
4.62028767 100% SFRS1 1837 1840 AGGA 
4.62028767 100% SFRS1 1988 1991 AGGA 
4.62028767 100% SFRS1 2011 2014 AGGA 
4.62028767 100% SFRS1 2014 2017 AGGA 
4.1881759 90% SFRS1 2035 2038 UGGA 
4.1881759 90% SFRS1 2054 2057 UGGA 
4.1881759 90% SFRS1 2094 2097 UGGA 













4.62028767 100% SFRS1 2113 2116 AGGA 
4.62028767 100% SFRS1 2174 2177 AGGA 
4.1881759 90% SFRS1 2195 2198 UGGA 
4.1881759 90% SFRS1 2436 2439 UGGA 
4.62028767 100% SFRS1 2495 2498 AGGA 
4.62028767 100% SFRS1 2590 2593 AGGA 
4.62028767 100% SFRS1 2595 2598 AGGA 
4.62028767 100% SFRS1 2630 2633 AGGA 
4.56783337 89% SFRS13A  7 13 AAAGGCU 
4.53689248 88% SFRS13A  314 320 AGAGAAC 
4.6654368 91% SFRS13A  596 602 AAAGGUC 
4.36580275 85% SFRS13A  656 662 AGAGGCC 
4.35761592 85% SFRS13A  697 703 AAAGGUG 
4.23671904 82% SFRS13A  889 895 CAAGAAC 
4.21372674 82% SFRS13A  1335 1341 CAAGGAC 
4.63161115 90% SFRS13A  1840 1846 AAAGGCG 
4.52870565 88% SFRS13A  2078 2084 AAAGAAA 
4.52870565 88% SFRS13A  2156 2162 AAAGAAA 
4.52870565 88% SFRS13A  2453 2459 AAAGAAA 
4.71593081 92% SFRS13A  2593 2599 AAAGGAU 
4.50571335 88% SFRS13A  2628 2634 AAAGGAA 
6.63255189 93% SFRS9 146 150 AGGAG 
6.63255189 93% SFRS9 328 332 AGGAG 
7.08652094 100% SFRS9 1337 1341 AGGAC 
5.83023148 82% SFRS9 1390 1394 AGCAC 
7.08652094 100% SFRS9 1448 1452 AGGAC 
5.83023148 82% SFRS9 1668 1672 AGCAC 
6.63255189 93% SFRS9 1816 1820 AGGAG 
7.08652094 100% SFRS9 1819 1823 AGGAC 
6.63255189 93% SFRS9 2011 2015 AGGAG 
7.08652094 100% SFRS9 2174 2178 AGGAC 
7.08652094 100% SFRS9 2495 2499 AGGAC 
8.883996 87% SNRPA  29 35 UGGAGAU 
5.20593127 81% Vts1 54 60 GCAGGUG 
5.53207395 86% Vts1 426 432 GCGGGGC 
5.20593127 81% Vts1 675 681 GCAGGUG 
5.50877846 85% Vts1 1749 1755 GCGGGUG 
5.6035868 87% Vts1 1906 1912 GCAGGCU 
5.42581595 84% Vts1 1910 1916 GCUGGGC 
5.53207395 86% Vts1 1932 1938 GCGGGGC 
5.73001591 89% Vts1 2445 2451 GCUGGCA 
6.33890598 100% YBX1 1402 1407 CCUGCG 
6.33890598 100% YBX1 1929 1934 CCUGCG 













7.9456913 84% ybx2-a 1345 1350 AAGAUC 
7.89298258 84% ybx2-a 2022 2027 AACACC 
5.8842352 94% YTHDC1 191 196 GCAUGC 
5.27877629 84% YTHDC1 501 506 GACUGC 
5.62897815 90% YTHDC1 777 782 UCAUGC 
5.62897815 90% YTHDC1 1596 1601 UCAUGC 
6.23570757 100% YTHDC1 1971 1976 GAAUGC 
5.27877629 84% YTHDC1 2197 2202 GACUGC 
5.98045052 95% YTHDC1 2582 2587 UAAUGC 













































Appendix T- (a) Diagram showing secondary structure of 2.5 kb 657 bp of the (-allelic form of the COL5Al 3'-UTR. Insert A shows region 

















Appendix T- (b) Diagram showing secondary structure of 2.5 kb liS7 bp of the T-allelic form of the COL5Al 3'-UTR. Insert A shows region 
containing miR-608 binding site (i), the Mboll octamer and the AGGG VNTR have been removed (ii) . lnsert B contains miR12Sa-Sp binding site . 
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